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Abstract 
“Pre-clinical trials for Machado-Joseph Disease: Hypothesis-based and hypothesis-free 
therapeutic approaches” 
Polyglutamine (PolyQ) diseases are a family of neurodegenerative disorders characterized by 
the expansion of a CAG trinucleotide repeat in specific genes. This leads to the production of 
pathogenic proteins containing critically expanded tracts of glutamines. Although polyQ diseases are 
rare disorders, this group includes nine progressive, severe and fatal disorders, which in general begin 
in adulthood and progress over 10 to 30 years, normally implicating the full time patient care by a 
member of the family. Thus, the economic and social impact of these neurodegenerative diseases is 
quite significant. This has led several researchers worldwide to investigate the pathogenesis 
mechanism and therapeutic strategies for polyQ diseases. In this study, hypothesis-based and 
hypothesis-free approaches were used in order to study candidate therapeutic compounds for 
Machado-Joseph Disease (MJD) using the CMVMJD135 mouse model.  
 Valproic acid (VPA) is an FDA-approved compound which showed therapeutic benefits in other 
neurodegenerative diseases, and also in C.elegans and Drosophila models of MJD, suggesting that it 
could be a promising compound for treatment of this disorder. Chronic pre-symptomatic VPA treatment 
(200mg/kg) led to mild improvements in balance and motor coordination in the CMVMJD135 mouse 
model, not changing the aggregation of mutant ataxin-3 (ATXN3) in affected brain regions. Although not 
a positive result, this pre-clinical trial still leaves an open window for other VPA dosages to be tested 
pre-clinically before exclusion of the compound’s therapeutic potential. 
 In an unbiased screening of FDA/EMA-approved small molecules, citalopram was identified as 
a promising compound for suppression of neurological dysfunction and ATXN3 aggregation in 
C.elegans. Citalopram is an FDA-approved antidepressant, widely prescribed for clinical use, and 
therefore a good treatment opportunity. Chronic pre-symptomatic citalopram treatment at 8mg/kg led 
to significant balance and motor coordination improvement, rescued diminished body weight loss, 
suppressed ATXN3 nuclear inclusions in affected brain regions, reduced neuronal loss and astrogliosis 
in the CMVMJD135 mouse model. Chronic pre-symptomatic citalopram treatment with a higher dosage 
(13mg/kg) produced only mild effects at the behavior level and in ATXN3 aggregation phenotypes. This 
study also led to the characterization of new and relevant pathological features of the CMVMJD135 
mouse model.  
 x 
 
 Chronic citalopram post-symptomatic treatment (at an 8mg/kg dosage) in a group of 
CMVMJD135 mice presenting higher severity of disease led to an improvement of some the motor 
symptoms, albeit much less marked than for pre-symptomatic treatment. The mechanisms of action of 
citalopram in MJD were explored by expression analysis of candidate pathways but they remain to be 
clarified.  
 In summary, this work suggests activation of serotonergic signaling as a relevant mechanism 
for protection against MJD pathogenesis, and suggests citalopram as a promising compound to be 
tested in human clinical trials in MJD.   
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Resumo 
“Ensaios pré-clínicos para a Doença de Machado-Joseph: Estratégias terapêuticas 
baseadas em hipótese e independentes de hipótese” 
As doenças de poliglutaminas (poliQ) são uma família de doenças neurodegenerativas 
caracterizadas pela expansão de uma repetição do trinucleótido CAG em genes específicos. Esta 
expansão leva à produção de proteínas patogénicas contendo sequências altamente expandidas de 
glutaminas. Embora as doenças poliQ sejam doenças raras, este grupo inclui nove doenças 
progressivas, graves e fatais, que em geral começam na idade adulta e progridem ao longo de 10 a 30 
anos, normalmente implicando a assistência ao paciente em tempo integral por um membro da 
família. Assim, o impacto económico e social destas doenças neurodegenerativas é bastante 
significativo. Isto tem levado diversos investigadores por todo o mundo a investigar o mecanismo de 
patogénese e estratégias terapêuticas para doenças poliQ. Neste estudo, foram utilizadas abordagens 
independentes de hipótese e baseadas em hipótese no estudo de compostos terapêuticos candidatos 
para a DMJ, utilizando o modelo de ratinho CMVMJD135. 
O ácido valpróico (VPA) é um composto aprovado pela FDA, que mostrou benefícios 
terapêuticos noutras doenças neurodegenerativas, e também em modelos de C.elegans e Drosophila 
melanogaster da DMJ, sugerindo que pode ser um composto promissor para o tratamento desta 
doença. O tratamento crónico pré-sintomático com VPA (200mg/kg) levou a melhorias moderadas no 
equilíbrio e coordenação motora no modelo de ratinho CMVMJD135, não alterando a agregação da 
ataxina-3 (ATXN3) mutante em regiões afetadas do cérebro. Embora não seja um resultado muito 
positivo, este ensaio pré-clínico ainda deixa em aberto a possibilidade de outras dosagens de VPA 
serem testadas pré-clinicamente antes da exclusão do potencial terapêutico deste composto. 
Num rastreio não dirigido de pequenas moléculas aprovadas pela FDA/EMA, o citalopram foi 
identificado como um composto promissor para a supressão da disfunção neurológica e da agregação 
de ATXN3 em C. elegans. O citalopram é um antidepressivo aprovado pela FDA, amplamente prescrito 
para uso clínico e, portanto, um bom candidato para tratamento. O tratamento crónico pré-sintomático 
com citalopram na dose de 8 mg/kg levou a uma melhoria bastante significativa da coordenação 
motora, resgatou a diminuição de peso corporal, suprimiu as inclusões nucleares de ATXN3 em 
regiões cerebrais afetadas, reduziu a perda neuronal e a astrogliose no ratinho CMVMJD135. O 
tratamento crónico pré-sintomático com citalopram numa dose mais elevada (13 mg/kg) produziu 
apenas efeitos moderados ao nível do fenótipo de comportamento e na agregação da ATXN3. Este 
 xii 
 
estudo também conduziu à caracterização de novas características patológicas relevantes do modelo 
de ratinho CMVMJD135. 
O tratamento crónico pós-sintomático com citalopram na dose de 8mg/kg num grupo de 
ratinhos CMVMJD135 que apresentavam maior gravidade da doença levou à melhoria de alguns dos 
sintomas motores, embora muito menos marcada do que para o tratamento pré-sintomático. Os 
mecanismos de ação do citalopram na DMJ foram também explorados através da análise da 
expressão de genes de vias candidatas, precisando ainda de serem mais amplamente esclarecidos. 
Em resumo, este trabalho sugere a activação da sinalização serotonérgica como um 
mecanismo importante para a protecção contra a patogénese da DMJ, e sugere o citalopram como um 
composto promissor para ser testado em ensaios clínicos em humanos. 
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1. Neurodegenerative diseases 
 Over the last several decades, life expectancy in industrialized countries has been rising causing 
a higher prevalence of neurodegenerative diseases. These diseases are hereditary or sporadic age-
related disorders that are a growing health problem, exerting a huge emotional burden of both affected 
patients and society as a whole. They are often associated with atrophy of the affected central and 
peripheral structures of the nervous system responsible for affecting memory, cognition, abstract 
thinking, emotional feelings, skilled movements and other abilities1. There is no effective and lasting 
treatment for the majority of these disorders, therefore there is an urgent need for novel therapies to 
either halt and/or reverse their progression. This group of disorders includes Alzheimer’s disease (AD), 
Parkinson’s disease (PD), Huntington’s disease (HD), and other polyglutamine-related disorders (PolyQ) 
including several forms of Spinocerebellar Ataxias (SCA’s), Amyotrophic Lateral Sclerosis (ALS) and 
transmissible spongiform encephalopathies (TSE)2,3. This complex group of pathologies are defined by 
two major hallmarks: i) the presence of altered processing and accumulation of misfolded proteins in 
inclusions and/or plaques (either sporadic or due to mutations in their respective disease-causing 
genes) and ii) the presence of neuronal specificity and vulnerability which defines the characteristic 
clinical symptoms associated with each disease (Figure 1). Since the past years, emerging studies and 
efforts in vitro and in vivo have been focusing in understanding the pathogenic mechanisms that lead to 
neuronal degeneration; however, despite the current knowledge, these molecular pathways are still 
unclear. Meanwhile, several therapeutic strategies based on the putative mechanisms hypothesis-
based and free of hypothesis are being studied, although with no effective treatment so far.  
This dissertation will focus on the development of therapeutic strategies for Machado-Joseph 
disease (MJD) or Spinocerebelar ataxia type 3 (SCA3) using two different FDA-approved compounds 
and the study of their mechanism of action on the context of this disease. 
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Figure 1. Overview of the anatomical location and characteristic macro and microscopic changes of the neurodegenerative 
diseases with evidence for histopathological aggregated proteins. Adapted from3. 
 
1.1 Polyglutamine diseases 
 PolyQ diseases are a large group of inherited neurodegenerative disorders characterized by the 
pathological expansion of cytosine-adenine-guanine (CAG) repeats in the coding sequences of distinct 
genes. PolyQ diseases include Machado-Joseph disease (MJD/SCA3)4, Huntington’s Disease (HD)5, 
spinal and bulbar muscular atrophy (SBMA)6, dentatorubral-pallidoluysian atrophy (DRPLA)7,8, and other 
spinocerebellar ataxias (SCA1, 2, 7, and 17)9–15 (Table 1). The frequency of polyQ diseases averages 1–
10 cases per 100.000 people16. Of these, HD and SCA3 have the highest prevalence worldwide17. All 
are progressive, ultimately fatal disorders which typically begin in mild-life and progress over 10 to 30 
years. PolyQ diseases are dominantly inherited in an autosomal manner, with the exception of SBMA, 
which is X-linked, and they only manifest when the glutamine expansion exceeds a certain threshold18. 
Above the pathogenic threshold the CAG tracts are unstable across generations, and they can expand 
or contract, depending partially on the transmitter gender19. Frequently, but not always, maternal 
meioses tend to lead to contractions, while paternal transmissions tend to lead to expansions. This 
intergenerational instability causes earlier age-at-onset and increased severity of the symptoms in the 
successive generations, a phenomenon known as anticipation20–22. In addition to meiotic instability, 
tissue-specific mosaicism has been observed in some polyQ diseases resulting in cell populations, 
carrying different CAG repeat lengths, within or between tissues. CAG repeat instability is behind some 
features of polyQ disorders and may also contribute to their pathogenic mechanism. 
 At the molecular level, the disease-causing proteins are ubiquitously expressed in the Central 
Nervous System (CNS) and the peripheral tissues; however, each polyQ disease is characterized by the 
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loss of specific neuronal populations resulting in typical patterns of neurodegeneration and clinical 
symptoms23. A common feature of all polyQ disorders is the accumulation of the mutant protein in the 
cytoplasm and mostly in the nucleus of the neuronal cells, forming neuronal intranuclear inclusions 
(NIIs), which are found in patient brains and transgenic models of the disorders24. These inclusions are 
a common hallmark of all these diseases, however it is still controversial if they are pathogenic or not25–
28. Several studies have explored which type of structure formed by the expanded polyQ is responsible 
for the disease. The theory that a toxic structure of the expanded polyQ causes the disease explains its 
length-dependence (specific for each polyQ disease) and implies a common pathogenic mechanism in 
these diseases. Nevertheless, it is not enough to clarify the selective toxicity pattern of these causative 
proteins, that leads to their different neuropathologic and clinical manifestations29. 
 
Table1. PolyQ diseases, causative genes, proteins, brain regions affected and main clinical features. Adapted from29–32. 
PolyQ 
Disease 
Locus Protein 
Protein 
localization 
CAG repeat size 
Brain regions Clinical Features 
Normal Pathological 
HD 4p16.3 Huntingtin Cytoplasmic 6–35 36–12 
Striatum and 
cerebral cortex 
Chorea, dystonia, dementia 
MJD/SCA3 14q24-q31 Ataxin-3 
Nuclear and 
cytoplasmic 
12–40 62–86 
Cerebellum, 
brainstem and 
spinal cord  
Ataxia, spasticity, 
polyneuropathy, diplopia, 
dystonia. 
SBMA Xq11-q12 
Androgen 
receptor 
Nuclear and 
cytoplasmic 
6–36 38–62 
Anterior horn of 
spinal cord, bulbar 
neurons and 
dorsal root ganglia 
Weakness, bulbar symptom, 
fasciculations, tremors, 
gynecomastia 
DRLPA 12p13 Atrophin-1 Cytoplasmic 3–38 49–88 
Pallidum, 
subthalamic, 
dentate nuclei and 
red nucleus 
Myoclonus epilepsy, ataxia, 
chorea, dementia. 
SCA1 6p23 Ataxin-1 Nuclear 6–39 41–83 
Cerebellum and 
brainstem 
Ataxia, bulbar symptom, 
spasticity, polyneuropathy, 
cognitive impairment. 
SCA2 12q24 Ataxin-2 
 
Nuclear and 
cytoplasmic 
14–32 34–77 
Cerebellum, pons, 
medulla oblongata 
and spinal cord 
Ataxia, slow saccades, 
ataxia, polyneuropathy, 
parkinsonism 
SCA6 19p13 CACNA1A Cytoplasmic 4–18 21–30 
Cerebellum and 
brainstem 
Ataxia, dysarthria, down-
beating nystagmus. 
SCA7 3p21-p12 Ataxin-7 Nuclear 7–18 38–200 
Cerebellum and 
brainstem 
Ataxia, retinal degeneration, 
ophthalmoplegia. 
SCA17 6q27 TBP Nuclear 25–43 45–63 
Cerebrum, 
cerebellum and 
brainstem 
Ataxia, dementia, psychosis, 
seizures, extrapyramidal 
signs 
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1.1.1 The modulatory role of protein context of polyQ diseases 
 Since the polyQ-associated proteins share no sequence homology, except the presence of an 
expanded polyQ tract, it is generally accepted that this is the trigger for the development of 
neurodegeneration. Several studies suggests that the polyQ tract confers a toxic gain of function to the 
proteins, associated with protein misfolding and aggregation; however, the identity of the toxic species 
(i.e., misfolded monomers, soluble oligomers, and/or insoluble fibrils) remains unclear18,23,33–35. 
Furthermore, the protein context also seems to influence the initiation and progression rate of the 
polyQ diseases. PolyQ-mediated neuropathology is markedly specific, at least at early stages of the 
diseases, affecting well-defined subsets of cells, despite the ubiquous expression of the proteins. The 
context of the polyQ proteins and their modifying or interacting proteins, which may function or be 
expressed in a cell-specific manner, may determine the selective neuronal loss seen in distinct brain 
regions in the different polyQ diseases36.  
 The first example of the polyQ tract as a trigger of neurotoxicity per se, was the generation of a 
transgenic mouse expressing an expanded CAG tract into a different genetic context (HPRT locus) 
leading to several common features of the human polyQ diseases. This study proved that CAG polyQ 
repeats do not need to reside in one of the typical repeat disorder genes to have neurotoxic effects34. 
On the other hand, in the absence of any additional protein context, the simple expression of a polyQ 
tract is also toxic, as demonstrated in cell culture, Mus musculus, Drosophila melanogaster and 
Caenorhabditis elegans (C.elegans) studies37–40. Concerning protein context, one example was the 
insertion of a polyQ tract of the human HD gene into the mouse huntingtin gene (Hdh). Mice with an 
insertion of 90-111 repeats, which is pathologic in humans, in the Hdh gene, revealed no neurological 
symptoms, with only mild functional alterations reported for 72 and 80 polyQ repeats in other models. 
A more severe neurological phenotype was only observed in Hdh150Q mice, although its phenotype 
was not as severe as in humans, even with similar polyQ length and expression levels41–45. Therefore, it 
is notable that a pathological number of glutamines in the human protein is not so deleterious in the 
context of the mouse protein. Additionally, the same CAG repeat size in human patients causes 
different ages at onset for different polyQ diseases, showing that the protein context play an important 
role in these diseases46. Another interesting example of toxicity modulation determined by protein 
context is in the SCA1 study, where Emamian and colleagues replaced one single aminoacid (aa) in 
ataxin-1 (ATXN1) out of its polyQ tract and observed a considerable reduction of the ability of mutant 
ATXN1 to cause disease in vivo47.  
CHAPTER 1 
 
 
 
7 
 It is unquestionable that protein context plays an important role in pathogenesis, and despite the 
existence of common mechanism among polyQ diseases, the striking differences in clinical and 
pathological features also suggest disease-specific effects. 
 
1.2 Pathogenic mechanisms of neurodegeneration in polyQ diseases 
 In the last years, a growing number of studies has emerged with possible pathogenic 
mechanisms of polyQ diseases, and although the exact mechanisms are still unclear, several 
hypothesis and relevant clues are contributing to new insights in these diseases. PolyQ diseases most 
likely share similar pathogenic mechanisms and main characteristics, making them variations of a 
common polyQ neurological disorder. First, the onset of symptoms occurs in adulthood and progresses 
for decades. This suggest that there is something changing with aging that allows the toxic gain of 
function that is associated with polyQ expansion polypeptides to reveal itself. The accumulation of 
mutant proteins inside neurons, causing their dysfunction and eventually death, is another unifying 
feature of these disorders. Figure 2 summarizes the pathogenic mechanisms that have been suggested 
for polyQ diseases and the possible therapeutic strategies directed at these mechanisms (discussed in 
the next section).  
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Figure 2. PolyQ pathogenesis and common possible therapeutic approaches. The disease proteins could be located in 
cytoplasm and/or in the nucleus, although, as a simplification, here they are shown originating in the cytoplasm. 
Pathogenic pathways (blue arrows); possible therapeutic approaches (red arrows). The pathogenic process generally starts 
with the synthesis of a protein with an expanded polyQ tract (a). This polyQ tract changes the native protein conformation 
dynamics, modulated by the presence of molecular chaperones (b). A fraction of abnormally folded proteins is addressed 
for lysosomal-dependent proteolysis (c) and the remaining fraction of the abnormal proteins is ubiquitinated (Ub) and 
subjected to proteasome degradation (d). Cleavage of the abnormal folded protein produces an N-terminal fragment that 
favors the aggregation process by a seeding effect (e). The mutant protein (whole or cleaved) could shift from a monomeric  
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(Figure 2.) (cont.) random coil or β-sheet into oligomeric β-sheets and ultimately into insoluble aggregates (amyloid 
fibrils) (f). These species couldrepresent a protective mechanism to reduce the toxicity of the intermediate aggregates, or 
might contribute to pathology through abnormal interactions with cellular proteins (g). The intermediate aggregates inhibit 
proteasome processing (h). On the other hand, the monomers and oligomers directly activate caspases or disrupt 
mitochondrial and ER functions, leading to indirect activation of caspases (i). Proto-aggregates translocate into the nucleus 
(j) and recruit specific nuclear factors, co-activators and co-repressors (k) inhibiting their normal activities and resulting in 
transcriptional dysregulation (l). This pathogenic mechanisms suggests several potential therapeutic approaches, including: 
(1) inhibition of mutant protein expression at the level of transcription and translation; (2) improving the chaperone function; 
(3) proteolysis inhibition; (4) aggregation inhibition; (5) mitochondrial stabilization and protection; (6) caspase inhibition; (7) 
inhibition of histone deacetylation activity and (8) transcriptional modulation. Adapted from 48. 
 
1.2.1 Misfolding and aggregation of mutant polyQ proteins - proteostasis disruption 
 It is hypothesized that polyQ diseases are the consequence of a toxic gain of function that occurs 
at the protein level. The role of aggregation in the pathogenesis of these diseases is still controversial. It 
is not entirely understood whether the toxicity of the expanded polyQ proteins results from the presence 
of visible aggregates or from smaller intermediary species during aggregation process and the question 
remains: are the inclusions toxic or protective to the cells?  
 NIIs were first described in an animal model of HD49 and the major theory was that they are 
pathogenic as they may contain and/or sequester several proteins such as ubiquitin (Ub), chaperones, 
proteasome subunits as well as transcription activators and/or co-activators50–53 interfering with their 
normal function54–56 and representing the end products of the upstream toxic event. For example, in the 
case of SBMA, Apostolinas and colleagues described that neuronal death was associated with NIIs 
specifically restricted to the affected motor neurons of the spinal cord and brainstem57. Later, Poletti 
and colleagues described that in fact, motor neuronal cell death is not correlated with aggregate 
fomation58. Additionally, several other studies have suggested that the NIIs could have a protective role 
showing the inconsistency between inclusion formation and cell death28,59. Indeed, in several polyQ 
diseases such as HD, SCA7 and SCA17, NIIs were detected in spared regions26,27,60,61, whereas in SCA1, 
SCA2, SCA3 and DRPLA, NIIs were absent in Purkinje cells, which are key targets of 
neurodegeneration in some of these polyQ diseases26,62. Even in cellular and animal model studies, it 
was demonstrated the presence of cell death when fewer or no NIIs was observed28,63–65. For instance, in 
rat primary striatal neurons, the NIIs were not a pre-requisite for cell death but mutant huntingtin (htt) 
had to be present in the nucleus to induce apoptosis64. In case of MJD, two transgenic mouse model 
were described showing a neurological phenotype with few and smaller NIIs which appeared later in 
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life66 or even no inclusions67. On the contrary, a knock-in MJD mouse model was recently described with 
prominent aggregate pathology without evident neurological phenotype68. 
 Despite this scientific controversy in the field concerning NIIs, it is undeniable that protein 
aggregates may be harmful for neurons by affecting their proteostasis. The cellular homeostasis 
disturbance hypothesis suggests that the sequestration of chaperones and proteasome subunits into 
polyQ aggregates could result in an increased protein misfolding and reduced clearance of other crucial 
cellular proteins, leading to a homeostatic imbalance69–71. This suggests the involvement of the ubiquitin-
proteasome system (UPS) degradation pathway in these diseases, and also the activation of the heat 
shock response (HSR) machinery in order to either refold or degrade the mutant polyQ proteins. In fact, 
heat shock proteins (HSPs) play an important role in the cell stress response induced by the presence 
of polyQ expansion proteins. These proteins are able to move freely and only transiently associate with 
the agregates72. Their overexpression in cellular and animal models of polyQ diseases has been 
demonstrated to modulate polyQ toxicity and/or disease manifestation73–75. Moreover, the proteasome 
appears to be permanently recruited into polyQ aggregates and it is functionally impaired by aggregated 
polyQ poteins, interfering with the degradation of other proteins76,77. Proteasome inhibition might also 
increase the intracellular load of misfolded, oxidized, or otherwise damaged proteins, leading to 
neuronal toxicity. Several reports have shown that reducing or inhibiting proteasomal activity is 
sufficient to induce neuronal death78–80. 
 A recent work also proposed that aggregate-associated chaperone competition leads to both 
gain- and loss-of-function phenotypes since chaperones become functionally depleted from multiple 
clients, leading to the decline of multiple cellular processes81. Altogether, these events may lead to a 
stressful cellular milieu that will finally culminate in neuronal dysfunction and eventually neuronal 
death.  
 
1.2.2. Post-translational modifications of mutant polyQ proteins 
 The pathogenic mechanism of several polyQ disorders including HD, SBMA and SCA3, appears 
linked to proteolytic cleavage resulting in production of toxic polyQ-containing fragments82–86, which may 
be required for the beginning of the aggregation process and for neuronal harmful effects. It is 
described that these fragments may also more easily translocate into the nucleus, where they can exert 
toxic effects87–89. Several studies have shown in vitro cleavage of several polyQ proteins, especially by 
caspases and calpains. Caspase-mediated cleavage sites were identified or predicted in htt, atrophin-1, 
ataxin-3 (ATXN3) and androgen receptor (AR)90–93. As a consequence, the resulting fragments could (i) 
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have an enhanced toxic effect37,85,94, (ii) more easily enter the nucleus95,96 and/or (iii) more rapidly 
aggregate95,97. In fact, truncated proteins with polyQ expansions appear to be more prone than full-length 
proteins to form inclusions and/or cause cell death by apoptosis54,85,98,99. However, in a C.elegans model 
of MJD both full-length and truncated forms of ATXN3, with different Q-lengths, results in a consistent 
pattern of neuronal cell-type-specific aggregation, being the truncated protein more aggregation-prone100. 
Extensive research supports a model in which proteolysis of polyQ expanded proteins, formation of 
protein aggregates and subsequent sequestration of crucial cell proteins (including normal polyQ 
proteins) is required for disease onset. However, proteolytic cleavage may not be an essential step in 
the onset of pathogenesis of all polyQ diseases, rather in accelerating disease progression. 
 In addition to proteolytic cleavage, other post-translational modifications of mutant polyQ 
proteins, such as phosphorylation and sumoylation, have been shown to play a role in pathogenesis of 
polyQ diseases. In case of MJD, for instance, ATXN3 has been described to undergo phosphorylation at 
S256 by glycogen synthase kinase 3β (GSK3β) causing a reduction in mutant ATXN3 aggregation in 
vitro101. CK2-dependent phosphorylation of ATXN3 at S236 and S340/S352 decreased the presence of 
NIIs and controlled the nuclear translocation of ATXN3 providing a reasonable therapeutic strategy for 
MJD102. In contrast, phosphorylation of mutant ATXN1 at S776 is related with the increased formation of 
aggregates and neurodegeneration103. Collected, these observations suggest that post-translational 
modifications play an important role in the expression and/or progression of the disease, supporting  
the  idea  that  the  protein  context  in  which  the  polyQ expansion is located influences the pathology 
of these diseases. 
 
1.2.3 Mitochondrial dysfunction and oxidative stress 
 Neurons have very high energy demands and are very dependent on oxidative energy 
metabolism. This points to the impairment of mitochondrial function and impaired energy metabolism 
as key events of neurodegenerative diseases104,105, including polyQ diseases, leading to cell death. Most 
insights were gained in the field of HD106,107 but several studies also highlight the role of mitochondria in 
the pathology of SCA’s108–110. In polyQ diseases, the process of mitochondrial dysfunction is 
accompanied by impaired respiration, stress induced mitochondrial depolarization, increased reactive 
oxygen species (ROS) production leading to oxidative damage, and abnormal  energy metabolism111,112. A 
mild or gradual energy disturbance may also lead to the release of pro-apoptotic factors, mainly 
cytochrome C from the mitochondria, and an apoptotic cascade being initiated. For instance, in SCA3 
and SCA7 it was shown that the mRNA and protein levels of Bcl-xL were down-regulated in cerebellar 
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neurons when polyQ expanded ATXN3 and ataxin-7 (ATXN7), respectively, were overexpressed, causing 
activation of caspase-3 and caspase-9, two main caspases involved in mitochondrial induced 
apoptosis108,113. Then, a direct interaction was shown between ATXN3 and Bcl-xL suggesting that mutant 
ATXN3 promotes the interaction between Bcl-xL and Bax, activating the mitochondrial apoptotic 
pathway108. 
 Excessive Ca2+ accumulation has also damaging effects, leading to the oxidative damage and 
activating an apoptotic cascade. In addition, but also important, non-excitable cells, such as astrocytes 
and microglia, are likewise strongly dependent on the intracellular Ca2+  concentration and signaling to 
maintain their normal function114.  
 Besides changes in mitochondrial bioenergetics and transcription of important proteins 
associated with mitochondrial function and cell death, modifications in mitochondria shape and motility 
have been observed in HD models115. Both retrograde and anterograde mitochondrial transport along 
axons were described to be impaired by mutant htt in cultured cortical neurons of mouse and rat 
models116,117. Therefore, a large body of evidence suggested that mitochondrial impairment, including 
fission/fusion dynamics, is also a common feature in the pathogenesis of polyQ diseases. 
 
1.2.4 Role of nuclear localization of mutant polyQ proteins  
 The presence of polyQ proteins in the nucleus of cells has been shown to play an important role 
in the disease pathogenesis, disrupting nuclear organization and function118 and/or affecting gene 
expression23,119,120. Yang and colleagues, demonstrated that in mammalian cells, polyQ aggregates were 
highly toxic when localized in the nucleus and less so in the cytoplasm121. Several studies showed that 
the nuclear accumulation of mutant proteins and inclusions is predominant in HD, SCA1, 3 and 7, 
DRPLA and SBMA patients22; however, inclusions in the cytoplasm, namely in axons, have also been 
found in affected brain regions of SCA2, SCA3 and HD patients122–125. In disease models, the presence of 
polyQ aggregates in the nucleus seems to be associated with more severe phenotypes. In the case of 
MJD, studies in mice showed that mutant ATXN3 nuclear localization is required for the disease 
manifestation, whereas the artificially induced export of ATXN3 out of the nucleus prevents the 
manifestation of the phenotype126.  
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1.2.5 Transcriptional dysregulation in polyQ diseases 
 Extensive evidence has reinforced the notion that major alterations in gene expression occur in 
polyQ diseases127. Interestingly, both htt, atrophin-1, ATXN1, ATXN3 and ATXN7 are capable of 
modulating transcription by related or unrelated mechanisms52,53,128–131. Three main mechanisms have 
been suggested to cause the polyQ-dependent transcription regulation/modulation: (i) the recruitment 
of transcription-related factors (TFs) in the NIIs, (ii) the direct inhibition of acetyltransferase activity of 
transcription modulators and/or (iii) the direct repression of the transcriptional machinery. 
 The mutant polyQ proteins interact with several cellular proteins and may sequester them into 
cytoplasmic or nuclear aggregates contributing to cellular dysfunction74,132. In addition to proteasome 
subunits and molecular chaperones, poly-Q aggregates co-localize with crucial cellular components 
such as the TFs cyclic AMP response element-binding protein (CREB), CREB-binding Protein (CBP), 
TATA-Binding Protein (TBP), Specificity Protein 1 (SP1) and TAFII130 (which encodes a TBP-Associated 
Factor). The sequestration of TFs together with other relevant cellular components would be expected 
to promote profound effects on cellular homeostasis. Overexpression of some of these TFs was shown 
to overcome polyQ toxicity, both in vitro in cellular models of MJD, SBMA and HD53,133, as well as in vivo 
of a Drosophila polyQ model134. Additionally, the transcriptional activator CREB, along with its activator 
CBP, has been strongly associated in expanded polyQ-induced gene repression51. CBP is an essential 
mediator of survival signals in neurons. It has a histone acetyltransferase (HAT) activity, which is 
important for allowing TFs to access to DNA. In the presence of mutant htt or atrophin-1, CBP is 
sequestered into aggregates52. The recruitment of CBP into NIIs or its interaction with mutant polyQ 
proteins are also described in SBMA, SCA3, and SCA7128,133,135. In SCA1, CBP is not irreversibly 
sequestered into NIIs but it is quickly exchanged. Although CBP has a short residence time within the 
NIIs, this may be enough to disrupt its normal function in sustaining cellular homeostasis136. It seems 
that the disruption of CREB/CBP-mediated gene expression may be a common mechanism of 
neurodegeneration in polyQ diseases. Contradicting this model, it was described that in the R6/2 HD 
mouse model, CREB-mediated transcription was increased137 and CBP was not depleted in knock-in HD 
mouse brains138. TBP was also found to co-localize with htt, ataxin-2 (ATXN2) , ATXN3, and atrophin-1 
inclusions in human brains139–141, but like for CBP, the levels of TBP were not reduced in HD mouse 
model138. 
 SP1 contains a glutamine-rich activation domain, which is responsible for regulation of the 
transcriptional machinery of transcription factor II D (TFIID), a protein complex composed of TBP and 
multiple TBP-associated factors (TAFIIs), including TAFII130142. The role of SP1 in polyQ toxicity is not 
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completely clear. TAFII30 itself also interacts with mutant htt and it was shown to co-localize with 
atrophin-1 and ATXN353,143. Another TAF, TAFII130, was described to be sequestered in ATXN7 NIIs144. 
Alternatively, polyQ proteins might exert their toxic effect through direct inhibition of HATs or 
transcription modulators, causing a reduction in histone acetylation and consequently, gene 
transcription activation. Two TFs that regulate gene expression through their acetylase activity are CBP 
and PCAF145. A mutant truncated fragment of htt has been shown to inhibit transcription, through the 
repression of the HAT activity of CBP/p300/PCAF transcriptional co-activator146. Wild-type (WT) ATXN3 
has been described to be a double co-repressor of transcription by the interaction with CBP, p300 and 
PCAF, inhibiting CREB-dependent gene transcription through its C-terminal and through its N-terminal 
interaction with histones128. 
 Relevant studies from Barco and colleagues concluded that the combination of histone 
acetylation and gene expression screenings demonstrates that histone deacetylation and transcriptional 
dysregulation are two early, largely independent, manifestations of polyQ diseases, and they propose 
that additional epigenetic marks or mechanisms are required to explain the full range of transcriptional 
alterations associated with these disorders147. On the other hand, microarray studies in polyQ diseases 
are crucial to understand the gene expression changes along the disease progression. For instance, in 
R6/2 HD mice a considerable number of genes have an altered pattern of expression but this pattern 
shows little sign of regional specificity148. Comparison of gene expression profiles of HD and SBMA 
mouse models revealed a considerable overlap in the genes showing altered gene expression. Such 
context-independent genes suggest the existence of pathways that are common among the different 
polyQ diseases149. Recently, several efforts are being performed in transcriptome profiling, providing 
valuable information regarding possible causes and consequences of the onset and progression of 
these diseases150–152. 
 Besides the analysis of the indirect consequences of the polyQ expression in cell or animal 
models, the connection of mutant polyQ proteins to the direct repression of the transcriptional 
machinery as cause of neurodegeneration remains to be fully understood. However, either by 
sequestration of TFs or by aberrant interactions with other transcription regulators, the transcriptional 
dysregulation seems to be a common hallmark of the polyQ diseases, which highlights the importance 
of studying this phenomenon as a potential therapeutic target.   
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1.2.6 Defects in Axonal transport 
 Mutant polyQ proteins can also affect cytoplasmic processes, such as axonal transport, which 
have a crucial role in building and maintaining the functional architecture of neurons. The precise 
mechanism is not completely clear but it has been suggested that some of the disease-causing proteins 
might have normal functions in the axonal transport system and cause axonal blockages when 
mutated, and/or that polyQ aggregates might physically block transport within the narrow axonal 
processes153–158.  
 It was described that htt is both anterogradely and retrogradely transported in rat sciatic nerve  
axons159 and studies with Drosophila overexpressing mutant htt and ATXN3 constructs, showed an 
axonal accumulation of vesicles154,160 that was comparable to that seen in axonal transport defects in 
kinesin- and dynein- mutants161. A few years ago, Li and colleagues suggested that htt interacted with 
motor proteins (namely a subunit of dynactin) via Huntingtin-associated protein 1 (HAP1)162. Studies in 
transgenic HD mouse models and human patient brains revealed evidence for axonal transport 
dysfunction in HD pathogenesis157,163–166. Additionally, a few studies described that HD dystrophic striatal 
and corticostriatal neurites exhibited characteristics of blocked axons, specifically, accumulation of 
vesicles and organelles in swollen axonal projections and termini associated with htt aggregates167,168. 
The presence of htt accumulations has also been demonstrated in axons of striatal projection neurons 
in R6/2 and knock-in mouse models of HD and in human patient brains165. ATXN3 was also shown to 
interact with dynein intermediate chain 2 (required for agresome formation and transport of misfolded 
proteins)169 and to be a microtubule associated protein170, enhancing the idea that ATXN3 plays a critical 
role in the cytoskeleton; this was later proven to be true also in neurons171. However, evidence is still 
lacking for defects in axonal transport in MJD.  
 
1.2.7 Apoptosis in polyQ diseases  
 The mechanism of cell death in polyQ diseases is likely very complex, and it seems to appear 
lately in the polyQ disease process. Much of the attention in the cell death field has been focused in the 
major cell death pathway - apoptosis, which is often used as a synonymous of programmed cell death. 
Additional programmed cell death pathways studies are gradually changing this notion. Activation of 
cell death pathways, even without resulting in cell death could be harmful to the neurons. The 
persistent activation of the cell death by the interaction of mutant polyQ proteins with their regulators or 
of stress responses, such as UPR and/or autophagy, together with the presence of mitochondrial 
abnormalities, transcriptional dysregulation, proteasome impairment and defects in axonal transport 
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may potentiate apoptosis phenomena in polyQ diseases. Several proteins usually involved in apoptosis 
are sequestered, redistributed or activated by expanded polyQ proteins. Activated caspases, which are 
a usual feature of apoptotic cell death108,172–175, can also be recruited in inclusions176. However, the 
morphological features of apoptosis do not always seem to accompany the neuronal cell death in polyQ 
disease models. Part of the struggle in resolving this issue lies in the fact that many model systems 
display polyQ toxicity on a time scale of days, whereas the human disease develops over decades.  
 In cellular models of polyQ toxicity, there is a divergent and contradictory amount of results 
concerning the relevance of apoptosis. This is given by the fact that several studies use different polyQ 
substrates to model toxicity in many types of cells64,94,99,176–182, and different cell types vary in the specific 
death modulators (e.g. Bcl-2 family members) and caspases (both initiators and effectors) that they 
express. Some researchers have described that polyQ toxicity is mediated, at least in part, by activated 
caspases64,181, whereas others have demonstrated that caspase inhibitors do not block death but only 
modify aggregate formation or the time course of death180,182. Some studies have shown morphologic 
features consistent with apoptosis37,64, whereas others shown cell death that contrasts with usual 
apoptosis178,182. Overall, these results seem to suggest that expanded polyQ proteins can cause neuronal 
cell death through a caspase-dependent mechanism that exhibits some features of apoptosis. 
 In animal models, the studies also show some divergence to answer these questions. In polyQ 
Drosophila models, the anti-apoptotic P35 gene has a slight or no ability to block degeneration183,184, 
showing that cell death mediated by expanded polyQ in flies is not only apoptotic. On the other hand, 
neuronal cell death in a C. elegans model of HD could comprise apoptotic pathways, since death 
required Ced3 caspase activity185. Studies in mouse models also present some variability due to 
transgenic approach and/or transgene promoter used in each study. An HD mouse model expressing 
full length htt showed striatal degeneration along with positive TUNEL staining suggestive of apoptosis, 
however with no morphological changes typical of this type of cell death186. Another example is the YAC 
mouse model expressing full length htt which showed degenerative changes in the striatum consistent 
with apoptosis by electron microscopic approach187. However, the selective degeneration of striatal 
neurons was seen in transgenic mice expressing full length, but not in truncated htt. In case of MJD 
there is also some disagreement concerning the presence of cell death between different cells lines 
and models. Some studies proposed that the expanded ATXN3 induces apoptosis in cultured cells37, 
while in vivo some models presented apoptosis179 and others did not67. Despite the controversy between 
different models in this field, it is undoubtedly important to study and identify which of the many 
molecules are implicated in apoptosis are contributing to neuronal dysfunction and cell death in polyQ 
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diseases. Furthermore, it is possible that other non-apoptotic cell death coexist with apoptosis in the 
brains of affected patients188–190. 
 
1.3 Therapeutic strategies for polyQ diseases 
 Despite great progress in elucidating the pathomechanisms underlying polyQ diseases, an 
effective treatment is still lacking. The current strategies towards development of therapies for these 
diseases could be divided in hypothesis-based and hypothesis-free approaches. The most common are 
those based on hypothetic pathological mechanisms which can also be divided in two categories: i) 
those targeting the expression, processing or conformation of the polyQ protein and ii) those preventing 
the toxic effects of the polyQ protein, such as mitochondrial dysfunction and oxidative stress, 
transcriptional dysregulation, UPS impairment, excitotoxicity, or activation of apoptotic pathways191. On 
the other hand, hypothesis-free approaches are gaining relevance, mostly through the analysis of large 
libraries of compounds with high throughput methodologies. This approach often reveals interesting 
disease-modifying agents, contributing not only to provide new avenues for defining the 
pathomechanisms of the disease, but also for a direct pathway to therapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Therapeutic strategy workflow for polyQ diseases. 
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1.3.1 Hypothesis-based approaches 
 
1.3.1.1 Gene silencing 
  The most straightforward therapeutic approach for polyQ diseases may be decreasing the 
expression levels of the mutant protein and consequently prevent the downstream deleterious events. 
Down-regulation of the expression of the abnormal gene(s) was shown to be an effective strategy to halt 
disease progression in conditional tetracycline-regulated mouse and rat models of HD192,193, MJD194 and 
in a doxycycline-regulated mouse model of SCA1195. Upon shutting down the mutant polyQ protein 
expression in these models, a reduction in the amount of NIIs as well as behavioral phenotype 
improvement was observed. Another example was shown in a pan-neuronal conditional Drosophila 
model of SCA7 in which the expression of truncated protein was interrupted leading to an increase in 
lifespan196. Once this proof-of-concept was obtained, several techniques targeting polyQ expression 
started being explored including small interference RNA (siRNA) and short-hairpin RNA (shRNA). The 
first description of interference RNA (iRNA) approaches for polyQ diseases, was made in an in vitro cell-
based model, in which the inhibition of expression of a truncated version of the human AR through 
double-stranded RNA strikingly reduced polyQ-mediated cell death, caspase-3 activity and protein 
aggregation197. The applicability of iRNA in vivo was then validated in a SCA1 mouse model using shRNA 
for human ATXN1, which led to an improvement in motor coordination, reduction in NIIs and restored 
cerebellar morphology198. Later, microRNAs suppressing the expression of mRNA for ATXN1 and 
subsequently reducing the protein levels were shown to be effective in human cells199. Recently, the 
microRNA miR-25 was shown to reduce both WT and polyQ-expanded mutant ATXN3 protein levels, 
therefore increasing cell viability, decreasing early apoptosis, and down-regulating the accumulation of 
mutant ATXN3 protein aggregates in MJD model cells200. Extensive evidence for the efficacy of iRNA 
therapy was also presented in models of HD using different viral vector to deliver shRNA silencing the 
mutant htt. These treatments showed positive effects in behavior features, such as motor performance 
or clasping, and NIIs201–203. In case of MJD, several efforts were developed in the iRNA field by Pereira de 
Almeida and colleagues with successful results. Using lentiviral-mediated allele-specific silencing of the 
mutant ATXN3 the authors were able to prevent the development of the motor and neuropathological 
phenotype of rat and mouse models of MJD204,205. However, the model systems used did not closely 
mirror the human disease given the regionally limited expression of the transgenes and the treatment 
efficacy was only assessed in a short period. Another study with iRNA in MJD in a different model of the 
disease showed that despite efficacy, safety and lifelong suppression of ATXN3 expression in the deep 
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nuclei of the cerebellum, the motor impairment was not ameliorated in treated MJD mice during the 
pre-clinical trial and the lifespan was not prolonged206. This is likely due to the more widespread 
pathology presented by this model which expresses ATXN3 under its endogenous promoter and its 
native genomic context. However, there is still an open window to use other nucleotide-based gene 
silencing molecules more broadly to the brain and delivered at early stages of disease. 
  iRNA therapeutic application has progressed remarkably and reveals to be very promising due 
to efficient and specific gene silencing. However, in order to be delivered in the CNS, several challenges 
still need to be overcome to take full advantages of this potential technology.  
 
1.3.1.2 Preventing/reducing aggregation 
 One major question still remains in polyQ diseases: are the inclusions as toxic as the monomeric 
species of the polyQ proteins? Although the question is continuously debated, it is more widely 
accepted that the polyQ proteins are toxic due to their acquired misfolded conformations when 
compared to their WT counterparts. In normal conditions, cells own an extremely well-organized protein 
quality control machinery to regulate proteostasis and to guarantee that misfolded proteins do not 
accumulate207,208. As a pathological hallmark of polyQ diseases, aggregation was one of the first 
therapeutic targets in the polyQ field. 
 Chaperones or HSPs are crucial proteins which maintain the normal folding and/or the 
assembly of other macromolecular structures and a defect in their normal function may per se have 
pathogenic implications209–211. A growing number of studies along the years reinforced that 
overexpression of molecular HSPs in cellular and animal models of polyQ diseases have a protective 
effect, decreasing polyQ aggregation and/or neurodegeneration. In 1999, Warrick and colleagues 
showed that overexpression of HSP70 was able to suppress polyQ toxicity even with no detectable 
effect on aggregation, in a Drosophila model212. In cell models of SBMA, the overexpression of HSP70 
and HSP40 suppressed aggregate formation and apoptosis213 and enhanced the degradation of 
expanded AR214. The protective role of HSP70 overexpression was also observed in SCA1 cell, fly and 
mouse models73,215. In the case of MJD, the overexpression of two HSP40s, DNAJ-1 and DNAJ-2, was 
able to suppress the aggregation of mutant ATXN371. The HSR (including the HSP production) can also 
be induced through overexpression of heat shock transcription factors, which has also been described 
to reduce aggregation and cell death in polyQ disease cell models216–218.  
 Beyond transgenic overexpression of HSPs, the HSR and HSPs expression can also be induced 
by a number of promising small chemical compounds. Trehalose, a chemical chaperone, is able to 
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stabilize polyQ proteins in their native conformation and also activates autophagy. This compound was 
shown to be efficient in HD cellular and animal models219 and recently in a SCA17 mouse model220. 
Geranylgeranylacetone, a molecule capable of enhancing the expression of HSP70, HSP90, and 
HSP105 through induction of heat-shock factor 1 (HSF-1) activity, proved to inhibit nuclear 
accumulation of mutant AR, ameliorate motor behavior and increase survival in a SBMA mouse 
model221. Another small molecule, with the ability to increase HSP70, YM-1, was recently described to 
increase degradation of mutant AR in cell culture and to rescue toxicity in a SBMA Drosophila model222. 
Extensive evidence supports the use of two analog compounds, 17-AAG and 17-DMAG, also capable of 
up-regulating HSP40, 70 and 90, dependently on HSF-1 induction. They have been described to have 
promising effects on aggregation load, toxicity and motor behavior in several cell, Drosophila, C. 
elegans and mouse models of polyQ diseases100,218,221,223–228. Recently, the compound arimoclomol, a 
coinducer of HSPs, has been shown to ameliorate the symptoms in SBMA and ALS mouse models229–231.  
Congo red, minocycline and chlorpromazine are valuable aggregation inhibitors in vitro and were tested 
in mouse models of HD, however, with mild or absent improvement in phenotype232–234. Cystamine may 
also reduce polyQ aggregation and survival by transglutaminase (TG) inhibition; TG is thought to 
crosslink expanded polyQ proteins and facilitate their aggregation. This compound improved survival in 
HD mice by decreasing htt aggregation235.  
 Another strategy in polyQ aggregation inhibition is centered on the use of small antibody 
fragments expressed intracellularly called intrabodies, which are a biotechnological tool to disturb, 
modulate or define the functions of a wide range of target antigens at the post-translational level236.  In 
the case of htt, intrabodies were described to reduce neuropil aggregation and ameliorate neurological 
phenotypes in HD mouse models237,238. Results for ATXN3 have not been so promising, since only one 
aggregate-exacerbating intrabody against fibrilar polyQ proteins was tested, causing and increasing 
cytotoxicity and cell death when combined with ATXN3239. 
 
1.3.1.3 Inducing degradation: UPS and Autophagy 
 Increasing the clearance of the polyQ proteins to avoid their toxic downstream effects has been a 
focus of therapeutic strategies for several years. Cellular mechanisms for degrading unwanted proteins 
include the UPS and autophagy. In several cellular and animal models of polyQ diseases, as well as in 
the patients post-mortem brains, polyQ inclusions co-localize with Ub and proteasome subunits, raising 
the possibility of UPS involvement in these diseases167,215. Some studies show that stimulating 
ubiquitylation and degradation of polyQ proteins through the UPS can rescue pathology in cell and 
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animal models. By increasing UPS activity, the Y-27632 (rho-associated kinase inhibitor, already used 
in clinical trials as an anti-ischemic, anti-vasospastic and anti-hypertensive agent) decreased polyQ 
toxicity in a HD Drosophila model240, and reduced aggregation levels of mutant htt and ATXN3 cell 
models by its capability of modulating both UPS and autophagy241. Another compound shown to 
increase enzymatic activity of UPS is amilorid and its derivative, benzamil, also widely used in clinics; 
treatment with these compounds led to a reduction of mutant protein aggregation and toxicity in HD 
models242. 
 An additional strategy is the direct modulation of proteasome function. Ubiquitin-specific 
protease 14 (USP14) is a deubiquitylating enzyme (DUB) connected with the proteasome, which blocks 
the degradation of ubiquitylated substrates. IU1, a selective small molecule inhibitor of USP14, was 
described to accelerate proteasomal degradation of polyQ proteins, such as ATXN3, but also of other 
proteins associated with neurodegenerative diseases such as tau, TDP43 and oxidized proteins243. 
Interestingly, however, mutations in USP14 leads to an ataxic neurological phenotype in mice244 which 
could be reverted upon USP14 neuronal specific-expression245. This urges caution in using inhibition of 
drug this target as therapy in SCA’s. 
 Ub ligases are enzymes that determines the substrate UPS specificity. The overexpression of Ub 
ligase CHIP (C terminus of Hsc70 interacting protein) confers neuroprotection by enhancing 
ubiquitylation and consequent clearance of polyQ-expanded proteins, delaying the disease phenotype in 
SCA1 and SBMA animal models246,247. Parkin was also shown to ubiquitylate ATXN3 reducing polyQ 
toxicity in cells248,249. More recently, it was shown that the Nrf1 and Nrf2 transcription factors can 
regulate the UPS. Sulforaphane is a small molecule capable to induce Nrf2 activation, and therefore 
increase proteasome levels and activity250,251 as well as enhance UPS function in vivo252. Through this 
action, this molecule was able to decrease the mutant htt and alleviate polyQ toxicity in neuronal 
cells252. These studies suggests that the UPS is a versatile system that can be targeted to increase the 
clearance of polyQ-expanded proteins.  
 Autophagy is another prominent therapeutic target for the degradation of aggregated proteins 
and is negatively regulated by the mammalian target of rapamycin (mTOR)253. Upregulation of 
autophagy by inhibiting mTOR with rapamycin in different animal models of neurodegenerative 
diseases showed beneficial effects by enhancing autophagy function254–258. For example, a rescue of 
polyQ toxicity in cell, fly and mouse models was observed upon rapamycin treatment, as well as an 
increase the clearance of both soluble and insoluble species of the polyQ-expanded proteins259,260. 
Autophagy can also be modulated independently of mTOR by the use of several compounds, such as 
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lithium chloride (LiCl), sodium valproate, carbamazepine, rilmenidine and compounds that inhibit 
inositol monophosphatase261,262. Since these compounds have been used for several years to treat 
human CNS and heart diseases, they may have also promising effects in polyQ diseases. LiCl 
treatment in an HD mouse model ameliorated motor performance and depression in post-symptomatic 
treatment, with no effect in survival263. In SCA1, treatment of the knock-in mouse model with LiCl also 
improved the neurological and pathological phenotypes264. In contrast, in the case of MJD, LiCl therapy 
led to no overall improvement in motor function265. Rilmenidine is a hypertensive agent that was also 
tested in an HD mouse model, leading to amelioration of the disease symptoms presented in these 
mice and also to a reduction in the mutant htt levels266. Other approaches may consist in modulating 
the expression of proteins or molecules to induce autophagic degradation267,268. For instance, upon C. 
elegans bec-1, Ce-atg7 and Ce-atg18 gene knockdown or knockout, the polyQ aggregate formation and 
polyQ-expanded protein toxicity increased269. Therefore, modulating these autophagic genes in the 
opposite direction could enhance the autophagic polyQ degradation. Overexpression of histone 
deacetylase 6 (HDAC6) leads to the autophagy process compensating for UPS impairment in a SBMA 
Drosophila model270. More recently, the lentiviral vector-mediated overexpression of beclin-1 was 
described to be protective in neuronal culture and in a lentivirus-based rat model of MJD271. Overall this 
strategy seems to be attractive, however, it is important to identify new safe autophagy modulators to 
be used in chronic treatment, and to validate them in clinical trials.  
 
1.3.1.4 Proteolysis inhibition 
 Misfolded polyQ-expanded proteins may undergo proteolytic cleavage generating smaller 
fragments which could have an higher toxic effect179,272 and/or more quickly aggregate95. The “toxic 
fragment hypothesis” suggests that proteolytic formation of polyQ fragments is a pre-requisite of polyQ 
disease manifestation. Therefore, modulation of the activity of cleavage proteases or decreasing the 
levels of toxic fragments seem to be reasonable therapeutic approaches for these diseases. There are 
several proteolytic enzymes associated with the cleavage of polyQ proteins. The first described were the 
caspases in HD90, followed by calpains (a class of calcium-dependent cysteine proteases); even if they 
contribute to the majority of cleavage effects, several other fragmentation events could not be explained 
by their proteolytic activity. A great number of studies in different cell and mouse models, 
demonstrated promising effects of caspase-1, -3 and -6 and calpain inhibition, as well as inhibition of 
matrix metalloproteinases (MMP’s) activity in HD-associated toxicity175,180,273–276. Additionally, the cleavage 
of mutant htt by caspase-6 has been suggested to be required for the HD-related behavioral phenotype 
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and selective neuropathology in the YAC128 mouse model of HD. Furthermore, caspase-6 resistant 
mutant htt mice presented a delay in nuclear translocation of expanded htt277. More recently, a 
transgenic mouse expressing the N-terminal 586 aa of htt, a putative cleavage fragment mediated by 
caspase-6, showed behavioral deficits as well as nuclear accumulation of htt aggregates. Although their 
phenotype was less severe than that HD mouse models expressing shorter fragments, these studies 
suggest that the caspase-6 fragment is an intermediate of the cascade leading to disease 
progression278. Atrophin-1 is also cleaved by caspases at aspartate 109, and cleavage site mutations 
reduce nuclear localization, aggregate formation and cytotoxicity272. This was also shown in the context 
of MJD, in which general caspase inhibition in a Drosophila model delayed the neurodegeneration 
progression caused by the expanded ATXN3 expression279. Targeting the expression of endogeneous 
inhibitors, such as calpastatin, was also proposed in MJD280–282, being this inhibition able to prevent the 
nuclear localization and aggregation of mutant ATXN3 and its toxicity. Recently, it was also described 
that calpain inhibition in a Drosophila model of HD mediates autophagy-dependent protection against 
polyQ toxicity283. Another strategy is to modulate alternative cleavage pathways. For example, the levels 
of caspase-1 and -3 were decreased by treating R6/2 mouse model of HD with a tetracycline 
derivative, retarding the disease progression and death284. Recently a genetic approach was also 
proposed using antisense oligonucleotide-mediated protein modification. Modulating cleavage by 
inducing the skipping of exon 12 in htt pre-mRNA inhibits the formation of an N-terminal fragment 
involved in HD toxicity285.  
 The generation and development of protease inhibitors to prevent the conversion of polyQ 
proteins into more toxic fragments seems to be a promising therapeutic strategy. However, it is 
important to be careful with the specificity of these inhibitors, since other several essential signaling 
pathways in which proteases are involved286,287 could also be affected.   
 
1.3.1.5 Mitochondria stabilization and reduction of oxidative stress 
 Mitochondrial dysfunction and oxidative stress are thought to play an important role in polyQ 
pathogenesis288,289. Several compounds improving energy metabolism defects or reducing oxidative 
stress have been successfully tested in cellular and mouse models of polyQ diseases (described 
above). Although the degree of oxidative stress involvement is not completely known, antioxidant 
treatment may be able to exert some neuroprotective effects. Coenzime Q10 (CoQ10) is a cofactor of 
the electron transport chain which supports mitochondrial energy function, preserves cell viability, acts 
as a potent antioxidant in vivo and induces increase of mitochondrial vitamin E concentrations290. Co-
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treatment with CoQ10 and remacemide, an NMDA receptor antagonist, improved neurological 
symptoms and extended survival in different models of HD244. CoQ10 alone was also able to reduce 
weight loss and NIIs as well as greatly improve the motor performance in R6/2 mouse model of 
HD291,292. Supplementation of CoQ10 together with creatine, also exerted additive neuroprotective effects 
in HD models293. Creatine supplementation alone was also able to improve brain pathology, phenotype 
as well as increase survival in R6/2 mouse294. Also in the N171-82Q model of HD, survival was 
extended with creatine treatment295. Resveratrol, another natural phenol antioxidant, ameliorated the 
mutant polyQ toxicity in neuronal cells and C. elegans model of HD296. Tauroursodeoxycholic acid 
(TUDCA) is a hydrophilic endogeneous bile acid with multiple neuroprotective properties, including 
antioxidant and anti-apoptosis activities. This compound decreased the apoptosis of striatal neurons 
and improved motor and cognitive deficits in HD mouse models297. Several other antioxidants such as 
melatonin, selenium, quinolinic acid, idebenone, lycopene, lipoic acid, pyruvate or L-carnitine also 
proved to exert neuroprotective effects in HD models298.  
 Also related with this field is the Nrf2/antioxidant response element (ARE) signaling pathway, 
which is involved in antioxidant and anti-inflammatory responses299. For example, the triterpenoids 
CDDO-ethyl amide and CDDO-trifluoroethyl amide were described to up-regulate Nrf2/ARE genes, 
therefore reducing the oxidative stress and striatal atrophy, improving the motor deficits and increasing 
lifespan in the N171-82Q mouse model of HD300.   
 Together, these results indicate that a therapy based on antioxidants and other promising 
molecules capable of improving mitochondrial function and reducing oxidative stress could be effective 
for polyQ diseases. However, human clinical trials have not shown efficacy for CoQ or creatine in 
HD301,302. Several factors could underlie these failures, for example, the dosage used, the severity of the 
disease and the post-symptomatic treatment, among others.   
 
1.3.1.6 Transcription modulation 
 The current conceptual model is that mutant polyQ proteins frequently interact abnormally with 
HATs and/or histone deacetylases (HDACs), changing physiological histone modification patterns and 
thus altering gene expression303. The normalization of the dysregulated gene transcription, usually by 
targeting histone acetylation and methylation has been a growing field of research. The inhibition of 
HDAC activity, as a repressor of transcription, has been proposed as a transcription normalization 
method, and is the most widely tested in mouse models of polyQ diseases. Though HDAC inhibitor 
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(HDACi) molecules frequently lack specificity, and thus they may also perturb the expression of other 
unrelated genes, some of them exhibit promising therapeutic properties.  
 HDACi’s such as sodium butyrate (SB), phenylbutyrate, suberoylanilide hydroxamic acid (SAHA 
or vorinostat) and valproic acid (VPA), which are proposed to increase gene expression, have shown 
efficacy in a variety of polyQ disease models. Pharmacological treatment of the R6/2 mouse model of 
HD with SB improved body weight loss and motor phenotype, significantly extended the lifespan by 
more than 20%, and delayed the neuropathological damage through the increase in acetylation of H3 
and H4 and also of SP1304. An improvement in neurological phenotypes and increased survival, together 
with an increased acetylation of histones in neuronal tissues was also observed in a transgenic mouse 
model of SBMA treated with SB305. In a DRPLA transgenic mouse model presenting hypoacetylation of 
histone H3 in brain, SB treatment ameliorated the motor impairments and extended survival306. Chou 
and colleagues demonstrated that SB treatment in a transgenic mouse model of MJD reversed the 
histone hypoacetylation and the transcriptional down-regulation in the cerebellum, leading to an 
improvement in the ataxic symptoms and increased survival307. Also for SCA7, but in a conditional pan-
neuronal Drosophila model with globally decreased histone acetylation, treatment with SB improved 
survival time of the neurons in primary neuronal cultures196. In spite of significant improvements in 
many neuropathological phenotypes, SB was not able to reduce the mutant polyQ protein aggregation 
in some cases304,305.  
 Another HDACi, phenylbutyrate, reduced brain atrophy and ventricular enlargement, and 
improved lifespan in the N171-82Q model of HD86. SAHA has been tested in the R6/2 mouse model of 
HD showing beneficial effects in the motor phenotypes and neuronal atrophy, however with no 
improvement in body weight. Like SB, SAHA rescued the hypoacetylation of histones in these animals 
but with no effect on polyQ aggregates308. More recently, the same authors demonstrated that SAHA 
decreased HDAC2 and HDAC4 at the protein level in the cortex and brainstem, but not at the mRNA 
level309. VPA is a well-tolerated antiepileptic drug, also with HDACi properties. This compound has been 
proven to delay the disease onset, to reduce neurological deficits and/or to prolong survival in several 
models of neurodegenerative diseases, including HD, SBMA and ALS310–312. In MJD, VPA was reported to 
alleviate neurodegeneration in a Drosophila model of the disease313 and to attenuate mutant ATXN3-
induced cell toxicity in a human neuronal cell model314. Thomas and colleagues successfully treated 
R6/2 mouse model of HD with a benzamide-type HDACi, HDACi 4b. This compound showed a lower 
toxicity in vitro when compared with previously tested HDACi, together with prevention on motor deficits 
and neurodegenerative processes in vitro in a post symptomatic treatment approach315.  
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 Other chromatin remodeling approaches, though not so well studied as the previous ones, 
comprise for instance the use of chromomycin and mithramycin antibiotics that were able to rescue the 
down-regulation of a subset of affected genes, improved motor and neuropathological phenotypes and 
increased the lifespan of transgenic mouse models of HD316,317. Another compound shown to alleviate 
the transcriptional dysfunction is the phosphodiesterase type IV inhibitor rolipram, which increases the 
phosphorylation and activity of CREB. Rolipram ameliorated neuropathology, slowed progression of 
neurological phenotype and extended lifespan in R6/2 mice. Additionally, BDNF levels, which are 
impaired in this HD mouse318,319, were induced in treated mice through restored function of CREB320. A 
subsequent study show that rolipram also prevented the sequestration of CBP into NIIs321. 
Dimethylcurcumin (ASC-J9), a drug that specifically disrupts the interaction of mutant AR with CBP, 
was shown to be symptomatically beneficial in an AR-97Q SBMA mouse model322.  
 In spite of the promising results obtained with HDCAi’s in models of polyQ diseases, this strategy 
still lacks some specificity. In spite of their neuroprotective effects modulating the transcriptional 
defects, they could also increase the acetylation of other non-histone proteins, such as tubulin323 and 
HSP90324 and upregulate levels of HSPs325,326 via transcription-independent mechanisms. These issues 
stickle the translation of some promising results to clinical application, together with some toxic effects 
associated with HDACi treatment. Further studies of their actual molecular mechanism, and 
development of more selective HDACi’s with less toxicity, might offer better opportunities327. Lastly, and 
assuming the increased knowledge on HATs and their function in neuronal survival, the stimulation of 
HAT function appears to be a new therapeutic possibility in this field328. 
 
1.3.1.7 Other treatment possibilities 
 The overactivation of NMDA glutamate receptors and consequent excitotoxicity leading to 
death has been supposed to have a role in pathogenesis of HD329. Supporting this concept, the use of 
compounds that block the excessive glutamate release, as riluzole, has been effective in HD mouse 
models concerning survival, motor performance and agregation330. Two compounds affecting the 
glutamate levels in the synaptic cleft, LY379268 and 2-methyl-6-(phenylethynyl)-pyridine, consistently 
with riluzole, significantly increased the lifespan of R6/2 mice331. Administration of  remacemide (NMDA 
antagonist) and/or of CoQ10 also prolonged the lifespan rates of HD mice291. Another option is 
apoptosis inhibition; anti-apoptotic drugs, such as minocycline and caspase inhibitors have shown 
promise in polyQ animal models. Administration of minocycline in R6/2 mice extended the survival332, 
and when combined with CoQ10 further improved survival, neuropathology and motor phenotype when 
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compared with any of the treatments alone333. However, long-term studies will be required to find out 
possible side-effects associated with suppression of these key cellular pathways. Caspase inhibition 
could have other beneficial effects, through a decrease in generation of caspase-cleaved fragments of 
mutant proteins. In fact, a general caspase inhibitor, z-Val-Ala-Asp-fluoromethylketone, extended 
lifespan and ameliorated the rotarod performance in R6/2 mice276. The combined administration of 
caspase 1 and 3 inhibitors, Tyr-Val-Ala-Asp-chloromethylketone and Asp-Glu-Val-Aspaldehyde-
fluoromethylketone, respectively,  also increased the lifespan in HD mice332. Other still emergent 
strategies for polyQ diseases may comprise neural cell replacement therapy and 
neuroprotection strategies. The replacement of dead and/or damaged neurons by new neural 
cells with the proper ability to integrate, function334 and also contribute to neurogenesis and the 
production of trophic factors335,336 may provide additional neuroprotection and promote the 
reestablishment of neuronal homeostasis. The attractiveness of these strategies lies partially in the fact 
that they might be effective even after disease manifestation. 
 
1.3.2 Hypothesis-free approaches 
 Hypothesis-based drug design, although a theoretically rational approach, is only one strategy for 
drug discovery, and although this approach can offer promising results, it is limited to known targets 
and drugs, and it cannot unravel novel targets and disease pathways. 
 In the last years, hypothesis-free approaches for polyQ therapies are gaining relevance due to 
their numerous advantages and the novel technical possibilities for screening. High-throughput 
screening (HTS) allows the testing of the effects of thousands of compounds in one or more biological 
assays against a chosen set of defined targets. The small molecules used in HTS’s are often readily 
commercially available and are generally classified into three groups: i) Food and Drug Administration 
(FDA)/European Medicines Agency (EMA) approved compounds, which comprise bioactive, natural 
products and synthetic small organic molecules; ii) novel synthetic compounds, comprising a vast 
collection of novel organic molecules and iii) natural products. The FDA/EMA approved compounds 
have the potential to rapidly translate into the clinic and of a faster interpretation of pathophysiological 
mechanism due to their often known targets and mechanisms of action. The synthetic compounds 
could comprise molecules for additional unexpected targets and can be easily improved and modified 
for increased potency or decreased side effects, for instance, together with their lower costs. The 
natural products could also contain novel structures and may be superior in terms of biological 
activities and chemical complexity but are usually associated with higher costs and limited availability.  
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 Besides the compound library selection, the most critical step is the choice of the target which 
must faithfully reflect the disease process and be compatible with automation. In polyQ diseases, the 
drug discovery is hampered by to the lack of validated targets and the incomplete knowledge of the 
molecular pathways. Nevertheless, the strategy consists in screening against a specific disease 
hallmark in the available cellular or inferior animal models, since they can recapitulate at least some 
disease-associated phenotype. In these diseases the most common target is polyQ protein aggregation, 
which is an important aspect of cellular pathology, either as a primary event or as a robust indicator of 
abnormal protein conformation. Other described targets for polyQ HTS have been cell death, mutant 
protein clearance (degradation), transcriptional dysregulation and other events thought to contribute to 
toxicity. The HTS assays can be in vitro, cell-based or, less often, whole organism based. Any such 
model will have intrinsic advantages as well as limitations. A summary of the described polyQ HTS’s is 
depicted in Table 2. Although the majority of the HTS’s have been centered on HD, several concepts 
could be applied to the other polyQ diseases. 
 
 
Table 2. Chemical HTS for polyQ diseases. 
Target 
PolyQ 
construct 
Assay 
system/readout 
Compounds 
tested 
Hits Secondary assays Ref. 
Aggregation 
GST-HTT 
exon 1 Q51 
In vitro screen 
by filter 
retardation 
assay 
184,880 small 
molecules 
Benzothiazoles 
Immunoblotting, electron 
microscopy, mass 
spectrometry, 293 Tet-Off 
cells 
337 
GST-
HTT171 
Q58 
In vitro screen 
by filter 
retardation 
assay 
1,040 FDA-
approved drugs 
and bioactive 
compounds 
Gossypol, gambogic 
acid, juglone, 
celastrol, sanguinarine 
and anthralin 
Htt localization phenotype in 
HdhQ111/Q111 striatal cells 
338 
GST Q62 In vitro screen 
Phage display 
library 
Six tryptophan-rich 
peptides (polyQ-
binding peptide 1)  
PolyQ turbidity, CFP/YFP 
FRET in HD COS-7 cell model, 
cell death and aggregation 
339 
AR127 Q65 
In vitro screen 
by CFP/YFP 
FRET assay 
2,800 
biologically 
active 
compounds 
Y-27632 (Rho 
associated-kinase 
p160ROCK inhibitor) 
Aggregation and 
neurodegeneration in HD 
Drosophila model 
240 
GST-HTT 
exon 1 Q51 
In vitro screen 
by filter 
retardation 
assay 
11 small 
molecules 
Congo red, thioflavine 
S, chrysamine G and 
direct fast yellow 
Electron microscopy, 
SDS/PAGE, and MS and HD 
COS-7 cells  
340 
HTTNT 
fragment 
In vitro screen 15 peptides 
HTTNT-related inhibitor 
peptides 
Cell-penetrance and 
cytoplasmic localization in SH-
SY5Y cells 
341 
HTT Q72-
Luciferase 
HEK-293 celll-
based screen 
by luciferase 
activity and 
FRET 
2,687 small 
molecules  
Leflunomide and 
teriflunomide 
Size and number of 
aggregates upon treatment 
and cycloheximide (CHX)-
chase experiments 
342 
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Target 
PolyQ 
construct 
Assay 
system/readout 
Compounds 
tested 
Hits Secondary assays Ref. 
Aggregation 
and toxicity 
GST-HTT 
exon 1 Q51 
In vitro screen 
by filter 
retardation 
assay 
5,000 natural 
substances 
EGCG and related 
polyphenols  
Aggregation in HD Yeast 
model and photoreceptor 
degeneration and motor 
function in Drosophila model 
343 
AR127 Q65 
HEK-293 celll-
based screen 
by CFP/YFP 
FRET 
3 libraries 
(4.140 
compounds) 
EGFR inhibitor #3, 
EGFR inhibitor #4, 
gefitinib, nadolol, 
fosfosal, piceatannol, 
levonordefrin, 
todralazine, 
hydralazine, 
molsidomine, Ac-
YVAD-cmk 
Aggregation in PC12 cells, 
phenotype in Htt exon1 in 
Drosophila 
344 
HTT Q103-
EGFP 
Yeast cell-based 
screen by 
growth and 
EGFP 
fluorescence 
16,000 
compound 
library 
C2-8 
Microscopy and PC12-Q103 
cells, HD COS-7 cells, brain-
slices and HD Drosophila and 
R6/2 models 
345 
ΔProQ103  
Yeast-based 
assay by growth 
readout 
11,000 natural 
extracts 
compounds 
Actinomycin D 
Chaperone levels and PC12 
cell aggregation  
346 
Cell death  
 
AR Q112 
HEK-293 cell-
based assay by 
caspase-3 
activation and 
fluorescence 
1,400 
compounds 
Nerifolin, Peruvoside, 
Digitoxin, Suloctidil 
Rescue of Q112-related cell 
death by FACS 
347 
 
HTT exon 1 
Q103-EGFP 
PC12 cell-
based by LDH 
release and 
absorption 
1,040 
compounds  
12 compounds 
including cannabinoids 
and caspase inhibitors 
NA 348 
HTT Q148 
Inducible PC12 
cell-based by 
LDH release 
and absorption 
1,040 
compounds 
Nipecotic acid, 
Mycophenolic acid, 
acivicin, isoproterenol 
HCl and Propafenone 
HTT aggregation by 
immunofluorescence 
cytochemistry  
349 
HTT Q120 
Temperature 
sensitive ST14A 
striatal cell-
based assay by 
calcein AM cell 
viability and 
fluorescence 
43,685 
compounds 
29 compounds (R1-
R29) 
Survival of Q103-related cell 
death in PC12, yeast, 
C.elegans and Drosophila and 
brain slices 
350 
Cell death 
and toxicity 
 
HTT exon 1 
Q25 and 
Q103-EGFP 
PC12 cell-
based screen 
by cycloaddition 
chemistry and 
in-gel 
fluorescence 
scanning  
68,887 
synthetic and 
natural 
compounds 
16F16, thiomuscimol, 
cystamine 
HD and AD cortico-striatal 
brain slice models 
351 
HTT exon 1 
Q150  
C. elegans ASH 
neuron-based 
screen by GFP 
expression 
9 compounds 
LiCl, TSA, SAHA and 
mithramycin 
NA 352 
Toxicity 
  
HTT480 
Q68 
Striatal 
neuronal 
primary culture-
based screen 
40,000 
compounds 
NA NA 353 
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Target 
PolyQ 
construct 
Assay 
system/readout 
Compounds 
tested 
Hits Secondary assays Ref. 
HTTN90 Q8 
and Q73 
Cortical and 
Striatal 
neuronal 
primary culture-
based screen 
by fluorescence 
scanning 
400 small 
molecules 
Inhibitors of Rho 
kinase, 
phosphodiesterase, 
adenosine 2A receptor 
and IKKβ 
NA 354 
HTTN90 
Q73 
Rat brain slice-
based screen 
74 drug-like 
compounds 
Inhibitors of IKK 
complex, CXCR3 
chemokine receptor, c-
Jun N-terminal kinase 
and adenosine 2A 
receptor 
NA 355 
HTT 588 
C38 and 
Q15 
Drosophila 
primary 
neuronal 
culture-based 
screen  
2,600 small 
molecule 
Camptothecin, OH-
camptothecin, 18β-
glycyrrhetinic acid and 
carbenoxolone 
HD Drosophila larvae survival, 
pupal lethality and climbing 
behavior 
356 
Clearance 
(Degradation) 
 
HTT573 
Q72 
HN10 neuronal 
cell-based 
screen by time-
resolved FRET  
10,000 natural 
compounds 
TSA analogue, 
staurosporine, 
anisomycin, 
cycloheximide, 
borrelidin, BAY 61-
3606 
NA 357 
HTT573 
Q25 and 
Q72 
HN10 neuronal 
cell-based 
screen by time-
resolved FRET 
2x106 
compounds 
Heat shock protein 90 
inhibitors as NVP-
AUY922 
HdhQ150 embryonic stem 
cells and embryonic stem cell-
derived neurons 
358 
Q103-EGFP 
Inducible PC12 
cell-based by 
protein 
concentration 
with EGFP 
fluorescence 
37,000 
synthetic 
compounds 
31 compounds 
α-complementation, Q103-
related cell death 
359 
NA 
Yeast-based 
assay by growth 
readout 
50,729 
compounds 
21 SMIRs and 12 
SMERs 
PC12 (A53T α-synuclein) 
clearance, HD exon 1 (Q74)-
EGFP, autophagy with 
embryonic fibroblasts, COS, 
HeLa cells and Drosophila 
360 
HSF-1 
activation  
 
NA 
HeLa cell-based 
screen 
1x106 
compounds 
A1, A3, C1, D1, F1 
HD mammalian cellular and 
C. elegans model 
361 
NA 
Yeast-based 
assay 
10,000 
compounds 
HSF1A (TRiC/CCT 
complex) 
HD mammalian cellular and 
C. elegans model 
362 
Transcription 
dysregulation   HTT Q138 
Inducible HEK-
293 cell-based 
assay by 
Luciferase 
reporter gene 
24,000 
compounds  
47 compounds 
Cell viability adenosine 
triphosphate assay in primary 
striatal neurons transfected 
with N171-Q82 
363 
Fly motor 
impairment HTT Q128 
Drosophila 
neuron-based 
screen 
521 
quinazoline-
derived 
compounds 
EVP4593 
YAC128 medium spiny 
neurons 
364 
Abbreviations: GST = glutathione S-transferase; FDA = Food and drug administration; CFP/YFP = cyan fluorescent protein/yellow fluorescent protein; 
FRET = fluorescence resonance energy transfer; EGCG = Epigallocatechin gallate; EGFR = Epidermal growth factor receptor; EGFP = Enhanced Green 
Fluorescent Protein; FACS = Fluorescence-activated cell sorting; LDH = Lactate dehydrogenase; GFP = Green fluorescent protein; LiCL = Lithium chloride; 
TSA = Trichostatin A; SAHA = suberoyl anilide hydroxamic acid; NA = Not available; SMER = Small-molecule enhancer; SMIR = Small-molecule inhibitor. 
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1.3.2.1 Aggregation assays 
 The first HT screens were planned to identify compounds that would avoid the formation of 
and/or disrupt HD aggregates in vitro. Examples of these assays include aggregate quantification by 
filter retardation assay with fluorescent ELISA readouts337,338,340,343. Although optimization of this method 
required much more time than the current HTS’s, Heiser and colleagues were able to screen 18,4880 
small molecules and to identify 25 benzothiazoles able to inhibit aggregation of the HTTQ51 protein, 
some of them already described to be effective for ALS treatment365. As a second assay, these 
compounds were tested in HEK293 cell, expressing HTTQ51, the majority of them being toxic to cells 
and later to in vivo models. This HTS emphasized the importance of the risks of translation from in vitro 
to cell cultures. Another in vitro aggregation assay was performed by Wang and colleagues, with a 
longer htt fragment, identifying 19 compounds inhibiting aggregation by more than 50%338. Curiously, 
one of the hits was celastrol which is an anti-inflammatory and antioxidant compound that has been 
also proposed for AD therapeutics366. To incorporate cellular context, a pioneering screen to monitor 
polyQ aggregation in cells was developed using a fluorescence resonance energy transfer (FRET)-based 
assay which is based on the transfer of energy between two fluorophores that are in close spatial 
proximity. With this method, Pollit and colleagues screened a 2,800 compound library and identified 
the Rho kinase (ROCK) inhibitor Y-27632 of mutant AR aggregation as a hit compound240 and 
consequent validate it in a HD Drosophila model. The discovery of the ROCK inhibitors in aggregation 
context allowed the characterization of the ROCK-profilin signaling pathway367,368. For instance, the FDA-
approved ROCK inhibitor HA-1077 was able to rescue retinal degeneration in the R6/2 mouse model of 
HD, showing that ROCK inhibition is an HD-related mechanistic pathway369. With the same strategy, the 
group screened a set of biologically active compounds and found hits capable of inhibiting the 
aggregation of a pure polyQ stretch, suggesting that these compounds could be essential tools for 
understanding and counteracting the aggregation mechanisms in polyQ diseases. Some of the 
compounds were also able to alleviate the neurodegeneration in a HD Drosophila model344. Recently, in 
search of a more robust and quantitative method to assess protein aggregation dynamics, Fuentalba 
and colleagues developed a novel aggregation-sensitive luciferase-based reporter to quantify polyQ 
aggregation in cellulo, based on an expanded htt fragment342. With this method the authors identified 
leflunomide and its active metabolite teriflunomide, which prevent incorporation of expanded polyQ 
proteins into aggregates. This compound could hold promise for polyQ diseases, as it was already 
tested in multiple sclerosis patients, however its long-term safety profile remains unknown370. In addition 
to the use of mammalian cells in these assays, aggregation of htt has also been studied in simple yeast 
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systems. This biological system is less susceptible to polyQ-mediated toxicity, and easily subject to 
genetic analysis, allowing the study of other cellular factors in the aggregation process. In 2005, a 
primary aggregation screen was established with 16,000 compounds in a yeast strain, using a 
galactose-inducible htt construct with 103Q’s tagged with EGFP345. Nine hits were identified and 
microscopically validated. Four compounds were found to inhibit the aggregation of this fusion protein 
also in PC12 cells. However, the compound activity was weak in a cell-filter retardation assay, 
demonstrating that the compound did not directly interfere with polyQ aggregation. A recent study also 
used a yeast model of polyQ proteotoxicty to screen a large amount of natural product extracts, 
identifying actinomycin D as a strong inhibitor of polyQ aggregation, an effect that was accompanied by 
its impact in increasing the levels of different HSPs346. This compound also suppressed aggregation in 
mammalian cells, suggestive of a conserved mechanism and therefore placing this as an interesting 
compound for polyQ diseases. Efforts were also made to establish brain slice assays that could closely 
mirror the aggregation events in mouse models for HD371–374 and although the authors could confirm the 
anti-aggregation properties of Congo Red in this system, the predictive value of this assay for the 
compounds activity in animals and patients still needs to be validated. 
 Diverse in vitro and cell-based assays have allowed the identification of several small molecule 
inhibitors and some of them were also found to be active in vivo (for e.g. in the Drosophila model). 
However, some limitations are still present and platforms need to be optimized and to evolve in terms 
of comparing different toxicity patterns in different systems, or different genetic constructs that could 
led to different compound outcomes.  
 
1.3.2.2 Cell death assays 
 In addition to aggregation assays, more complex biological assays aiming at phenotypic 
endpoints associated with the disease process could be used. Though the exact role of cell death in 
polyQ pathogenesis is still discussed375,376, this downstream consequence of toxicity is being used as an 
assay readout for the identification of novel small molecules. Caspase-3 activation is a key event in the 
apoptotic cell death and its genetic or small molecule inhibition showed to be beneficial in cell cultures 
and mouse models of HD377,378. A cell-based assay was used to identify inhibitors of caspase activation in 
a model of SBMA, in which expression of mutant AR Q112 induces caspase-3 activation and cell 
death347. A 1,400 compound collection was screened and the researchers identified 15 compounds 
inhibiting caspase-3 activity by more than 70%, however only four cardiac glycosides were confirmed to 
enhance cell viability without causing cytotoxicity. Curiously, these compounds do not inhibit caspase-3 
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directly, suggesting that there are other targets upstream in the cascade of death pathway. Thus, the 
study of the mechanisms of action of these compounds could disclose new and unexpected biological 
targets in the HD context. Apart from this molecular endpoint, there are also HTS’s based on the 
phenotypic endpoint, the cell death itself. Aiken and colleagues used an inducible PC12 cell model, 
with a construct containing 103Q’s, previously described379, which underwent rapid cell death and 
quantified lactate dehydrogenase (LDH) or measured mitochondrial activity with an MTS assay. With 
this model, the group screened 1,040 compounds and identified 12 that completely rescued cell 
death. Among these compounds, cannabinoids were efficient for protection against cell death348, 
through a possible mechanism related with their described antioxidant effects380. Another screen with 
the same compounds, in an inducible PC12 cell model, but with a construct with 148Qs, identified 5 
compounds preventing cell death, three of them (acivicin, nipecotic acid and mycophenolic acid) also 
decreasing aggregation349. It is important to note that, although performed with the same inducible 
model and the same compound library, these two HTS’s do not present overlap in the hit compounds 
with the exception of caspase inhibitors, alerting for the importance of the cellular model and polyQ 
construct when designing the assay and for validation of findings in several models. Thus, it is valuable 
to perform HTS’s in cell lines that mirror as much as possible the cell types known to be affected in the 
disease context. With that purpose, Varma and colleagues used a stable striatal neuronal cell line 
expressing N-terminal 548 aa fragment of htt with 120Qs, which undergoes cell death upon serum 
deprivation at 39ºC350. In a collection of 43,685 compounds, they identified 29 hits rescuing cell death 
specifically in mutant but not in parental striatal cells suggesting that the targets of these compounds 
are specifically activated by mutant htt and consequently are possibly relevant therapeutic targets. As 
secondary assay, the authors tested these 29 compounds in three additional HD models – PC12 cells, 
yeast and C.elegans – four of them being active in these models, and two of them also active in a rat 
brain slice HD assay. Although their mechanism of action is still under study, these compounds seem 
to specifically target mutant htt toxicity across cell, tissue and organism-based HD models.  
 One of the major concerns of in vitro and cell-based assays is whether the hits will be also 
effective in a whole animal model of the disease. In this context, C. elegans is a powerful model for 
drug-testing in whole animal context, due to its short life cycle, small size and easiness of culturing in 
liquid medium. Moreover, several neurobiological and anti-parasitic drug studies in C.elegans provide a 
strong basis to use this organism in drug discovery identification381,382. Voisine and colleagues used a 
C.elegans model of polyQ neurotoxicity expressing N-terminal 171 aa fragment of human htt with 
151Qs in neurons, and mimicking the degeneration and cell death of the human disease (dependent 
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on both age and the length of the polyQ tract)185. The authors tested different candidate compounds 
previously identified in cell cultures and animal studies in the C.elegans model and found that two FDA 
approved compounds, LiCl and mithramycin, independently and in combination, alleviated HD 
neurotoxicity352. Due to its easiest genetic manipulation, C.elegans is also valuable to study the drugs’ 
mechanisms of action by turning on/off possible targets, accelerating drug discovery field for polyQ 
diseases.  
 
1.3.2.3 Clearance/Degradation assays 
 A different strategy than those referred above is to perform a HTS to tackle the cellular 
degradation of soluble or aggregated forms of mutant polyQ proteins. With the purpose of identifying 
compounds promoting clearance of the mutant polyQ protein in mammalian cells, Coufal and 
colleagues used the htt gene encoding a protein with 103Qs in fusion with EGFP, placed under control 
of an inducible ecdysone control element in PC12 cells379. These authors screened a library of 37,000 
compounds, basing their screen on fast degradation of the Q130-EGFP fusion proteins 24 hours 
succeeding of the inducer removal. After toxicity studies, they identified 31 compounds that accelerated 
degradation, of which two structurally similar compounds, A28 and A31. For this last one, a second 
assay aiming to study these compounds in terms of their specificity for a mutant (Q79) or a WT (Q23) 
htt protein in PC12 cells, showed that A31 increased clearance and cell viability for the mutant htt but 
not for the WT protein359. Another HTS screening to search for modulators of autophagy was performed 
in a Saccharomyces cerevisiae model by Sarkar and colleagues360. The mTOR kinase is a major 
negative regulator of autophagy383, an thus an interesting drug target in protein aggregation-related 
diseases, although the utility/safety of its chronic inhibition is under debate. In this HTS, 15,000 
compounds were screened and the authors identified 12 novel small-molecule enhancers (SMERs) of 
autophagy, modulating the levels of htt and A35T α-synuclein, and 21 inhibitors (SMIRs) of the 
cytostatic effects of rapamycin in yeast. The SMERs were shown to be independent or functioning 
downstream of mTOR, and proved to attenuate mutant htt toxicity in HD cell and Drosophila models. 
 Another cell-based assay through a time-resolved FRET analysis was performed by Paganetti 
and colleagues, the main advantage of which was the possibility to adapt the design for protein 
visualization in intracellular imaging assays, with fixed and permeabilized cells357. To validate the 
system, the authors tested 10,000 compounds for their ability to modulate intracellular htt levels with a 
parallel cytotoxicity readout. Then, by screening a natural product library, the authors identified six 
molecules that efficiently reduced or increased the mutant htt present in the neuronal HN10 cells. 
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Recently, a HTS using a hippocampal HN10 cell line expressing mutant htt through a time-resolved 
FRET assay, identified several hits, including heat shock protein 90 (HSP90) inhibitors358. These 
compounds strikingly decreased mutant htt levels without major toxic effects. The hit NVP-AUY922 was 
picked to deepen the degradation mechanism in HdhQ150 embryonic stem (ES) cells and ES cell-
derived neurons. This compound significantly decreased the soluble full-length mutant htt levels and 
enhanced mutant htt proteasomal degradation without induction of HSP70, suggesting it as a 
promising therapeutic molecule.   
 
1.3.2.4 Transcription dysregulation and other targets 
 As the knowledge of the pathogenic mechanisms of polyQ diseases evolves, more relevant 
quantifiable readouts could be used for HTS’s. Although the most of the pieces of the puzzle of 
transcription dysregulation of polyQ diseases are still not well understood, the fact is that this 
mechanism seems to play an important role in their pathogenesis. In this line, it is known that mutant 
htt is able to sequester the CREB co-activator CBP through direct polyQ interactions leading to reduced 
CREB-mediating transcription52. Taking this into consideration a recently study from Lazzeroni and 
colleagues described a novel phenotypic screening assay to identify modulators of htt-induced 
transcriptional dysregulation363. The authors used a stable cell line expressing a full-length mutant htt 
gene (138Q), together with a reporter gene under the control of the CRE. The full-length protein used 
here enabled a more disease-relevant cellular phenotype than that measured for models expressing 
exon-1 or other htt fragments previously described. As a proof-of-concept, upon treatment with Rho 
kinase inhibitor Y27632, one clone showed reversible inhibition of the reporter activity and was then 
used for a HTS of 24,000 compounds. 64 compounds were identified with different specificity levels for 
CRE-mediated transcriptional regulation and secondary assays needs to be performed to tackle their 
mechanisms of action and their effects on mutant htt aggregation.  
 Recent studies have also been focusing on other parameters of polyQ pathogenesis. One is the 
activation of the heat shock transcription-factor 1 (HSF-1) which has been shown to restore proteostasis 
in a wide range of neurodegenerative diseases218,223,226,362. A few small molecules were already identified 
as regulators of protein conformation through the activation of HSF-1 in cell361 and yeast-based 
assays362.  
Although the majority of the HTS’s are performed in a simple cell-based assays and the in vivo 
rodent models are only used as a last part of the screening before testing the compounds in clinical 
trials, other non-rodent in vivo models can actually be used for primary library screenings. Despite their 
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higher cost and throughput limitations, Drosophila and C.elegans are two models that can be used with 
the higher advantage of being multicellular organisms displaying polyQ disease-related quantifiable 
phenotypes for HTS. PolyQ-associated phenotypes, as motor impairment, for instance, could be used 
as first line readouts in Drosophila364 and C.elegans models in the future of polyQ HTS’s.  
 
In summary, in the last decade, a significant number of HTS assays have been established 
which lead to the identification of multiple of polyQ disease-modifying compounds, comprising both 
FDA/EMA approved drugs and novel chemical molecules. The next challenge is to test these molecules 
in clinical trials and use them as tools to enhance the understanding of the polyQ disease mechanisms, 
therefore unravelling novel therapeutics targets. So far, the best candidates will be the FDA/EMA 
approved compounds which cross the blood brain barrier (BBB) which, once they prove to be effective 
in animal models, they fast translate to clinical trials. The hurdles for the novel molecules are more 
complex, as they need to pass several filters including their analysis in different secondary assays in 
terms of their toxicity, potency, metabolic stability, adequate pharmacokinetic profile and their 
capability to cross the BBB. At this moment, a unifying handicap in polyQ disease therapeutics is that 
mutant polyQ expression is associated with the disturbance of several cellular mechanisms. These 
multi-affected mechanisms make the process of drug discovery difficult since it turns out to be difficult 
to know exactly which might be the most important aspect of disease mechanism to target. However, 
the hard but also productive pathway that we have travelled so far in this field, together with the 
improvement in biotechnology, means that we will have the best tools to tackle the emerging and old 
questions towards better therapeutic approaches for these devastating diseases. 
 
1.4 Clinical Trials in polyQ diseases 
 Despite the enormous efforts in the past decades, there is no effective treatment for polyQ 
diseases. However, several clinical trials were performed and numerous are ongoing in which, despite 
no clear overall improvement, some specific symptoms of the disease could be attenuated. Table 3 
summarizes the completed double-blinded, phase 2 and/or phases 3 randomized controlled clinical 
trials (RCTs), for polyQ diseases with 20 or more patients, available at clinicaltrials.gov and/or 
Pubmed, excluding open-label and retrospective trials. The main objective of this categorization was to 
cover the high quality evidence RCTs. 
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Table 3. Completed RCTs for polyQ diseases with available results at clinicaltrials.gov and/or Pubmed. 
PolyQ 
disease 
Therapeutic 
molecule 
Mechanism of action 
Treatment 
duration 
N Overall efficacy Ref. 
HD 
Latrepirdine  
Antihistamine, 
mitochondrial 
membrane stabilizer 
90 days 91 Improvement in the MMSE score mean 384 
26 weeks 403 No significant effect in cognition or global function  385 
Creatine 
Energy metabolism 
regulator 
1 year 41 
No significant effect in functional, neuromuscular, 
and cognitive status 
301 
Pridopidine  Dopaminergic stabilizer 4 weeks 58 
Trend towards improvement in affective symptoms. 
No significant effect in voluntary motor symptoms  
386 
Nabilone 
Cannabinoid CB1 and 
CB2 agonist 
15 weeks 44 
Significant effect for total motor score, chorea, 
UHDRS cognition, UHDRS behavior and for NPI.  
387 
Ethyl-EPA 
Multiple.Targets 
mitochondrial function 
6 months  316 No significant effect 388 
1 year 135  No significant effect 389 
Atomoxetine  NARI 10 weeks  20  No significant effect 390 
Fluoxetine SSRI 4 months  30 No significant effect 391 
Citalopram  SSRI 20 weeks 33 No significant effect in executive functions 392 
Lamotrigine 
Glutamate release 
inhibitor 
30 weeks 64 
No significant effect in delayed disease progression. 
Symptomatic improvement in some patients and a 
trend towards chorea decrease. 
393 
Riluzole 
Glutamate release 
inhibitor 
3 years 537 No neuroprotective or beneficial symptomatic effects  394 
8 weeks  63  
Improvement in chorea intensity. No improvement in 
functional capacity or other clinical features 
395 
Tetrabenazine  
Catecholamine-depleting 
agent 
12 weeks 84 
Improvement in chorea symptoms 
396 
5 days 30 397 
Clozapine D2 receptor antagonist 31 days 33 Little beneficial effects. 398 
Tiapride D2 receptor antagonist 
4 weeks 22 No significant effect in involuntary movements 399 
9 weeks  29 
Significant improvement in chorea and motor 
symptoms 
400 
Amantadine  
NMDA-receptor 
antagonist 
4 weeks 24 Only palliative benefit 401 
2 weeks 24 No significant effect in chorea symptoms 402 
Remacemide 
hydrochloride 
NMDA receptor 
antagonist 
5 weeks 31 No significant effect 403 
Remacemide 
hydrochloride and 
Coenzyme Q10 
NMDA receptor 
antagonist and 
antioxidant 
30 months 347 No significant effect 302 
Donepezil 
Acetylcholinesterase 
inhibitor 
12 weeks 30 No significant effect 404 
Baclofen  GABA agonist 42 months 60 No significant effect 405 
Modafinil Analeptic 3 weeks 20 
Improvement in alertness but not in cognition or 
mood 
406 
Mavoglurant Selective metabotropic 32 days 42 No significant effect in chorea symptoms 407 
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PolyQ 
disease 
Therapeutic 
molecule 
Mechanism of action 
Treatment 
duration 
N Overall efficacy Ref. 
(AFQ056) glutamate receptor 5 
antagonist 
PBT2 
metal protein-
attenuating compound 
26 weeks  109  No significant effect in cognition 408 
SBMA 
Leuprorelin 
gonadotrophin-releasing 
hormone (GnRH) 
analogue 
48 weeks 199 No significant effects on swallowing function 409 
Dutasteride 
Dual 5-α reductase 
inhibitor 
2 years 50 
No significant effect on the progression of muscle 
weakness 
410 
SCA1,2,6 Dalfampridine  
Potassium channel 
blocker 
10 weeks 20 Unreliable or uninterpretable data NPP 
SCA3/MJD 
Dalfampridine  
Potassium channel 
blocker 
10 weeks 20 Unreliable or uninterpretable data NPP 
Varenicline 
(Chantix) 
α4β2 neuronal nicotinic 
acetylcholine receptor 
agonist 
8 weeks 20 
Improvement of axial symptoms and rapid 
alternating movements. Nausea as a side effect. 
Large percentage of dropouts. 
411 
Lithium carbonate Anti-maniac 24 weeks 62 
No significant effect in NESSCA scores; minor 
progression on the PATA speech-rate, nondominant 
Click test, Spinocerebellar Ataxia Functional Index 
and in the Composite Cerebellar Functional Score 
412 
Trimethoprim and 
sulfamethoxazole 
(Bactrim) 
Antibiotic 24 weeks 22 No significant effect 413 
Abbreviations: N = number of patients (treatment and placebo); MMSE = Mini-Mental State Examination; UHDRS = Unified Huntington's Disease 
Rating Scale; NPI = neuropsychiatric inventory; NARI = Noradrealine reuptake inhibitor; SSRI = Selective serotonin reuptake inhibitor; Ethyl-EPA = 
Ethyl-eicosapentaenoic acid; NPP = No publication provided; NESSCA = Neurological Examination Score for the Assessment of Spinocerebellar 
Ataxia. 
 
 The vast majority of the clinical trials in polyQ diseases have been performed for HD, which is the 
most common of these disorders; however, in the case of remarkable outcomes, they may function as a 
good hypothesis to test in other polyQ diseases which frequently share some symptoms. Nevertheless, 
the design and success of polyQ clinical trials constitutes a challenging issue due to the particularities of 
these diseases, namely: i) highly variable clinical presentation and slow progression of symptoms; ii) lack 
of reliable and specific targetable biomarkers; iii) small number of patients and iv) high costs of clinical 
trials for rare diseases. In fact, the majority of clinical trials performed up to now have failed or produced 
slight success. Therefore, it is crucial to critically analyze the results obtained so far, to be able to design 
novel trials with novel suggestions for the future success of polyQ clinical trials. Some issues regarding 
patient risks and side effects, study duration, sample size, trial rationale and pre-clinical study results, 
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pharmacological and methodology questions and clinical trial design could underlie the current results. 
On the other hand, despite the considerable improvement of the knowledge on the genetics and 
pathophysiology of the polyQ diseases in the past decade, the field is still lacking relevant biomarkers of 
the disease manifestation. Improving the reliability and validity of performance measures of the 
composite rating scales and neuroimaging studies are also major investments that should be kept in the 
field and, finally, a more effective approach to early phase clinical trials is required to speed up the 
identification of suitable drugs for these diseases.  
 While no overall effective treatment is available, physical and/or palliative therapies to 
maintain the individual’s independence in all environmental contexts should be implemented for as long 
as possible. The working goal of this kind of therapy is to establish strategies to optimize sensorial 
information, to improve cognition through different activities, to enhance communication, to increase the 
quality and control of movement in different body postures, to improve approaches for an independent 
gait, to exercise against resistance, to improve hypotonia and motor control and speech therapy414–417. 
These small steps could may represent a great help and motivation leading to an improvement and 
sustainable life quality of patients and their families.   
1.5 Machado-Joseph Disease (MJD) 
 MJD, also known as SCA3, is the most common autosomal dominant ataxia worldwide22,418,419. The 
disease was first described in 1972 in a patient with Portuguese/Azorean ancestors, William Machado, 
by Nakano and colleagues, as an “autosomal dominant ataxia” and named as “Machado Disease”420. 
The Thomas family, also of Azorean ancestry, was reported in 1972 by Woods and colleagues with a 
disease characterized by some similar symptoms that was defined as “Nigro-spino-dentatal 
degeneration with nuclear ophthalmoplegia”421. A few years later, Rosenberg and colleagues described 
a “particular type of autosomal dominant hereditary ataxia” in the family of Antone Joseph, which was 
designated as Joseph disease422. In 1978, Coutinho and Andrade carry out several studies in a large 
number of Azorean families and presented an “autosomal dominant system degeneration in 
Portuguese families of the Azores Islands”423. In the 80´s, Lima and Coutinho proposed for the first 
time the name MJD, and described this as a single disorder characterized by a high clinical variability, 
proposing the clinical classification of patients into three types that clustered all this variability424. MJD is 
considered rare, (global prevalence of 1:10000022,425) with its prevalence varying according to the 
population studied; however, in the Azorean island of Flores its prevalence is reported to be 1:140. 
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Initially, MJD was considered a “Portuguese disease”, but nowadays numerous families have been all 
diagnosed around the world426,427. 
 
1.2.3 Clinical and Neuropathology presentation 
 The central clinical feature in MJD is a slowly progressive ataxia, being the average age at onset 
37 years and the mean survival time of 21 years424, during which the intellect is preserved423. The 
maintenance of the cognitive function is a key feature of MJD in its differential diagnosis among the 
vast group of SCAs. The severity of the disease is associated to the age of onset, an earlier onset being 
related with a more severe and rapidly progressive form of the disease. MJD patients usually present 
ataxia, pyramidal and extrapyramidal signs, progressive external ophthalmoplegia, peripheral 
amyotrophies, with weakness in the arms and legs, intention fasciculation-like movements of facial and 
lingual muscles, rigidity, and bulging eyes422,423,428. The clinical spectrum of MJD is highly pleomorphic 
and led to the definition of four clinical sub-types, according to the age of clinical onset and major 
symptoms of the disorder. MJD type I includes the MJD forms with early age at onset (10-30 years of 
age), faster progression and more intense pyramidal and extra-pyramidal signs such as dystonia, 
tremors and parkinsonism. MJD type II is the most frequent, and is characterized by intermediate 
age-at-onset (20-50 years of age) and progression, with patients presenting ataxia and 
ophthalmoplegia. MJD patients with MJD type III exhibit the latest age at onset (40-70 years of age), 
slow disease progression and more peripheral signs (peripheral neuropathy and amyotrophy). In 1983, 
Roger Rosenberg further added a fourth type, which is the rarest and includes MJD patients 
exhibiting Parkinsonic symptoms associated with the most typical symptoms of MJD418,429. 
 At neurophathological level, MJD is characterized by neuronal loss in the deep cerebellar nuclei, 
substantia nigra, thalamus, striatum, pontine nuclei, spinal cord and cranial nerves, pre-cerebellar 
brainstem, cholinergic and dopaminergic midbrain, as well as visual, auditory, vestibular, 
somatosensory, and ingestion and urination-related systems (Figure 4). Preserved integrity of the 
cortical and subcortical regions of the limbic system and mild degeneration of cerebral and cerebellar 
cortices, white matter of cerebellum, inferior olive and Purkinje cells, are also characteristic of MJD423,430–
435. The majority of the MJD patients’ brains with disease duration of more than 15 years showed 
reduced brain weight when compared with individuals without medical histories of neurological or 
psychiatric diseases436. An enlargement of the fourth ventricule, atrophy of the pons, cerebellar vermis 
and hemispheres, basal ganglia, midbrain, medulla oblongata and spinal cord was revealed through 
magnetic resonance imaging (MRI) and neuroimaging studies437–440. Concerning brain functionality, a 
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decreased metabolism in the cerebellum, brainstem, cerebral cortex, thalamus and putamen was 
observed through magnetic spectroscopy analysis, suggestive of axonal dysfunction, at symptomatic 
ages441–445.  
 
Figure 4. Main MJD affected brain regions are depicted in red. Adapted from31. STN: 
subthalamic nucleus, GP: globus pallidus, RN: red nucleus, SN: substantia nigra, PN: 
pontine nucleus, DN: dentate nucleus, LCN: lateral cuneate nucleus, Cer: 
cerebellum. 
 
 
 Another neurophatological feature of MJD, as of other polyQ diseases, is the presence of 
neuronal ubiquitylated inclusions; in which several other proteins are found, such as molecular 
chaperones, proteasomal components, TFs and both normal and pathogenic ATXN3139,177,446. 
 
1.2.3 MJD Genetics 
 MJD is transmitted in an autosomal dominant manner and, as other polyQ diseases, shows 
intergenerational instability of the expanded CAG repeat. Frequently in polyQ diseases, longer CAG 
tracts are associated with earlier onset and more severe symptoms20, a phenomenon called 
“anticipation”20,447. However, some factors other than the increase of the number of CAG repeat units, 
may play also a role in genetic anticipation of MJD448. 
 MJD is caused by a mutation in the ATXN3 gene mapped to the long arm of chromosome 14 
(14q32.1)4. The gene has around 48 kb and contains 13 exons (two of them recently described), with 
the (CAG)n tract located at exon 10449,450. The number of CAG repeats ranges from 12 to 44 CAG’s in the 
healthy population, whereas expanded alleles typically contain from 52 to 87 repeat units451,452. 
Individuals carrying intermediate CAG repeat units (45-51) may or may not manifest the disease451,453,454. 
It encodes at least, four different transcripts of approximately 1.4, 1.8, 4.5 and 7.5 kb ubiquitously 
expressed in neuronal and non-neuronal human tissues, reported by Northen-blot450,455. These different 
mRNA types are probably a result from differential splicing of exons 2, 10 and 11 of ATXN3 gene, and 
alternative polyadenylation of exon 104,450,456. From sequence analysis of cDNA clones, Ichikawa and 
colleagues described five cDNA variants: MJD1a, MJD1-1, MJD5-1, MJD2-1 and H24,450,456. The MJD1a 
was the first variant described and uses exon 10 to provide the 3’-terminal sequence. The MJD1-1 and 
MJD5-1 variants simply contrast in the size of their 3’ UTR, and have exon 11 as 3’-terminal sequence. 
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The MJD2-1 is similar to MJD1a except for the single nucleotide substitution in the exon 10 stop 
codon456 and n the H2, exon 2 is absent450.  
 A more recent study suggested the existence of 50 additional alternative splicing variants of 
ATXN3 gene, generated by different types of splicing events449 proposing that alternative splicing might 
be an important mechanism regulating ATXN3 expression. 
 
1.5.3 MJD protein: ATXN3 
 The ATXN3 gene encodes for a 42 KDa protein, ATXN3, which is ubiquitously expressed and 
contains a conserved N-terminal Josephin domain (1-198 aa), containing the putative catalytic triad 
aminoacids cysteine (C14), histidine (H119) and asparagine (N134). This domain is followed by two or 
three ubiquitin-interacting motifs (UIMs), depending on the protein isoform, and the polyQ region of 
variable length, whose expansion beyond a certain threshold is associated with MJD457,458. The UIMs can 
act either to bind ubiquitin or ubiquitylated proteins, or to promote ubiquitylation (mono-, oligo- and 
polyubiquitylation)459. In the case of ATXN3 they are thought to bind poly ubiquitylated chains. ATXN3 
also contains a conserved nuclear-localization signal (NLS)460. Similarly, 6 putative nuclear export signal 
(NES) sequences were found within the ataxin-3 primary structure449. 
 The ATXN3 gene is present in different organisms, including plants, nematodes and human. 
Sequence analysis shown that there is a high degree of conservation, at the DNA level, between human 
ATXN3 and the corresponding orthologues in rat461, mouse462, chicken463, and C. elegans464, suggesting 
evolutionary conserved functions and properties465. However, the long polyQ tract seems to be human-
specific because it is absent in other species such as mouse and worms that have only six and one 
glutamines in the ATXN3 homologue, respectively. 
 A crucial finding in the understanding of ATXN3 function was the discovery of its 
deubiquitylating (DUB) activity in vitro458,466,467. Although DUBs are frequently promiscuous, specific 
substrates have been suggested for ATXN3, namely proteins involved in endoplasmic reticulum-
associated degradation (ERAD)468. Lately, alpha5 integrin subunit469 and parkin470,471 were also found to be 
specific substrates of ATXN3. Several studies also described the involvement of ATXN3 in transcription 
regulation128,464,472, cytoskeletal organization170,171,469 and stress responses473–475. 
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1.5.4 Mouse models of MJD 
 Since the description of the disease-causing gene in MJD, several in vitro and in vivo models 
were generated in order to gain insight into the pathogenic mechanism(s) and to develop potential 
therapies. Although more difficult to generate and less genetically manipulable than cell and 
invertebrate models, rodent models share important molecular, anatomical and physiological 
similarities with humans and are relevant for pre-clinical studies aiming at drug discovery and 
development.  
 Several mouse (and rat) models have been described for MJD comprising 9 transgenic mouse 
models37,66,67,85,126,194,228,476,477, 1 lentiviral rat model478, 2 knock-out (KO) mouse models461,479 and 2 knock-in (KI) 
mouse models68,480. Transgenic models are the more appropriate not only to study several biological and 
mechanism feature of the disease, but also for pathology and behavioral phenotype and therefore for 
pre-clinical trials. 
 The first transgenic mouse model of MJD was generated in 1996 by Ikeda and colleagues using 
the truncated and full length cDNA of the ATXN3 gene, under the control of the L7 promoter which 
drives expression specifically to the Purkinje cells, which are only mildly affected in MJD37. No 
pathological changes were observed when full-length ataxin3 cDNA was expressed in the cells, while 
expression of the truncated cDNA led to an early and severe phenotype, together with an extensive 
degeneration of the cerebellar cortex, which does not reproduce the typical pathology in MJD patients.  
 Later, another mouse model was generated in an attempt to better replicate the temporal and 
spatial expression of the human disease gene, using yeast artificial chromosome (YAC) constructs 
carrying the full-length ATXN3 gene (plus two additional genes flanking it) with expanded polyQ and its 
regulatory elements476. This was the first heterozygous model expressing the entire human ATXN3 gene 
and it developed very mild and slowly progressive cerebellar deficits. With the disease progression, 
pelvic elevation became significantly flattened, accompanied by hypotonia, motor and sensory loss, 
tremors and reduced weight gain. This model also displayed cytoplasmic and nuclear ATXN3 
aggregates, and neurodegeneration in later stages476,481,482. The homozygous version of this model 
showed more pronounced effects, as characterized later206. 
 Three additional mouse models were generated by Goti, Bichelmeier, Chou and respective 
colleagues, expressing a pathogenic ATXN3 isoform (mjd1a or c) under the control of prion protein 
(Prnp) promoter85,126,477. These models display similar phenotypes with early onset motor dysfunction and 
intranuclear inclusions replicating the MJD symptoms, however, the neurodegeneration profile was not 
very noteworthy in any of these models. The referred mouse models reproduce many MJD features 
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such as ataxic symptoms, behavioral deficits, tremors and neuronal dysfunction, however, contrary to 
what occurs in human patients the neurological symptoms arise very early and the disease progression 
is very fast. Therefore, Boy and colleagues used the rat htt promoter to direct express the mutant 
ATXN3 in brain which led to weaker expression of the ATXN3 protein but in a ubiquitous manner and a 
brain distribution consistent with that seen in human patients66. This model presents late onset decline 
of motor coordination with slow progression, NIIs, significant neurodegeneration, however with 
hyperactivity during the first months. The same authors developed a conditional mouse model with the 
full-length human ATXN3 cDNA using a Tet-Off system, in order to analyze whether symptoms caused 
by ATXN3 with an expanded repeat were reversible in vivo194. These mice showed motor symptoms and 
reduced body weight gain but when the expanded ataxin-3 expression was turned off in early 
symptomatic stages, the phenotype was reversed. However, in this model the expression of the mutant 
protein in the cerebellum was limited to the glial cells, the involvement of which in MJD has not been 
described. Also, neurodegeneration was mostly present in Purkinje cells, typically not affected in MJD.   
 Another rodent model was obtained in 2008 by Alves and colleagues who injected lentivirus 
expressing human ATXN3 in the striatum of the rat reproducing several cellular aspects of MJD 
neuropathology such as formation of ubiquitinated NIIs and neuronal demise478,483,484.  
 One more model able to recapitulate many features of human disease was described in 2010 by 
Silva-Fernandes and colleagues, directing the expression of mutant ATXN3 under the control of 
cytomegalovirus (CMV) promoter67. The mutant protein was ubiquitously distributed throughout the 
body but only the cerebellum, pontine nuclei, substantia nigra and thalamus were shown to degenerate 
as the disease progresses. No NII’s were observed in any age of the transgenic mice even with the 
early symptoms of motor uncoordination. More recently, the same authors described an identical 
model but with a higher number of repeats which closely recapitulates the human disease in terms of 
motor symptoms, neuropathology, with severe and progressive phenotype228. Recently, two knock-in 
MJD models have also been described, displaying prominent aggregate pathology but with only one of 
them displaying a very mild and late onset of motor symptoms68,480.  
 The importance of having many different animal models of MJD is unquestionable since together 
they provide the improvement in the clarification of several MJD features and pathogenesis. Despite the 
pros and cons of each model, some are valuable to understand the different mechanisms of disease 
progression and others for the development of therapeutic strategies, as they exhibit several MJD-like 
symptoms.  
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1.6 Aims of the study 
 Since there is no effective treatment so far for Machado-Joseph disease, the overall objective of 
this thesis was to develop potential therapeutic strategies for this disorder (hypothesis-based and -free) 
using the CMVMJD135 mouse model, with phenotypic and neuropathologic features of MJD. With this 
purpose we aimed to: 
 
1.  Study the therapeutic efficacy of chronic treatment with valproic acid in the CMVMJD135 mouse 
model; 
2. Study the therapeutic efficacy of citalopram in the CMVMJD135 mouse model; 
3. Unravel the molecular effects of citalopram in the CMVMJD135 mouse model;  
4. Study the therapeutic efficacy of citalopram in the CMVMJD135 mouse model using a post-
symptomatic treatment and a more severe disease state. 
 
1.2.3 Thesis planning 
 The current thesis is divided into 6 chapters. The Chapter 1 consists of a general introduction; 
Chapter 2 to 5 comprises the hypothesis-based and hypothesis-free therapeutic approaches in the 
CMVMJD135 mouse model (in research articles form, published and in preparation); and, in Chapter 6 
is provided a general discussion of the thesis.  
 
In Chapter 1 a general introduction to the thesis is provided. A brief overview on polyglutamine 
diseases and the major potential pathomechanisms underlying these diseases is presented. A more 
extensive part of the introduction centers on a general state of the art of the existent therapeutic 
strategies as well as the complete clinical trials in humans patients for polyQ diseases. In addition, a 
summary of Machado-Joseph disease and its available mouse models is presented.  
 
In Chapter 2 the work “Limited effect of chronic valproic acid treatment in a mouse model of 
Machado-Joseph Disease”, describes a hypothesis-based therapeutic approach with valproic acid. We 
show that chronic VPA treatment in the CMVMJD135 mouse model had limited effects in the motor 
deficits of these mice seen, mostly at late stages, without changing the ATXN3 inclusion load in 
affected brain regions. 
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In Chapter 3 the work entitled “Serotonergic signaling suppresses ataxin-3 aggregation, improves 
motor balance and coordination and exerts neuroprotection effects in a mouse model of Machado-
Joseph disease” is provided. In this work, we tested the therapeutic efficacy of chronic pre-symptomatic 
citalopram treatment in CMVMJD135 with two different dosages. This compound reduced ataxin-3 
neuronal inclusions, mitigated neuronal loss and astrogliosis, strikingly ameliorated motor symptoms 
and exert molecular neuroprotective effects. These results suggest that modulation of serotonergic 
signaling could be a promising therapeutic strategy for MJD. 
 
Chapter 4,”Dissecting the molecular effects of chronic citalopram treatment in an MJD mouse 
model” focuses on unraveling the molecular changes in the brain responsible for the phenotype 
amelioration upon citalopram treatment. Some interesting trends was observed towards an increase in 
neuroprotective molecules, however; without statistical differences. The continuous efforts in 
understanding, at pathological and molecular levels, the citalopram mode of action in MJD may shed 
light into the underlying pathogenesis of this disease and into the identification of novel therapeutic 
targets. 
 
In Chapter 5, “Assessement of chronic citalopram post-symptomatic treatment in a MJD mouse 
model with increased severity“ is presented. In an attempt to better mirror the patients treatment, we 
performed a post-symptomatic citalopram treatment in a high severity disease condition of the 
CMVMJD135 mouse model. Citalopram post-symptomatic treatment led to mild improvement in 
balance and motor coordination in this group of animals with no impact on ATXN3 aggregation and 
astrogliosis. Efficacy post-symptomatic treatment of citalopram may not be able to improve the 
symptoms when the disease condition is too severe and fully established, validating this approach but 
also suggesting that early onset of treatment may be more effective in human patients. 
 
A general discussion of this thesis work and future perspectives are presented in Chapter 6. 
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Abstract 
Machado-Joseph disease (MJD) is an inherited neurodegenerative disease, caused by a CAG 
repeat expansion within the coding region of ATXN3 gene, and which currently lacks effective 
treatment. In this work we tested the therapeutic efficacy of chronic treatment with valproic acid (VPA) 
(200mg/kg), a compound with known neuroprotection activity, and previously shown to be effective in 
cell, fly and nematode models of MJD. We show that chronic VPA treatment in the CMVMJD135 mouse 
model had limited effects in the motor deficits of these mice, seen mostly at late stages in the motor 
swimming, beam walk, rotarod and spontaneous locomotor activity tests, and did not modify the 
ATXN3 inclusion load and astrogliosis in affected brain regions. However, VPA chronic treatment was 
able to increase GRP78 protein levels at 30 weeks of age, one of its known neuroprotective effects, 
confirming target engagement. In spite of limited results, the use of another dosage of VPA or of VPA in 
a combined therapy with molecules targeting other pathways, cannot be excluded as potential 
strategies for MJD therapeutics. 
 
Introduction 
Polyglutamine (PolyQ) diseases are neurodegenerative disorders caused by an expansion of 
trinucleotide CAG repeats within the coding region of specific genes1. This group of disorders includes 
spinal bulbar muscular atrophy (SBMA), Huntington’s disease (HD), Dentatorubral-Pallidoluysian 
atrophy (DRPLA), and  six types of spinocerebellar ataxias (SCA’s)2. Machado-Joseph disease (MJD) or 
Spinocerebellar Ataxia type 3 (SCA3) is the most common dominantly inherited SCA worldwide and is 
caused by the expansion of a polyQ tract in the C-terminus of the ATXN3 gene product3. Both the 
normal and expanded ataxin-3 (ATXN3) proteins are expressed ubiquitously, although the 
neurodegeneration in MJD is limited to some brain regions, mainly in cerebellum, brainstem and spinal 
cord4. The symptoms include ataxia, progressive external ophthalmoplegia, pyramidal and 
extrapyramidal signs, peripheral amyotrophies, intention fasciculation-like movements of facial and 
lingual muscles, rigidity, and bulging eyes5–7. The pathological hallmark of the disease is the presence of 
neuronal intranuclear inclusions (NIIs) of aggregation-prone expanded ATXN3 in the patients' brain, 
being the pathogenic relevance of these aggregates still unclear8–11. 
Despite the recent efforts towards the understanding of the pathogenesis of this disorder, the 
molecular pathways that ultimately lead to neuronal demise remain mostly unknown and no effective 
treatments are yet available for MJD, as for other polyQ diseases. Nevertheless, there seem to be 
common pathways between all polyQ diseases that were shown to be altered, which could be explored 
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in the development of therapeutics, related to transcriptional dysregulation, mitochondrial dysfunction, 
oxidative stress, Ubiquitine Proteasome System (UPS) impairment, excitotoxicity, DNA damage and 
activation of apoptotic pathways12.   
Nevertheless, the translation of candidate therapies to clinical trials is a very long process due 
to uncertainty for human safety and has not improved significantly in the last years. In this context, 
drug re-purposing strategies, which relies on finding new uses for existing FDA-approved compounds, 
has been gaining attractiveness due to the faster translation to the clinic, with predictably less safety 
issues.   
VPA is an FDA-approved compound that has been used over the years as an anticonvulsant 
and mood-stabilizing drug in the treatment of epilepsy, bipolar disorder and migraine13, with a relatively 
safe profile in clinical use. In the last years, a growing body of evidence indicates that VPA holds 
promise in treating other neurodegenerative diseases due to its diverse mechanisms of action. Its 
pharmacological effects comprise a range of mechanisms, including inhibition of histone deacetylases, 
increased gamma-aminobutyric acid (GABA)-ergic transmission, reduced release and/or effects of 
excitatory amino acids, blockade of voltage-gated sodium channels and modulation of dopaminergic 
and serotoninergic transmission14. VPA treatment is also known to produce changes in the expression 
of multiple genes, involved in transcription regulation, cell survival, ion homeostasis, cytoskeletal 
modifications, signal transduction, endoplasmic reticulum stress and longevity13,15 This drug has been 
shown to delay the disease onset, to reduce neurological deficits and/or to prolong survival in several 
models of neurodegenerative diseases, including HD, SBMA and Amyotrophic Lateral Sclerosis (ALS)16–
18. In MJD, VPA was reported to alleviate neurodegeneration in a Drosophila model of the disease19 and 
to attenuate mutant ATXN3-induced cell toxicity in a human neuronal cell model20. Moreover, we have 
previously shown a significant reduction of mutant ATXN3 aggregation and neurological dysfunction in 
a C. elegans model of MJD upon VPA treatment through the protective role of the transcription factor 
DAF-16, supporting a role in protection against proteotoxicity related to aging and cell survival21. 
However, its therapeutic efficacy is still not demonstrated in a mammalian model of MJD.  The goal of 
this work was to test the therapeutic efficacy of chronic VPA treatment in a mouse model of MJD, 
CMVMJD13522. Our results show that chronic VPA treatment at the dosage used in this pre-clinical trial, 
lead to very limited and transient phenotypic effects in the CMVMJD135 mouse model, and did not 
change the ATXN3 inclusion load neither astrogliosis in affected brain regions.  
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Material and Methods 
Ethics statement. All animal procedures were conducted in accordance with European regulations 
(European Union Directive 2010/63/EU). Animal facilities and the people directly involved in animal 
experiments (SE, SDS, ANC and ASF) were certified by the Portuguese regulatory entity — Direcção 
Geral de Alimentação e Veterinária. All of the protocols performed were approved by the Ethics 
Subcommittee for Life and Health Sciences of the Life and Health Sciences Research Institute, 
University of Minho. All experiments were designed with commitment to the principles of refinement, 
reduction, and replacement and performed according to the FELASA guidelines to minimize discomfort, 
stress, and pain to the animals, with defined humane endpoints23. Humane endpoints for the pre-
clinical trial were defined as 20% reduction of the body weight, inability to reach food and water, 
presence of wounds in the body and dehydration), however they were not needed as the study period 
was conceived to include ages at which animals do not reach these endpoints.  
 
Transgenic mice model and drug administration. We used the CMVMJD135 (background 
C57BL/6) mouse model, expressing an expanded version of the human MJD1-1 cDNA (the 3 UIMs-
containing variant of ATXN3) under the regulation of the CMV promoter, ubiquitously and at near-
endogenous levels22. These animals show a slowly progressive motor phenotype and CNS pathology 
consistent with that of MJD patients22. Male transgenic and non-transgenic drug- and placebo- treated 
animals were sequentially assigned and housed at weaning in groups of 5 animals in filter-topped 
polysulfone cages 267 × 207 × 140 mm (370 cm2 floor area) (Tecniplast, Buguggiate, Italy), with 
corncob bedding (Scobis Due, Mucedola SRL, Settimo Milanese, Italy) in a conventional animal facility. 
DNA extraction, animal genotyping and CAG repeat size analyses were performed as previously 
described 24, with the mean repeat size (±SD) for all mice of (133±1). Male littermates wild-type (WT) 
animals were used as controls. All animals were maintained under standard laboratory conditions: an 
artificial 12 h light/dark cycle (lights on from 8:00 to 20:00 h), with an ambient temperature of 21±1 
°C and a relative humidity of 50–60%; the mice were given a standard diet (4RF25 during the gestation 
and postnatal periods, and 4RF21 after weaning, Mucedola SRL, Settimo Milanese, Italy) and water ad 
libitum. We administered Valproic acid sodium salt (PG-4543, Sigma) during five consecutive days per 
week through intraperitoneal injection (i.p), in a dosage of 200mg/kg dissolved in 0,9% saline. Control 
animals were given a placebo of injection buffer (0.9% NaCl) with the same frequency. Treatment was 
initiated at five weeks of age, i.e. one week before the onset of the first neurological symptoms, until 30 
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weeks of age. for pre-clinical trial. For a pilot study, WT animals were treated for 5 consecutive days 
with i.p. injections of VPA at 200mg/k or saline.  
 
Western-blot. Cerebellum tissues were thawed and homogenized with a Potter-Elvejhem 377 
homogenizer with a Teflon pestle, at 300 rpm, in lysis buffer (150 mM NaCl, 50 mM Tris, 5 mM EGTA, 
1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, pH 7.5) supplemented with 100 nM okadaic 
acid, 25 mM NaF, 1 mM Na3VO4, 1 mM DTT, 1 mM PMSF, 1 μg/mL of protease inhibitor cocktail 
(chymostatin, pepstatin A, leupeptin and antipain), 1 μM trichostatin A (HDACs inhibitor) and 10 mM 
nicotinamide (sirtuins inhibitor). The homogenates were then sonicated for 15 s and centrifuged at 
20,800 g for 10 min to remove cell debris. The pellet was discarded, the supernatant (total extract) 
was collected and protein content quantified by Bio-Rad protein assay (Bio-Rad). Total extracts were 
denatured with denaturing buffer (50 mM Tris-HCl pH 6.8, 2% SDS, 5% glycerol, 600 mM DTT, 0.01% 
bromophenol blue) at 95 ºC, for 5 min. Equivalent amounts of protein (30µg) were separated on a 15% 
SDS-PAGE gel electrophoresis and electroblotted onto polyvinylidene difuoride (PVDF) membranes. The 
membranes were blocked for 1 h in Tris-buffered saline (TBS) solution containing 0.1% Tween (TBS-
Tween) and 5% BSA, followed by an overnight incubation with primary antibodies (rabbit anti-acH3 
(1:1,000, Milipore), rabbit anti-Lamin B1 (1:1000, Abcam) rabbit anti-GRP78 (1:1000, Abcam) and 
mouse anti-actin (1:5000, Ambion), at 4ºC, with gentle agitation. Membranes were then washed 3 
times, for 10 min, with TBS-Tween, and incubated with secondary antibodies conjugated with alkaline 
phosphatase (1:10,000), for 1 h, at room temperature, with gentle agitation. Immunoreactive bands 
were visualized by alkaline phosphatase activity after incubation with ECL substrate, in a ChemiDoc 
Imaging System (Bio-Rad). Bands were quantified using the Image Lab software (Bio-Rad). 
 
Gene expression quantification (qRT-PCR). Cerebellum total RNA was isolated from 18 week-old 
CMVMJD135 littermate mice, vehicle- and VPA-treated (n=4 for each group) using TRIZOL (15596-026, 
Invitrogen, Calrsbad, USA) according to the manufacturer’s protocol. RNA samples were treated with 
DNase I (EN0525, Thermo Scientific®, USA) according to the manufacturer’s protocol. First-strand 
cDNA, synthesized with iScript cDNA Synthesis kit (#170-8891, Bio-Rad, USA) was amplified by 
quantitative reverse-transcriptase PCR (qRT-PCR) as previously described24. The following primers were 
used for expression quantification: GADD45α (F 5-AGACCGAAAGGATGGACACG-3’); GADD45α (R 5’-
TGACTCCGAGCCTTGCTGA-3’); BIM (F 5’-CGGATCGGAGACGAGTTCA-3’); BIM (R 5’-
TTCAGCCTCGCGGTAATCA-3’); B2m (F 5’-CCTTCAGCAAGGACTGGTCT-3’ and B2m (R 5’-
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TCTCGATCCCAGTAGACGGT-3’). Primers were designed using PRIMER-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/).  
 
Behavioral analysis 
Behavioral analysis was performed during the diurnal period in groups of 5 male animals per cage 
including CMVMJD135 hemizygous transgenic mice and WT littermates (n=10-15 per genotype) treated 
and non-treated with VPA. All behavioral tests started in a pre-symptomatic stage of the disease (4 
weeks of age) and were conducted until an age at which the phenotype is fully established (30 
weeks)22. The animals were weighed one week before the start of drug treatment (4 weeks) and then 
every two weeks until 30 weeks of age (Fig. 2). 
 
Neurological examination (based on SHIRPA protocol). Based on the SHIRPA protocol we 
established an adapted protocol for phenotypic assessment applied since 4 weeks until 24 weeks of 
age, in which we used the tests for which, based on our previous experience, CMVMJD135 mice 
usually present significant phenotypic alterations22. We assessed motor function through the 
spontaneous activity test, by counting wall-leanings during five minutes, and locomotor activity in which 
we counted the number of squares travelled over 30 secs, in an arena (55×33×18 cm) with 15 labeled 
squares. Other observational measurements included tremors and limb clasping, in which we 
suspended the animal by the tail and classified the extensor reflexes. In this protocol we also included 
the hanging wire test, as a measure of muscle strength and fine motor coordination of the paws. This 
protocol was adjusted in order to minimize animal handling and to generate uniformity in waiting times 
between the tests25.  
 
Footprint analysis. To evaluate the dragging of the paws, the footprint test was used since 10 weeks 
of age. To obtain footprints, the hind‐ and forepaws of the mice were coated with black and red non‐
toxic paints, respectively. We used a clean rectangular paper sheet placed on the floor of the runway for 
each run. The animals were allowed to walk along a 100‐cm‐long × 4.2 cm width × 10 cm height 
corridor in the direction of an enclosed black box. Each animal was allowed to achieve one valid trial 
per age. To evaluate the severity of foot-dragging through age the footprinting pattern was classified at 
each time point considering six consecutive steps (0=absent dragging, up to three steps; 1=moderate 
dragging, less than three steps out of six; 2=severe dragging, all steps out of six show dragging). The 
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stride length was also measured through the footprinting pattern by measuring the length between 
three consecutive steps.  
 
Motor swimming test. To assess swimming movement coordination, the time that animals take to 
reach a safe platform at the end of a container (60 cm distance) with 15 cm depth of water at 24‐
26°C was recorded bi-weekly since 22 weeks of age. The protocol consisted of 2 days of training with 
three trial followed by three days of test with two trials as previously described22,26. 
 
Beam walk test. Balance and fine motor coordination of mice were assessed by measuring the ability 
of the mice to traverse, without falling, a graded series of narrow beams to reach an enclosed safety 
platform as previously described22,26. During training, mice were placed at the start of the 12 mm square 
beam and trained over 3 days (3 trials per day) to traverse the beam to the safe platform. On the fourth 
day, they were tested in the training beam (12 mm square) and 11 mm round beam (2 trials per 
beam).  
 
Rotarod test. To evaluate motor skill learning and coordination with another paradigm, mice were 
tested in a rotarod apparatus (TSE systems, Bad Homburg, Germany). The protocol is comprised of 3 
training days at a constant speed (15 rpm) for a maximum of 60 s in four trials, with a 10 min interval 
between each trial. On the fourth day, animals were tested for each of 6 different speeds (5 rpm, 8 
rpm, 15 rpm, 20 rpm, 24 rpm and 31 rpm) for a maximum of 60s in two trials, with a 10-min-long 
interval between each trial, as previously described24. 
 
Immunohistochemistry and quantification of ataxin-3 neuronal inclusions and 
astrogliosis. Thirty week-old WT and CMVMJD135 littermate mice, VPA-treated and non-treated (n=4 
for each group) were deeply anesthetized- with a mixture of ketamine hydrochloride (150 mg/kg) plus 
medetomidine (0.3 mg/kg) and transcardially perfused with phosphate-buffered saline (PBS) followed 
by 4% paraformaldehyde (PFA) (Panreac, USA). Brains were removed and post fixed overnight in PFA 
4% and embedded in paraffin. Slides with 4-µm-thick paraffin sections were subjected to antigen 
retrieval (Buffer Citrate, 1M) and then incubated with mouse anti-ATXN3 (1H9) (1:1000, MAB5360, 
Milipore) and GFAP (1:500, Z0334, Dako corporation) which were detected by incubation with a 
biotinylated anti-polyvalent antibody, followed by detection through biotin-streptavidin coupled to 
horseradish peroxidase and reaction with the DAB (3, 3'-diaminobenzidine) substrate (Lab VisionTM 
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Ultra-VisionTM Detection kit, Thermo Scientific). The slides were counterstained with 25% hematoxylin 
according to standard procedures. ATXN3 positive inclusions in the facial motor nucleus (7N) and 
lateral reticular nucleus (LRt), and GFAP positive cells in substantia nigra (SN) of vehicle or VPA-treated 
animals (n=4 for each conditions, 4 slides per animal) were quantified and normalized for total area 
using the Olympus BX51 stereological microscope (Olympus, Japan) and the Visiopharma integrator 
system software (Visopharm, Denmark) as previously described22. The total area of 7N,LRT and SN 
were chosen based on the mouse brain atlas27. 
 
Determination of Valproic acid Plasma Levels. The plasma valproic acid levels were measured 
applying the VALP assay using the Dimension Vista® System (VALP Flex® reagent cartridge) – 
SIEMENS. 
 
Statistical analysis. The experimental unit used in this study was a single animal. Experimental 
design was based on power analyses for optimization of sample size 28. Mouse sample size calculations 
were performed for each behavioral test and pathological analyses assuming a power of 0.8 and a 
significance level of p < 0.05. The effect size was calculated aiming at detecting 50% improvement. We 
used n = 10 to 15 per genotype/treatment for behavioral tests, and a group size of four animals per 
group for quantification of ATXN3 NIIs analysis. Data was analyzed through the non-parametric Mann-
Whitney U-test when variables were non-continuous or when a continuous variable did not present a 
normal distribution (Kolmogorov-Smirnov test, p<0.05) (Rotarod). Continuous variables with normal 
distributions and with homogeneity of variance (Levene’s test) were analyzed with Repeated-Measures 
ANOVA for longitudinal multiple comparisons, using Tukey test for post-hoc comparisons and One-way 
ANOVA for paired comparisons Non-continuous categorical variables were analyzed through Chi-Square 
Fisher exact test. All statistical analyses were performed using SPSS 22.0 (SPSS Inc., Chicago, IL) and 
G-Power 3.1.9.2 (University Kiel, Germany). A critical value for significance of P < 0.05 was used 
throughout the study. Values  were  expressed  as  mean ± SEM  for  continuous  variables  and  as  
percentages  for  non‐continuous variables. 
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Results 
 
Effect of VPA acute treatment in histone acetylation and neuroprotective molecules in the 
cerebellum  
Although CMVMJD135 mouse model do not present a general hypoacetylation of histones in 
specific brain regions, we measured the H3 acetylation and we observed a trend towards an increase in 
H3 acetylation levels upon 5 days of VPA acute treatment (Fig. 1A). 
This result did not present statistical difference due to high variability between samples, 
however, a trend was observed to an hyperacetylation of histone H3 in the cerebellum upon VPA 
treatment, when normalized to the nuclear protein Lamin B1. Furthermore, and considering our 
previous results in C.elegans model of MJD upon VPA treatment, we also assessed the mRNA levels of 
GADD45α and BIM, two genes related to stress resistance and apoptosis regulation, respectively 29–32, in 
the cerebellum of CMVMJD135 mice, where a trend towards an increase upon VPA acute treatment was 
also observed (Fig. 1B). 
Plasma VPA concentration was also assessed after 30 and 120 minutes post-injection. An 
average of 252 ± 15.8 µmol/L after 30 minutes was observed in VPA-treated animals while a 25.7 ± 
8.7 µmol/L concentration was detected after 120 minutes post-injection (Fig. 1C).  
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Figure 1. VPA acute treatment effects in cerebellum of CMVMJD135 mouse model. (A) A trend towards an increase in the 
H3 histone acetylation upon VPA acute treatment; (B) a trend towards an increase in GADD45α and BIM mRNA levels upon 
VPA acute treatment and (C) VPA concentration in the plasma after 30 and 120 minutes post-injection. Bars represent the 
mean ± SEM (n=4 males for each group), One-Way ANOVA. 
 
VPA treatment had limited effects in neurological deficits and decreased the body weight 
gain in CMVMJD135 mice 
Chronic VPA treatment was initiated at 5 weeks of age, with a dosage of 200mg/kg, for 5 
consecutive days each week, until 30 weeks of age. A battery of neurological and motor coordination 
tests was performed since 4 weeks of age until 30 weeks of age (Fig. 2). 
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Figure. 2. Schematic representation of the VPA pre-clinical therapeutic trial. 
  
No differences were found between WT and CMVMJD135 mice at 4 weeks of age before the beginning 
of the injections. CMVMJD135 mice start showing less body weight gain at 16 weeks of age, being 
statistically different from age-matched WT littermates at 24 weeks of age (Fig. 3A). VPA treatment 
significantly reduced the already diminished body weight gain of the transgenic animals since very early 
in this trial (Fig. 3A) suggesting some toxicity to these animals. 
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Figure 3. Minor effects in neurological deficits and body weight gain presented by CMVMJD135 mice upon 
VPA treatment. (A) Decreased body weight gain in CMVMJD135 VPA-treated animals compared to CMVMJD135 vehicle-
treated animals; (B) no improvement of VPA-treated animals in grip strength as assessed through the hanging wire test; (C) 
Improvement in spontaneous locomotor activity at 24 weeks of age; (D,E,F) No improvement in spontaneous activity 
(vertical movement), in tremors and limb clasping, respectively, (G) transient improvement in footdragging severity at 14 
weeks, and (H) tendency toward an improvement in stride length at 22 and 24 weeks of age. Bars represent the mean ± 
SEM (WT veh, n=10; WT VPA, n=15; CMVMJD135 vehicle, n=10; CMVMJD135 VPA, n=13), * represent p<0.05, ** 
represent p<0.01 and *** represent p<0.001, black asterisks represents the difference between WT and CMVMJD135, blue 
asterisks represents the difference between non-treated and VPA-treated CMVMJD135 (Repeated-measures ANOVA, Tukey 
correction for continuous variables, One-Way ANOVA for differences between groups in specific ages of the continuous 
variables and Chi-square Fisher’s exact test for categorical non-continuous variables).  
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Other than reduced weight gain, no apparent clinical symptoms indicative of significant health 
impact were observed during long-term VPA treatment of WT and transgenic animals, and no more than 
20% of their total body weight was lost at any instance. The first sign of neurological disease in the 
CMVMJD135 mouse model is the presence of muscular grip strength abnormalities at 6 weeks of age, 
given by the significant decrease in the latency to fall off in the hanging wire test 22. VPA treatment did 
not alter the progression of the CMVMJD135 animals in the hanging wire, demonstrating an absence of 
effect in muscle strength and/or fine motor coordination of the paws (Fig. 3B). Spontaneous locomotor 
activity of transgenic animals, given by the number of squares travelled in the arena, was markedly 
increased upon VPA treatment at 24 weeks of age (Fig. 3C). However, spontaneous vertical exploratory 
activity, tremors and clasping were not improved by VPA treatment (Fig. 3D,E,F).  
Gait abnormalities were assessed qualitatively by the analysis of the footprint pattern. 
CMVMJD135 mice model presented foot dragging already at 12 weeks progressing through age. VPA 
was able to decrease the severity of this phenotype only at 14 weeks (Fig. 3G), while no effect was 
observed at more advanced stages of the trial. In addition, stride length was also measured and 
although not significant, a trend towards and improvement in transgenic animals upon VPA treatment 
was observed at 22 and 24 weeks of age (Fig. 3H).  
 
Long-term VPA treatment led to limited improvement in balance and motor coordination 
at later disease stages 
Since chronic VPA treatment induced a decrease in body weight of transgenic animals, 
behavior performance in the motor and balance coordination tests was normalized to body weight. 
Results of behavioral tests without normalization to body weight are included in supplementary data 
(Fig. S1).  
VPA treatment ameliorated balance and motor coordination of CMVMJD135 mice at 24 weeks 
of age, after 20 weeks of daily treatment, as assessed by the time taken to cross the 11 mm circle and 
12 mm beams in the balance beam walk test. However, this improvement was not maintained at 30 
weeks of age (Fig. 4A,B). 
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Figure 4. Balance and motor coordination performance normalized for animal body weight. (A,B) No 
differences were observed between non-normalized and normalized performance for body weight in balance beam walk test; 
(C) improvement motor swimming test at 22 and 30 weeks of age and (D) improvement at 22 weeks of in 8 and 20 rpm of 
Rotarod test. Bars represent the mean ± SEM (WT veh, n=10; WT VPA, n=15, CMVMJD135 vehicle, n=10; CMVMJD135 
VPA, n=13), * represent p<0.05, ** represent p<0.01 and *** represent p<0.001, black asterisks represents the difference 
between WT and CMVMJD135, blue asterisks represents the difference between non-treated and VPA-treated CMVMJD135, 
(Repeated-measures ANOVA, Tukey correction for continuous variables, One-Way ANOVA for differences between groups in 
specific ages of the continuous variables and Mann-Whitney U test for continuous variables without normal distribution 
(Rotarod). 
 
In the motor swimming test, VPA-treated CMVMJD135 mice also had a better performance 
later in life (22 and 30 weeks of age) when compared to vehicle-treated mice (Fig. 4C). Other motor 
deficits observed in CMVMJD135 mice, namely the loss of motor coordination observed in the Rotarod 
test, were alleviated by VPA treatment at 22 weeks of age for 8 and 20 rpm, but not maintained at 30 
weeks of age (Fig. 4D,E).  
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VPA treatment did not change the ataxin-3 inclusion load and astrogliosis in specific 
brain regions of CMVMJD135 mice 
At the pathological level, CMVMJD135 mice show presence of ATXN3 NIIs in the nucleus of 
cells in different regions of the CNS including the pontine nuclei, reticulotegmental nucleus of the pons, 
spinal cord neurons, facial motor nuclei, anterior olfactory nuclei, ventral tenia tecta, inferior olive, 
dentate nuclei, locus coeruleus, cuneate nuclei and lateral reticular nuclei22. The analysis of brain tissue 
of VPA-treated and non-treated CMVMJD135 by immunohistochemistry of ATXN3 in facial motor nuclei 
(7N) and lateral reticular nuclei (LRt), did not reveal significant differences between groups (Fig. 6A-D). 
Astrogliosis observed in substantia nigra of the CMVMJD135 mouse model, was also not mitigated 
upon VPA treatment (Fig. 6E,F).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figue 5. Immnuhistochemistry and quantification of ATXN3 neuronal inclusions and astrogliosis of VPA-
treated and non-treated CMVMJD135. No differences in nuclear ATXN3 inclusion load were observed between groups 
in (A,B) 7N and (C,D) LRt brain regions. No differences in astrogliosis in substantia nigra (SN) between VPA-treated and non-
treated transgenic animals (E,F). Scale bar of ATXN3 figures, 20 µm; Scale bar of GFAP figure, 200 µm.Bars represent the 
mean ± SEM (n=4 for each group), One-Way ANOVA. 
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Chronic VPA treatment increases GRP78 protein levels in cerebellum of CMVMJD135 
mice 
One of the neuroprotective actions described for VPA is its ability to increase GRP78 protein 
levels, through HDAC inhibition15. GRP78, also known as binding immunoglobulin protein (BiP), is a 
stress chaperone protein found in the lumen of the endoplasmic reticulum (ER) which binds newly 
synthesized proteins as they are translocated into the ER, and keeps them in a competent state for 
subsequent folding and oligomerization33. We specifically investigated the potential role of HDAC 
inhibition by monitoring the GRP78 protein levels induction upon VPA treatment. We observe a striking 
increase in GRP78 protein levels in CMVMJD135-treated animals when compared to non-treated 
animals, in the cerebellum at 30 weeks of age (Fig. 6).  
 
 
 
Figure 6. Cerebellum western-blot and quantification of GRP78 protein 
levels in 30 week-old WT, VPA-treated and non-treated CMVMJD135 
mice. GRP78 protein induction in CMVMJD135 animals upon VPA 
treatment. Bars represent the mean ± SEM (n=4 for each group), * 
represent p<0.05, One-way ANOVA. 
 
 
 
Discussion 
In the past years, the use of VPA as a treatment for neurodegenerative disease models has 
been shown to improve neurological phenotypes, decrease cell degeneration and toxicity, together with 
the increase of histone acetylation and subsequent gene transcription activation34–39. The dosage of VPA 
of 200mg/kg used in this pre-clinical trial was previously described in a pre-clinical trial ALS, in which 
neuroprotective and histone acetylation effects were shown40,41. Here, we also show that five days 
treatment with 200mg/kg of VPA was able to exert a trend towards an increase in histone acetylation in 
cerebellum and a tendency to increase GADD45α and BIM mRNA levels, which may be used as VPA 
target engagement42–44. The acute treatment and/or high variability between animals may account for 
the lack of statistical differences between groups. Acute VPA treated animals presented therapeutic 
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levels of 252 ± 15.8 µmol/L and 25.7 ± 8.7 µmol/L in plasma, after 30 and 120 minutes post-
injection, respectively, which was within the usually accepted therapeutic range of VPA. Therefore, we 
performed a pre-clinical trial with five consecutive day treatment starting at 5 and ending at 30 weeks 
of age in CMVMJD135 mouse model. Animals in the pre-clinical trial were always maintained in an 
appropriate and healthy environment avoiding the development of any stressful condition that may 
interfere with their motor performance. Although previous findings by several groups suggested a 
therapeutic effect for VPA in cellular and invertebrate animal models of SCA3, in the present study, 
chronic VPA treatment of CMVMJD135 mice lead to a late and limited improvement in the motor 
performance, given by the beam balance, motor swimming, rotarod and spontaneous locomotor 
activity tests. For other general health and neuromuscular function, VPA-treatment had only marginal or 
even no effects comparing to vehicle-treated transgenic animals. In addition, the dosage used in this 
study is not considered toxic for mice and is already described as safe in the literature18,40,41,45. 
Nevertheless, chronic VPA treatment at similar dosage was already described to reduce the body mass 
gain in WT animals40, even though chronically treated human patients are known to increase their body 
weight upon VPA treatment46–48. Metabolic differences and biological system diversity could be the 
reason for these contradictory observations. 
At the pathological level, we examined the presence of ATXN3 neuronal nuclear inclusions in 
facial nuclei (7N) and lateral reticular nuclei (LRt), two regions described to be affected in MJD human 
patients49,50, as well as in CMVMJD135 mouse model22. No differences were observed in the amount of 
nuclear neuronal inclusions of ATXN3 in both VPA-treated and non-treated CMVMJD135 mice. 
Additionally, astrogliosis is a consistent pathological phenotype of CMVMJD135 mouse model and 
human patients, which was also not mitigated by VPA chronic treatment.  
The overexpression of specific chaperones has been shown to allow protection against cellular 
damage and/or death caused from an extensive group of agents and conditions including cytotoxic 
chemicals51, oxidative stress52 and ER stress33. Here we show that the induction of GRP78 protein levels 
upon VPA chronic treatment, whose overexpression may be neuroprotective in proteinopathies, 
including MJD53,54, could be one of its cytoprotective actions in the MJD context, enhancing the folding 
capacity of the ER. The induction of GRP78 also indicates VPA target engagement during the chronic 
treatment in the pre-clinical trial, as this protein is known to be induced by VPA15. Although we did not 
observe a statistical difference in the CMVMJD135 animals when comparing to WT, enhancing the 
expression of this molecular chaperone in the cerebellum of these mice could be one of the 
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neuroprotective mechanisms responsible for the late and mild improvement of the CMVMJD135 animal 
motor performance.  
The observed beneficial effects of VPA were transient, occurred mostly later in life and thus at 
an advanced stage of disease (between 22 and 30 weeks of age), mainly in behavioral tests more 
related with motor coordination. These results are comparable to some extent with previous findings, in 
which we have shown a significant reduction in neurological dysfunction in a C. elegans model of MJD 
after VPA treatment that was more relevant later in the worm’s life (day10) in spite of early treatment21. 
Previous evidence also suggested a protective role for VPA in the context of MJD, both in cell and 
Drosophila models, by attenuating mutant ATXN3 induced cell toxicity and alleviating polyQ-induced 
phenotypic abnormalities, without major impact on ATXN3 inclusion19,20; in C. elegans, there was some 
improvement of aggregation, but less prominent than that observed for other compounds, for instance 
Hsp90 inhibitors21.  
Although the effects observed in our mouse model were not striking, only one dosage of VPA 
was tested; thus, the possibility of testing other dosages, far from toxic and lethal ones55,56, should be 
considered, as they could exert more pronounced effects. Moreover, the complex activity and a broad 
range of VPA effects also create the need for further clarification of the effects of this drug not only at 
the symptom level, but also molecular and pathological levels in the CMVMJD135 mouse model. In 
fact, and although the use of HDACi’s in the context of polyQ diseases has showed promising results, 
the evidence for a globally decreased histone acetylation is not fully consistent57, and this strategy still 
lacks some target specificity/selectivity58 and requires a more in depth study of the mechanisms of 
action of these compounds in the central nervous system. Furthermore, chronic VPA treatment in 
human patients can produce some side effects, such as weight gain59,60, decreased reproductive 
potential61,62 and increased susceptibility to birth defects63–65. Nevertheless, the strategy of re-purposing 
FDA/EMA-approved molecules, as VPA, could be of benefit for MJD and other rare diseases lacking 
effective therapies. Additionally, there is still an open window for different VPA dosages to be tested and 
since in the past years, a growing number of efforts are being developed for the formulation of a new 
generation of more selective and specific compounds this could be useful for the treatment not only of 
MJD, but also of other polyglutamine diseases. 
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Supplementary data 
 
Figure S1. Balance and motor coordination were improved at later stages upon VPA treatment given by the 
balance beam and motor swimming performance. (A) Amelioration of balance and motor coordination at 24 weeks 
of age in 11 mm circle and (B) 12 mm square beams in beam walk test; (C) Motor swimming coordination improvement; 
(D,E) no improvement in increasing rotations in Rotarod were observed between VPA-treated and non-treated CMVMJD135. 
Bars represent the mean ± SEM (WT veh, n=10; WT VPA, n=15, CMVMJD135 vehicle, n=10, CMVMJD135 VPA, n=13), * 
represent p<0.05, ** represent p<0.01 and *** represent p<0.001, black asterisks represents the difference between WT 
and CMVMJD135, blue asterisks represents the difference between non-treated and VPA-treated CMVMJD135, (Repeated-
measures ANOVA, Tukey correction for continuous variables, One-Way ANOVA for differences between groups in specific 
ages of the continuous variables and Mann-Whitney U test for continuous variables without normal distribution (Rotarod)). 
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Abstract 
Polyglutamine diseases are a class of dominantly inherited neurodegenerative disorders for 
which there is no effective treatment. Here we provide evidence that activation of serotonergic signaling 
is beneficial in a mouse model of Machado-Joseph disease (MJD). Previous work in a C. elegans model 
of MJD identified citalopram, a selective serotonin re-uptake inhibitor (SSRI), in a screen of FDA-
approved small molecules for suppressors of mutant ataxin-3 induced neurotoxicity. In MJD C. elegans 
model, citalopram rescued mutant ataxin-3-mediated neuronal dysfunction and reduced aggregation. In 
this work, we tested the therapeutic efficacy of chronic citalopram treatment in the CMVMJD135 
mouse model with two different dosages. This compound reduced ataxin-3 neuronal inclusions, 
mitigated astrogliosis, decreased neuronal loss and strikingly ameliorated motor symptoms, together 
with a rescue of diminished body weight mainly at 8 mg/kg dosage. These results suggest that 
modulation of serotonergic signaling could be a promising therapeutic strategy for MJD, with beneficial 
effects in the enhancement of proteostasis.   
 
Introduction 
Polyglutamines (PolyQ) diseases are hereditary neurodegenerative disorders caused by an 
expansion of a trinucleotide CAG repeat within the coding region of specific genes. This group of 
disorders includes Huntington’s disease (HD), spinobulbar muscular atrophy (SBMA), dentatorubral-
pallidoluysian atrophy (DRPLA) and six forms of spinocerebellar ataxia1. MJD (or Spinocerebellar Ataxia 
type 3, SCA3), the most common dominantly inherited ataxia worldwide2, is caused by an expansion of 
a polyQ tract in the ataxin-3 protein (ATXN3)3. This adult-onset disorder is characterized by ataxia, 
ophthalmoplegia and pyramidal signs, associated with dystonia, spasticity, peripheral neuropathy and 
amyotrophy4, however without cognitive decline. At the pathological level, there is degeneration of the 
deep nuclei of the cerebellum, pontine and subthalamic nuclei, substantia nigra and spinocerebellar 
nuclei4–6 as well as the presence of ATXN3 intranuclear inclusions in these brain regions7,8.   
Despite the recent efforts towards the understanding of the pathogenesis of this disorder, the 
molecular pathways that ultimately lead to neuronal demise remain mostly unknown and no effective 
treatments are yet available for MJD, as for other polyQ diseases. In the last decades several emerging 
therapeutic strategies have been suggested for MJD, however not yet translated to the clinic. These 
strategies are based on the proposed pathogenic hypothesis and comprise the pharmacologic 
chaperone/kinetic stabilizer approaches and the use of small molecules or gene targeting to 
manipulate concentration, conformation, and/or the location of ATXN3. For example, modulating the 
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levels of molecular chaperones HSP70, alphaB-crystallin and HSP104 can prevent or inhibit ATXN3 
aggregation, and promotes its dis-aggregation9–11. Activation of autophagy, either by gene overexpression 
or by pharmacological activation of the pathway, can also ameliorate mutant ATXN3 pathogenesis in 
vivo12–14. Reversion of the polyQ-associated transcription down-regulation by an HDAC inhibitor (HDACi) 
also rescued ataxic symptoms15. Silencing of ATXN3 offers potential, however its impact has not been 
promising in MJD mice16,17. For the majority of these candidate therapies, their translation to clinical 
trials is a very long process due to uncertainty concerning human safety. Despite the investments in 
drug discovery and development during the past decades, the number of new drugs introduced into the 
clinic has not increased significantly. The traditional approach to drug discovery, which involves de 
novo identification and validation of new molecular entities, has been costly and time-consuming. 
Furthermore, as the average time required for drug development has increased, there has been a new 
interest in drug re-purposing strategies18. 
Our group has previously established a C. elegans model of MJD in which expression of mutant 
human ATXN3 in the worm’s nervous system led to its progressive aggregation in distinct neuronal 
subtypes and altered motor behavior19. This model was used by Teixeira-Castro et al20, to screen a 
library of >600 FDA-approved small molecules, and to identify compounds that rescued or ameliorated 
mutant ATXN3-mediated neurological dysfunction (Appendix I). Citalopram, belonging to the selective 
serotonine re-uptake inhibitor (SSRI) class, was identified in the screening through its neurotoxicity 
suppression mechanism and then proven to modify also ATXN3 aggregation. The main mechanism of 
action of SSRI’s is serotonin transporter (SERT) inhibition, increasing the serotonin (5-HT) levels, and 
therefore the serotonergic transmission. In spite of being a powerful platform to study 
neurodegenerative diseases and to perform HTS for small molecules, the direct translation from C. 
elegans outcomes to human is a huge step and may not faithfully predict the drug action in humans. 
Therefore, it is crucial to test the hit compounds’ efficacy in a mammalian model that may more closely 
mirror the human disease. Here we show that citalopram was able to improve the motor balance and 
coordination in the CMVMJD135 mouse model of MJD, together with suppression in ATXN3 
aggregation and astrogliosis, and neuroprotective effects, suggesting this FDA-approved compound as a 
very promising candidate to be translated to the clinic with few side effects.  
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Material and Methods 
Transgenic mouse model and drug administration. CMVMJD135 mice were generated as 
described previously14. DNA extraction, animal genotyping and CAG repeat size analyses were 
performed as previously described21. The mean repeat size (±SD) for all mice used was 130 ± 2. Age-
matched and genetic background-matched wild-type (WT) animals were used as controls. Only male 
mice were used in this study. We administrated citalopram hydrobromide (CAS 59729-32-7, kindly 
provided by Lundbeck, Denmark) in the drinking water at two doses (8 and 13 mg/kg/day) that 
roughly equate the higher dosage range prescribed to human patients for depression22. Treatment was 
initiated at five weeks of age, one week before the expected onset of the first neurological symptoms, 
according to our previous knowledge of this model14 and ended at 34 weeks of age. All animal 
procedures were conducted in accordance with European regulations (European Union Directive 
2010/63/EU). Animal facilities and the people directly involved in animal experiments (SE, SDS, ASF, 
ATC) were certified by the Portuguese regulatory entity — Direcção Geral de Alimentação e Veterinária. 
All the protocols were approved by the Animal Ethics Committee of the Life and Health Sciences 
Research Institute, University of Minho. 
 
Behavioral assessment. Behavioral analysis was performed during the diurnal period in groups of 5 
males per cage including CMVMJD135 hemizygous transgenic mice and WT littermates (n=13-16 per 
genotype) treated with citalopram or with vehicle (water). All behavioral tests started in a pre-
symptomatic stage (4 weeks of age) and were conducted until 30 or 34 weeks of age (Fig. 1A). 
Neurological tests and general health assessment were performed using a selection of tests from the 
SHIRPA protocol (tremors, clasping, gait quality, exploratory activity, locomotor activity, body curvature, 
strength to grab and hindlimb tonus) enriched with the hanging wire and vertical pole test. The 
dragging of the paws and the stride length were evaluated with footprinting analysis as described by 
Silva-Fernandes et al21. Motor behavior was further assessed using the balance beam walk test (12 mm 
square and 17 mm round beams) and the motor swimming test. All behavioral tests were performed 
as previously described21. Body weight was also registered for each evaluation time point. 
 
Immunohistochemistry. Thirty four week-old WT and CMVMJD135 littermate mice, citalopram-
treated and non-treated (n=4 for each group) were deeply anesthetized with a mixture of ketamine 
hydrochloride (150 mg/kg) plus medetomidine (0.3 mg/kg) and transcardially perfused with 
phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (PFA) (Panreac, USA). Brains were 
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removed and post-fixed overnight in PFA and embedded in paraffin. Slides with 4-µm-thick paraffin 
sections were subjected to antigen retrieval and then incubated with mouse anti-ATXN3 (1H9) (1:100, 
MAB5360, Milipore), rabbit anti-GFAP (1:1000, DAKO Corporation, Carpinteria) and mouse anti-
Calbindin D-28K (1:1000, AB1778, Millipore, USA,), which were detected by incubation with a 
biotinylated anti-polyvalent antibody, followed by detection through biotin-streptavidin coupled to 
horseradish peroxidase and reaction with the DAB (3, 3'-diaminobenzidine) substrate (Lab VisionTM 
Ultra-VisionTM Detection kit, Thermo Scientific). The slides were counterstained with hematoxylin 25% 
according to standard procedures. ATXN3 positive inclusions in the pontine nuclei (PN), 
reticulotegmental nucleus of the pons (RtTg), facial motor nucleus (7N) and lateral reticular nucleus 
(LRt), stained astrocytes (GFAP-positive) in the substantia nigra (SN) and Calbindin D-28K positive 
neurons in cerebellar cortex (CBX) of either vehicle or citalopram treated animals (n=4 for each 
conditions, 4 slides per animal) were quantified and normalized for total area using the Olympus BX51 
stereological microscope (Olympus, Japan) and the Visiopharma integrator system software 
(Visopharm, Denmark) as previously described21. 
Thirty four week-old WT and CMVMJD135 littermate mice, vehicle- and citalopram-treated (n=4 
for each group), were deeply anesthetized as mentioned above, transcardially perfused with NaCl 
(0,9%), and the mouse brains embedded in OCT and rapidly frozen in isopentane (CAS#78-78-4, 
Sigma-Aldrich, USA) chilled in liquid nitrogen. Slides with 30 µm-thick cryostat sections were incubated 
with goat anti-Choline Acetyltransferase (ChAT, 1:500, AB143, Millipore, USA) and stained with 
VECTASTAIN® ABC system (Vector Laboratories, UK), mouse anti-NeuN (1:500, MAB377, Milipore, 
USA), rabbit anti-Tyrosine Hydroxylase (TH, 1:300, AB152, Milipore, USA) which were detected with 
Lab VisionTM Ultra-VisionTM Detection kit protocol as described above. ChAT, NeuN and TH positive 
neurons were quantified and normalized as described above, in the 7N, PN and Substantia nigra pars 
compacta (SNc), respectively. 
Fifty µm-thick vibrotome spinal cord sections were incubated with goat anti-Choline 
Acetyltransferase (ChAT, 1:500, AB143, Millipore, USA) and stained with VECTASTAIN® ABC system 
(Vector Laboratories, UK). ChAT positive neurons in the ventral horn of the Lumbar spinal cord (LSC) 
were quantified and normalized for total area as described above. Fifty µm-thick vibrotome spinal cord 
sections were stained with thionin according to standard procedures for motor neuron countings. The 
number of large stained motor neurons in the ventral horn was quantified using ImageJ. 
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Western-blot analysis. Protein isolation from mouse brainstem tissue and Western-blot were 
performed as previously described21. The blots were blocked and incubated overnight at 4°C with the 
primary antibody rabbit anti-ataxin-3 serum (1:5000, kindly provided by Dr. Henry Paulson) and anti-
GAPDH (1:1000, G8795, Sigma, USA). As a loading control, mouse ataxin-3 and GAPDH were used. 
Western-blot quantifications were performed using Chemidoc XRS Software with Image Lab Software 
(Biorad, USA), according to the manufacturer’s instructions. 
 
Study design and statistical analysis. Experimental design was based on power analyses for 
optimization of sample size. Mouse sample size calculations were performed for each behavioral test 
and pathological analyses assuming a power of 0-8, and a significance level of p<0.05. Data was 
analyzed through the non-parametric Mann-Whitney U-test when variables were non-continuous or 
when a continuous variable did not present a normal distribution (Kolmogorov-Smirnov test, p<0.05). 
Continuous variables with normal distributions and with homogeneity of variance (Levene’s test) were 
analyzed with Repeated-Measures ANOVA for longitudinal multiple comparisons and One-Way ANOVA 
for paired comparisons, using Tukey for post-hoc comparisons. When these two latter assumptions 
were not valid, an appropriate data transformation (e.g., logarithmic) was applied, and the data were 
reanalyzed (body weight, balance beam walk test and motor swimming test). All statistical analyses 
were performed using SPSS 22.0 (SPSS Inc., Chicago, IL) and G-Power 3.1.9.2 (University Kiel, 
Germany). A critical value for significance of p<0.05 was used throughout the study. 
 
Results 
 
Citalopram treatment rescued weight gain and improved neurological symptoms of 
CMVMJD135 mice without improvement in muscle strength tests 
To validate the results previously obtained in a C.elegans model of MJD in a mammalian 
model, we assessed the therapeutic efficacy of citalopram in an MJD mouse model - CMVMJD135. As 
reported previously, CMVMJD135 transgenic mice displays a progressive neurological phenotype with 
neuropathology and intranuclear inclusions consistent with that of human patients14. Chronic treatment 
with citalopram 8mg/kg/day was administered in the drinking water. The treatment started at 5 weeks 
of age, one week before the expected onset of the first neurological symptoms, and was continued until 
34 weeks. A battery of behavioral tests was performed assessing limb strength, balance, gait, 
coordination, and other neurological parameters like tremors or limb clasping, among others. Tests 
were initiated in a pre-symptomatic stage of the disease (4 weeks of age) and conducted until an age 
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when the phenotype is fully established (34 weeks) (study design – Fig. 1A). When no improvement 
trend was observed along the age, tests were stopped at 30 weeks of age.  
The first sign of neurological disease in the CMVMJD135 model is the presence of grip strength 
abnormalities at 6 weeks of age, given by the significant decrease in the latency to fall off in the vertical 
pole test and in the hanging wire test. In the vertical pole test (Fig. 1B), citalopram failed to rescue the 
limb strength while in the hanging wire test (Fig. 1C), limited effects on the loss of limb strength were 
observed at some time points but no longer maintained with age. Another disease phenotype feature of 
the CMVMJD135 mouse model is their decreased body weight gain when compared to WT animals, 
which was prevented with oral administration of citalopram (Fig. 1D). While there was only marginal 
improvement in the dragging of the paws (Fig. 1E) and limited effects on exploratory activity, strength 
to grab and hindlimb tonus (Supplementary data), citalopram treatment restored stride length to WT 
animals at advanced stages of the trial (Fig. 1F,G). Moreover, treated animals showed reduced tremors 
(Fig. 1H), reduced limb clasping (Fig. 1I) and improved gait quality (Fig. 1J).  
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Figure 1. Impact of citalopram treatment at 8mg/kg/day on the neurological deficits of CMVMJD135 mice. (A) Schematic 
representation of the pre-clinical therapeutic trial. (B) No differences in vertical pole test and (C) limited improvement in 
hanging wire test upon citalopram treatment. Significant differences observed between vehicle (n=13) and cit treated 
CMVMJD135 mice (n=16) in (D) body weight (p=0.001, 20-34 weeks), in (E) foot dragging (p=0,035 at 14 weeks), and (F) 
stride length (p=0.015, 30 weeks). (G) Figure representation of stride length of WT, citalopram CMVMJD135-treated and 
non-treated at 30 weeks of age. (H) Tremors, (I) limb clasping and (J) gait quality were evaluated from 18 to 34 weeks of 
age with phenotype amelioration from 22 to 34 weeks of age. (n=13-16), *p<0.05, **p<0.01 and ***p<0.001 (Mann-
Whitney U test for non-parametric variables and ANOVA, Tukey correction for continuous variables). Data presented mean ± 
SEM.  
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Citalopram treatment improves motor balance and coordination of CMVMJD135 mice 
Citalopram treatment resulted in a remarkable improvement in balance and motor coordination 
when compared to vehicle-treated CMVMJD135 mice (Fig. 2). In the balance beam walk test, we 
observed major improvements in time taken to cross the 12 mm square beam from 20 to 34 weeks of 
age (Fig. 2A) and also saw these improvements at late disease stages in a wider (17 mm) circle beam 
(Fig. 2B). A smaller 11 mm circle beam (Fig. 2C) was also used for assessment of motor coordination, 
but no major improvements in performance were detected. This beam is more challenging to the mice, 
particularly at late stages, when non-treated transgenic animals often fall off the beam. However, a 
measure of the percentage of falls in this beam, at late stages, showed that citalopram treated-
CMVMJD135 mice fell significantly less than non-treated animals (Fig. 2D). The most notable benefits 
of citalopram were observed in the motor swimming test (Fig. 2E), since at many time points and until 
quite late in the trial citalopram treated animals were indistinguishable from WT, indicating that 
citalopram treatment significantly delayed disease progression in mice. 
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Figure 2. Citalopram treatment ameliorates balance and motor coordination. Significant differences observed between 
vehicle (n=13) and cit treated CMVMJD135 mice (n=16) in the (A) square beam (p<0.001, 20-34 weeks), and (B) 17 mm 
circle beam (p<0,05, 32-34 weeks). Significant improvement of cit treated CMVMJD135 mice at 20 weeks of age in (C) 11 
mm circle (p<0,05) with a significantly decrease in (D) percentage of falls of cit treated CMVMJD135 mice as compared 
with vehicle animals (p<0,05), 32-34 weeks). Significant differences since the beginning until 34 weeks of age in (E) motor 
swimming (p<0.001, 14-34 weeks) test. Data presented as mean ± SEM. *p<0.05, **p<0.01 and ***p <0.001 (Repeated 
measures ANOVA and One-way ANOVA, Tukey correction). 
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Importantly, citalopram treated WT mice behaved similarly to their untreated littermates, 
confirming the specificity of the citalopram effect in CMVMJD135 mice. Significant differences were 
only observed in the citalopram WT treated animals concerning body weight, which was increased (Fig. 
3). 
 
 
 
 
 
Figure 3. Impact of citalopram treatment at 8mg/kg/day on body 
weight and on motor behavior of WT mice. (A) Body weight, (B) 
beam walk and (C) motor swimming tests of vehicle and cit treated 
WT mice. Cit treatment resulted in a significant increase in body 
weight (p=0.033). No differences between WT and cit treated WT 
mice were observed in the beam walk (p=0.40) and motor 
swimming tests (p=0.839). (n=10), data presented as mean ± 
SEM. *p<0.05, **p<0.01 and ***p<0.001 (Repeated-measures 
ANOVA). 
 
 
 
 
Citalopram treatment reduced ATXN3 intranuclear inclusions without changing the 
overall levels of ATXN3 protein  
The analysis of brain tissue from CMVMJD135 mice showed that citalopram treatment 
(8mg/kg/day) reduced ATXN3 intranuclear inclusions in the brainstem (Fig. 4A), equivalent to the 
decrease of neuronal aggregates observed in C. elegans (Appendix I). This reduction was observed in 
the pontine nuclei (PN), reticulotegmental nuclei of pons (RtTg) and facial motor nuclei (7N) of 
CMVMJD135 treated mice when compared to their vehicle-treated counterparts (Fig. 4A); the impact of 
citalopram was less obvious in the lateral reticular nuclei (LRt). This reduced ATXN3 aggregation did 
not correspond to lower ATXN3 protein levels in the brainstem (Fig. 4B), suggesting that the effect of 
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citalopram in mice is comparable to that in C. elegans, which may affect folding and solubility of 
ATXN3 rather than clearance of the mutant protein. 
 
Figure 4. Citalopram effect in ATXN3 intranuclear inclusions and protein levels. (A) Immunohistochemistry of ATXN3 
neuronal inclusions in the PN, RtTg, 7N and LRt of vehicle and cit treated CMVMJD135 mice (n=4, 34 weeks). (B) 
Brainstem western-blot and quantification of total human ATXN3 protein from vehicle and cit treated CMVMJD135 mice 
(n=5, 34 weeks). Data presented as mean ± SEM., *p<0.05 and **p<0.01 (One-way ANOVA). Scale bars, 20 µm. PN, 
pontine nuclei; RtTg, reticulotegmental nuclei of pons; 7N, facial motor nuclei; LRt, lateral reticular nuclei. 
 
Citalopram treatment rescued cholinergic motor neurons in 7N and increase Calbindin D-
28k staining in Purkinje cells of CMVMJD135 mice  
Along with mutant ATXN3 aggregation suppression in facial motor nuclei (7N) of CMVMJD135 
mice, we observed that at 34 weeks of age, the loss of Choline Acetyltransferase (ChAT) positive 
neurons was also rescued upon citalopram treatment (Fig. 5A). Another pathological presentation of 
CMVMJD135 mice is the loss of Calbindin D28K staining in Purkinje cells in the cerebellar cortex (CBX) 
at 34 weeks of age (Fig. 5B) (without loss in Purkinje cell number – supplementary data). Although not 
statistically significant, possibly due to the lack of a larger animal sample, citalopram was able to 
relieve the loss of Calbindin D-28K positive neurons most likely contributing to the phenotype 
improvement observed in the behavior analysis. Even though not significant, a mild trend was also 
observed towards a decrease in the number of neurons (NeuN positive cells) in the pontine nuclei of 
CMVMJD135 mice, also with a tendency towards reversion upon citalopram treatment (Fig. 5C). 
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However, there was no difference in dopaminergic (TH-positive) neurons in the substantia nigra pars 
compacta (SNc) compared to vehicle-treated CMVMJD135 mice (Fig. 5D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Citalopram treatment shows neuroprotective effects in CMVMJD135 mice. (A) Immunohistochemistry of ChAT-
positive in the 7N, (B) Calbindin D-28K positive Purkinje cell in the CBX, (C) NeuN positive cells in PN and (D) dopaminergic 
(TH positive) cells in SNc from WT, vehicle and cit treated CMVMJD135 mice (n=4 per group, 34 weeks); (E) Quantification 
of (A), (F) Quantification of (B), (G) Quantification of (C) and (H) Quantification of (D) per total area from WT, vehicle and cit 
treated CMVMJD135 Data presented as mean ± SEM., *p<0.05 and **p<0.01 (One-way ANOVA). Scale bars, 200 µm (A, C 
and D) and 100 µm (B). CBX, Cerebellar cortex, SNc, Substantia nigra pars compacta. 
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Citalopram treatment reduced reactive astrogliosis in CMVMJD135 mice 
Reactive astrogliosis is observed in response to Central Nervous system (CNS) insults and 
strikingly evident in the substantia nigra of CMVMJD135 mice. Upon chronic citalopram treatment we 
saw a decrease in reactive astrogliosis observed in substantia nigra (SN), at 34 weeks of CMVMJD135 
mice (Fig. 6A,B,C). 
Figure 6. Citalopram effect in astrogliosis. (A) Quantification of GFAP-positive cells per area in SN from WT, vehicle and cit 
treated CMVMJD135 mice and corresponding (B) immunohistochemistry (n=5 per group, 34 weeks). (C) Brainstem 
western-blot and quantification of GFAP protein levels from WT, vehicle and ci treated CMVMJD135 mice (n=4 per group, 
34 weeksData presented as mean ± SEM., *p<0.05 and **p<0.01 (ANOVA, Tukey correction (A, B) and One-way ANOVA 
(C)). Scale bars, 20 µm. GFAP, Glial fibrillary astrocytic protein.  
 
Motor neuron loss in the spinal cord of CMVMJD135 is mildly alleviated upon citalopram 
treatment 
We observed a consistent motor neuron loss along the entire spinal cord of 34 week-old 
CMVMJD135 mice (Fig. 7A-D), being this loss of 50% in the lumbar region (LSC), which is particularly 
important for the flexibility and movement of the trunk. A deeper characterization of the LSC revealed a 
significantly decrease of the ChAT-positive neurons in this region (Fig. 7E). Although the differences 
were not statistically significant, citalopram showed a tendency to mitigate all these pathological 
features in CMVMJD135 mice.  
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Figure 7. Loss of spinal motor neurons in CMVMJD135 mice. Thionin stained spinal cord and motor neuron quantification 
in ventral horn of (A) Cervical; (B) Thoraccic; (C) Lumbar and (D) Sacral regions from WT, vehicle and cit treated 
CMVMJD135 mice (n=4 per group, 34 weeks); (E) Immunohistochemistry of ChAT in the LSC from WT, vehicle and cit 
treated CMVMJD135 mice (n=4 per group, 34 weeks). (F) Quantification of number of motor neurons and ChAT-positive 
cells per area in LSC. Data presented as mean ± SEM., *p<0.05 and **p<0.01 (One-way ANOVA). Scale bar, 200 µm. 
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Higher dosage does not increase citalopram efficacy in CMVMJD135 mice 
An increased dosage of citalopram (13mg/kg/day) was tested in CMVMJD135 mice in order to 
attempt to improve the response of the animals in the previously described behavioral tests. However, 
the results obtained with a higher dosage do not correspond to an increased effect when compared 
with the previous dosage tested. As occurred with 8mg/kg/day dosage, the muscle strength measured 
by the vertical pole and hanging wire test were not improved (Fig. 8A,B). This dosage also caused a 
significant increase in WT animals’ body weight, but no effect in the CMVMJD135 treated animals (Fig. 
8C). The dragging of the paws was not improved (Fig. 8D) nor the limb clasping (Fig. 8F). However, 
marginal beneficial effects were observed at late stages of the disease (30 and 34 weeks of age) for 
tremors and gait quality (Fig. 8E,G) .  
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Figure 8. Treatment with a higher dosage of citalopram (13 mg/kg/day) led to a limited improvement of neurological 
symptoms of CMVMJD135 mice. (A) Vertical pole test, (B) hanging wire test, (C) body weight, (D) footprinting, (E) tremors, 
(F) limb clasping and (G) gait quality. (n=14) and cit treated (13 mg/kg/day) WT (WT cit13) mice (n=17) and of vehicle 
(n=16) and cit treated (13 mg/kg/day) CMVMJD135 mice (CMVMJD135 cit13) (n=13). No differences were observed in 
vertical pole, hanging wire, body weight and footprinting tests between CMVMJD135 and CMVMJD135 cit13 mice. Cit 
treated WT mice showed a significant increase in body weight. Marginal improvement in late stages (30 and 34 weeks) were 
observed for tremors and gait quality while no effect was observed in limb clasping upon treatment. Data presented as 
mean ± SEM., *p<0.05, **p<0.01 and *** p<0.001. (Repeated-measures ANOVA, Tukey correction, One-way ANOVA and 
Mann Whitney U test for non-continuous variables). 
 
Regarding motor balance and coordination, treatment with 13mg/kg/day citalopram was able 
to improve the performance in 12 mm square beam at 20 and 24 weeks, and to decrease the 
percentage of falls from the 11 mm circle beam at 32 and 34 weeks (Fig. 9A,D). However, no 
improvement was observed consistently along the trial in the majority of the beams (Fig. 9A,B,C). The 
major effect of this dosage was observed in the motor swimming test, however not as prominent as the 
8mg/kg/day dosage (Fig. 9E). Higher dosages of citalopram, although with a trend towards 
improvement, did not significantly reduce the ATXN3 inclusions neither the total protein levels (Fig. 
9F,G) 
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Figure 9. Effect of citalopram 13mg/kg/day in motor and coordination tests and in ATXN3 inclusions and protein levels. 
Mild amelioration at 20 and 24 weeks of age observed in (A) 12 mm square and no improvement in (B) 17 mm circle and 
(C) 11 mm circle beams between CMVMJD135 and CMVMJD135 cit13 mice. (D) Decrease of percentage of falls of the 11 
mm circle beam and (E) improvement in motor swimming test in CMVMJD135 upon cit13 treatment. No differences 
observed in (F) ATXN3 inclusions in brainstem and (G) protein levels with 13mg/kg citalopram treatment. (n=13-16 for 
behavioral analysis and n=4-5 for pathological analysis). Data presented as mean ± SEM., *p<0.05, **p<0.01 and *** 
p<0.001. (Repeated-measures ANOVA, Tukey correction and One-way). 
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Discussion 
In this work, we tested citalopram, an FDA-approved compound commonly used for treating 
depression, with a re-purposing aim in the CMVMJD135 mouse model of MJD. The use of approved 
drugs has great advantages in terms of their safety and bioavailability in humans and therefore easy 
translation into the clinics. These compounds may also offer a quicker interpretation of 
pathophysiological mechanism due to their often known principal targets and mechanisms of action, 
and could additionally help unraveling many biological pathways and novel therapeutics targets. 
Our group previously identified citalopram in a FDA/EMA-approved compounds screening in 
C.elegans model of MJD. In this screening, many serotonergic modulators were identified as 
suppressors of ATXN3 pathogenesis, namely decreasing the locomotion defect and ATXN3 aggregation 
in this model (Appendix I). The subsequent studies in a higher mammalian organism that more closely 
mirrors the human disease is of extreme importance prior to starting a clinical trial in humans. For that 
reason we studied the therapeutic efficacy of citalopram in CMVMJD135 mouse model which displays 
a progressive neurological phenotype and brain pathology consistent with that of human patients14. The 
CMVMJD135 mouse model treated with 8mg/kg/day showed striking improvements in body weight, in 
balance and motor coordination tests and in several other neurological parameters. This phenotype 
improvement was accompanied by a striking reduction of ATXN3 aggregation in specific brain regions. 
However, the role of protein inclusions in polyQ diseases, including MJD, is still controversial, and 
although the presence of nuclear aggregates has been shown to correlate with neurotoxicity, to isolate 
the specific toxic species within this multi-step process of aggregation, has proven to be a very hard 
task23–28. In this context, we have assessed the number of Choline AcetylTransferase (ChAT) positive 
neurons in the facial motor nuclei of the brainstem and in the lumbar ventral horn of the spinal cord 
and found a rescue or amelioration upon citalopram treatment in CMVMJD135 mice. The facial motor 
nuclei are mixed nerve brain region, with efferent (motor and vegetative) and afferent (sensitive and 
sensory) nerve fibers of predominantly cholinergic neurons29, which are particularly affected in MJD 
patients30, as well as in CMVMJD135 mice14. Citalopram was able to suppress ATXN3 aggregation but 
also to rescue cholinergic motor neurons in these nuclei, confirming its neuroprotective effect. 
CMVMJD135 mice also present loss of Calbindin D-28K positive Purkinje cells in the cerebellar 
cortex at 34 weeks of age, with no decrease in total number of these cells. The essential activity mode 
of Purkinje cells is controlled by the sodium-potassium pump31 which is one of the main responsible for 
the correct function of the cerebellar cortex. Loss of these neurons may lead to motor incoordination 
and ataxic symptoms. There was a trend towards an increase in the number of Calbindin D28K-positive 
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cells upon citalopram treatment that suggests a functional recovery of these neurons; the absence of 
statistical significance could probably be corrected by increasing the number of animals analyzed.  
The pontine nuclei are involved in carrying the information from the motor cortex to the 
cerebellum and mostly involved in overall motor function, and they are most affected both in MJD 
patients32,33 and in mouse models14. ATXN3 inclusions are widely present in these nuclei in both humans 
and CMVMJD135 mice14,34. We assessed neuronal density in the pontine nuclei of WT, citalopram-
treated and non-treated CMVMJD135 mice. Despite some interesting trends, these results are not 
statistically different; they are however, suggestive of a neuronal dysfunction prior to a neuronal loss at 
34 weeks of age in CMVMJD135 mice.  
One previously established neuropathological feature of this mouse model is the loss of 
dopaminergic neurons (TH-positive) in the substantia nigra pars compacta, these neurons playing an 
important role in the control of multiple brain functions, including voluntary movement35. This 
pathological feature was not modified upon citalopram treatment, suggesting that this compound has 
no effect on dopaminergic neurons in the SNpc in this mouse model of MJD. In contrast, we observed 
that astrogliosis in the substantia nigra was strikingly decreased to WT levels in 34 week-old 
CMVMJD135 mice upon treatment. 
The majority of neuropathological studies in MJD are focused on the brain (mainly brainstem, 
basal ganglia and cerebellum), but less is known about spinal cord pathology and its clinical relevance 
in the disease, with the exception of the well-known Clarke’s column degeneration36. A recent paper in 
human MJD patients described cervical cord atrophy and antero-posterior flattening through MRI-based 
studies, as well as a correlation between spinal cord areas and disease severity37. MJD patients present 
pyramidal signs (predominantly in the legs) and urinary dysfunction38, which also suggest the 
involvement of spinal cord in the disease. Taking this into consideration, we assessed the motor neuron 
density in CMVMJD135 mice and observe a significantly loss of motor neurons (including cholinergic 
neurons at lumbar spinal cord) along the entire spinal cord. This loss of motor neurons was very 
slightly alleviated upon citalopram treatment, suggesting that its effect is more pronounced at the brain 
level than at the spinal cord. This is consistent with the effects seen at the motor behavior level, as 
motor coordination amelioration is more related to cerebellum and basal ganglia, where we observed 
striking improvements.  
When the citalopram dosage was increased to 13mg/kg/day the symptomatic effect was mild 
or lost in specific tests, consistently to what happens in C.elegans, where a U-shaped curve was seen, 
meaning that this compound could have a limited range of efficacy in these two MJD models.  
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SERT inhibition by citalopram likely results in increased extracellular 5-HT levels, which lead to 
enhanced serotonergic neurotransmission. Likewise, serotonin receptor agonists could also exert 
serotonergic neurotransmission enhancement-like effects39. Clinical trials with 5-HT1A agonist for the 
treatment of cerebellar ataxia revealed promising findings40. One open label study and two case reports 
of MJD patients showed that treatment with buspirone and tandospirone (5-HT1A partial agonist) 
significantly ameliorated gait and posture, specifically in patients showing mild ataxia40,41. More recently, 
opposing effects of tandospirone on ataxia were found in different types of spinocerebellar 
degeneration, which may arise from distinct patterns of pathology42. Moreover, the degree of ataxia 
severity and the disease type may also determine the treatment outcome. While a previous trial with 13 
MJD patients has shown no benefit of a 6-week fluoxetine treatment in motor function of MJD 
patients43, here we show that citalopram strongly ameliorated motor coordination and balance in MJD 
mice treated pre-symptomatically, starting one week before onset of disease manifestations. In HD 
mouse models, SSRIs treatment also resulted in striatal and memory preservation and extended 
survival, with no changes in huntingtin expression44. Citalopram has also been shown to be beneficial in 
models of Alzheimer’s disease (AD) and in healthy human volunteers by reducing Aβ in the CSF22. The 
need for chronic symptomatic treatment in MJD suggests a neuroprotective mechanism rather than 
immediate effects on signaling cascades22 or correction of an imbalance of 5-HT levels in MJD mice, 
which in fact were not altered to start with (Appendix I). Additionally, the observation of citalopram 
impacting on the ATXN3 protein aggregation, leads us to suggest an improvement of the proteostasis 
state of the cell, likely not related to increased ATXN3 degradation, as the total levels of this protein 
remained unchanged. Indeed, it has been recently described in C.elegans that the release of serotonin 
from neurons signals to distal tissues the activation of protective mechanisms to prevent 
proteotoxicity45. We hypothesize that citalopram action in the neuronal environment may mediate 
activation of stress response(s), making the cells more resilient to the proteotoxic effect underlying MJD 
and other proteinopathies.  
 
Conclusion 
The efficacy of citalopram in suppression of ATXN3 pathogenesis and its neuroprotective 
effects in CMVMJD135 mouse model (and in C.elegans, Appendix I), as well as its safety record of 
being widely used in depression patients, prompts us to suggest this drug for clinical trials in MJD 
patients. 
 
CHAPTER 3 
 
 
 
131 
References 
1. Ross, C. A. et al. Pathogenesis of neurodegenerative diseases associated with expanded glutamine 
repeats: new answers, new questions. Prog. Brain Res. 117, 397–419 (1998). 
2. Schöls, L., Bauer, P., Schmidt, T., Schulte, T. & Riess, O. Autosomal dominant cerebellar ataxias: 
clinical features, genetics, and pathogenesis. Lancet Neurol. 3, 291–304 (2004). 
3. Kawaguchi, Y. et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 
14q32.1. Nat. Genet. 8, 221–228 (1994). 
4. Coutinho, P. & Andrade, C. Autosomal dominant system degeneration in Portuguese families of the 
Azores Islands. A new genetic disorder involving cerebellar, pyramidal, extrapyramidal and spinal 
cord motor functions. Neurology 28, 703–709 (1978). 
5. Rosenberg, R. N. Machado-Joseph disease: an autosomal dominant motor system degeneration. 
Mov. Disord. Off. J. Mov. Disord. Soc. 7, 193–203 (1992). 
6. Sudarsky, L. & Coutinho, P. Machado-Joseph disease. Clin. Neurosci. N. Y. N 3, 17–22 (1995). 
7. Paulson, H. L. et al. Machado-Joseph disease gene product is a cytoplasmic protein widely 
expressed in brain. Ann. Neurol. 41, 453–462 (1997). 
8. Perez, M. K. et al. Recruitment and the role of nuclear localization in polyglutamine-mediated 
aggregation. J. Cell Biol. 143, 1457–1470 (1998). 
9. Robertson, A. L. et al. Small heat-shock proteins interact with a flanking domain to suppress 
polyglutamine aggregation. Proc. Natl. Acad. Sci. U. S. A. 107, 10424–10429 (2010). 
10. Warrick, J. M. et al. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a 
ubiquitin-associated mechanism. Mol. Cell 18, 37–48 (2005). 
11. Cushman-Nick, M., Bonini, N. M. & Shorter, J. Hsp104 suppresses polyglutamine-induced 
degeneration post onset in a drosophila MJD/SCA3 model. PLoS Genet. 9, e1003781 (2013). 
12. Nascimento-Ferreira, I. et al. Overexpression of the autophagic beclin-1 protein clears mutant 
ataxin-3 and alleviates Machado-Joseph disease. Brain J. Neurol. 134, 1400–1415 (2011). 
13. Menzies, F. M. et al. Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse 
model of spinocerebellar ataxia type 3. Brain J. Neurol. 133, 93–104 (2010). 
14. Silva-Fernandes, A. et al. Chronic treatment with 17-DMAG improves balance and coordination in a 
new mouse model of Machado-Joseph disease. Neurother. J. Am. Soc. Exp. Neurother. 11, 433–
449 (2014). 
CHAPTER 3 
 
132 
 
15. Chou, A.-H., Chen, S.-Y., Yeh, T.-H., Weng, Y.-H. & Wang, H.-L. HDAC inhibitor sodium butyrate 
reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse 
model of SCA3. Neurobiol. Dis. 41, 481–488 (2011). 
16. Alves, S. et al. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: 
no role for wild-type ataxin-3? Hum. Mol. Genet. 19, 2380–2394 (2010). 
17. Costa, M. do C. et al. Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease. 
Mol. Ther. J. Am. Soc. Gene Ther. 21, 1898–1908 (2013). 
18. Chong, C. R. & Sullivan, D. J. New uses for old drugs. Nature 448, 645–646 (2007). 
19. Teixeira-Castro, A. et al. Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by 
the DAF-16 and HSF-1 pathways. Hum. Mol. Genet. 20, 2996–3009 (2011). 
20. Teixeira-Castro, A. et al. Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity 
in animal models of Machado-Joseph disease. Brain J. Neurol. (2015). doi:10.1093/brain/awv262 
21. Silva-Fernandes, A. et al. Motor uncoordination and neuropathology in a transgenic mouse model 
of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products. 
Neurobiol. Dis. 40, 163–176 (2010). 
22. Cirrito, J. R. et al. Serotonin signaling is associated with lower amyloid-β levels and plaques in 
transgenic mice and humans. Proc. Natl. Acad. Sci. U. S. A. 108, 14968–14973 (2011). 
23. Davies, S. W. et al. Are neuronal intranuclear inclusions the common neuropathology of triplet-
repeat disorders with polyglutamine-repeat expansions? Lancet 351, 131–133 (1998). 
24. Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R. & Finkbeiner, S. Inclusion body formation 
reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805–810 (2004). 
25. Paulson, H. L. et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar 
ataxia type 3. Neuron 19, 333–344 (1997). 
26. Becher, M. W. & Ross, C. A. Intranuclear neuronal inclusions in DRPLA. Mov. Disord. Off. J. Mov. 
Disord. Soc. 13, 852–853 (1998). 
27. Truant, R., Atwal, R. S., Desmond, C., Munsie, L. & Tran, T. Huntington’s disease: revisiting the 
aggregation hypothesis in polyglutamine neurodegenerative diseases. FEBS J. 275, 4252–4262 
(2008). 
28. Ross, C. A. & Poirier, M. A. Opinion: What is the role of protein aggregation in neurodegeneration? 
Nat. Rev. Mol. Cell Biol. 6, 891–898 (2005). 
29. Toulgoat, F. et al. Facial nerve: From anatomy to pathology. Diagn. Interv. Imaging 94, 1033–
1042 (2013). 
CHAPTER 3 
 
 
 
133 
30. Rüb, U., Brunt, E. R. & Deller, T. New insights into the pathoanatomy of spinocerebellar ataxia type 
3 (Machado-Joseph disease). Curr. Opin. Neurol. 21, 111–116 (2008). 
31. Forrest, M. D., Wall, M. J., Press, D. A. & Feng, J. The sodium-potassium pump controls the 
intrinsic firing of the cerebellar Purkinje neuron. PloS One 7, e51169 (2012). 
32. Dürr, A. et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and 
neuropathological features. Ann. Neurol. 39, 490–499 (1996). 
33. Yoshizawa, T., Watanabe, M., Frusho, K. & Shoji, S. Magnetic resonance imaging demonstrates 
differential atrophy of pontine base and tegmentum in Machado-Joseph disease. J. Neurol. Sci. 
215, 45–50 (2003). 
34. Yamada, M., Tsuji, S. & Takahashi, H. Pathology of CAG repeat diseases. Neuropathol. Off. J. Jpn. 
Soc. Neuropathol. 20, 319–325 (2000). 
35. Chinta, S. J. & Andersen, J. K. Dopaminergic neurons. Int. J. Biochem. Cell Biol. 37, 942–946 
(2005). 
36. Rüb, U. et al. Consistent affection of the central somatosensory system in spinocerebellar ataxia 
type 2 and type 3 and its significance for clinical symptoms and rehabilitative therapy. Brain Res. 
Rev. 53, 235–249 (2007). 
37. Fahl, C. N. et al. Spinal Cord Damage in Machado-Joseph Disease. The Cerebellum 14, 128–132 
(2015). 
38. França, M. C., D’Abreu, A., Nucci, A. & Lopes-Cendes, I. Clinical correlates of autonomic 
dysfunction in patients with Machado-Joseph disease. Acta Neurol. Scand. 121, 422–425 (2010). 
39. Morrissette, D. A. & Stahl, S. M. Modulating the serotonin system in the treatment of major 
depressive disorder. CNS Spectr. 19 Suppl 1, 57–67; quiz 54–57, 68 (2014). 
40. Takei, A., Hamada, T., Yabe, I. & Sasaki, H. Treatment of cerebellar ataxia with 5-HT1A agonist. 
Cerebellum Lond. Engl. 4, 211–215 (2005). 
41. Takei, A. et al. Effects of tandospirone on ‘5-HT1A receptor-associated symptoms’ in patients with 
Machado-Josephe disease: an open-label study. Clin. Neuropharmacol. 27, 9–13 (2004). 
42. Takei, A. et al. Difference in the effects of tandospirone on ataxia in various types of spinocerebellar 
degeneration: an open-label study. Cerebellum Lond. Engl. 9, 567–570 (2010). 
43. Monte, T. L. et al. Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. 
Acta Neurol. Scand. 107, 207–210 (2003). 
44. Lauterbach, E. C. Neuroprotective effects of psychotropic drugs in Huntington’s disease. Int. J. Mol. 
Sci. 14, 22558–22603 (2013). 
CHAPTER 3 
 
134 
 
45. Tatum, M. C. et al. Neuronal serotonin release triggers the heat shock response in C. elegans in 
the absence of temperature increase. Curr. Biol. CB 25, 163–174 (2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
 
 
135 
Supplementary data 
 
Table1. Additional SHIRPA parameters analyzed in the citalopram pre-clinical trial with 8 and 13mg/Kg (ns=not 
significant). 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 1. Quantification of Purkinje cell number per total area in the cerebellum cortex of WT, CMVMJD135 and 
CMVMJD135 cit treated animals. 
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Abstract 
Machado-Joseph disease (MJD, also known as spinocerebellar ataxia type 3, SCA3), is an 
autosomal dominant neurological disorder, caused by an expanded polyglutamine (polyQ) repeat in the 
ataxin-3 (ATXN3) protein. MJD patients exhibit significant motor impairments such as gait ataxia, 
associated with multiple neuropathological changes including mutant ATXN3 inclusions, markedly 
neuronal loss and atrophy of the cerebellum. The mechanisms of neurodegeneration underlying this 
disease are not well understood and so far there is no effective treatment. We have previously 
demonstrated that chronic citalopram (a selective serotonin re-uptake inhibitor, SSRI) pre-symptomatic 
treatment in CMVMJD135 mice striking ameliorated motor coordination impairments, reduced mutant 
ATXN3 aggregation and astrogliosis, and exerted neuroprotective effects. Here, we explore the 
molecular mechanisms underlying the neuroprotective effects of citalopram in CMVMJD135 mice, by 
assessing candidate molecules through its RNA and protein expression levels. A trend towards an 
increase and/or induction of candidate molecules was observed, with no statistical differences. More 
specific studies, mainly RNA-seq analysis and immunohistochemistry of these candidate molecules in 
situ may shed light into the mechanism of action of citalopram in MJD, which is still unanswered.  
 
Introduction 
Polyglutamine (polyQ) diseases are inherited, fatal neurodegenerative diseases caused by an 
expansion of a coding trinucleotide (CAG) repeat, which is translated to an abnormally elongated 
glutamine tract in the corresponding mutant proteins1. There are nine polyQ diseases, the dominantly 
inherited ataxia Machado Joseph Disease (MJD)/Spinocerebllar ataxia type 3 (SCA3) being the most 
common spinocerebellar ataxia worldwide2,3. The genes underlying these diseases have no homology 
with each other except for the polyQ stretch itself, suggesting a common pathogenic mechanism; 
however, each disease present specific clinical and pathological symptoms. It is assumed that the 
common toxic gain-of-function mechanisms for the mutant polyQ protein are aggregation and 
deposition of misfolded proteins leading to neuronal dysfunction and eventually cell death4. Drug 
discovery strategies over the past few years have generated promising candidate targets and pathways 
which prompted to some very encouraging therapeutic advances; however, no effective treatment 
and/or prevention is yet available for these disorders. Some of the proposed therapeutic strategies are 
based on hypothetic pathogenic mechanisms and comprise: gene silencing, blocking aggregation, 
inducing degradation, proteolysis inhibition, mitochondrial stabilization, reduction of oxidative stress 
and transcription modulation among other possibilities. For many of these suggested therapies, the 
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translation to clinical trials may be limited by human efficacy and safety. Additionally, which of the 
cellular pathways is the most significant to the disease, and thus a good target, is still unclear. In this 
context, drug re-purposing strategies, which rely on finding new uses for existing FDA-approved 
compounds, has been gaining attractiveness due to the faster translation to the clinic, with predictably 
less safety issues5. We have previously performed an unbiased C.elegans-based screen of FDA/EMA-
approved small molecules for modulators of mutant ataxin-3 (ATXN3) induced neurotoxicity, and 
identified a selective serotonin re-uptake inhibitor (SSRI), citalopram, as having a therapeutic effect in 
vivo in two different models (nematode and mouse models of MJD). Chronic citalopram pre-
symptomatic treatment in CMVMJD135 mice rescued weight loss and improved gait, tremors and limb 
clasping. Motor coordination impairments were very strikingly ameliorated upon treatment. Mutant 
ATXN3 aggregation was also reduced in affected brain regions, recovery of cholinergic motor neurons 
loss was observed and astrogliosis mitigated. These results suggested that serotonergic signaling may 
be a promising therapeutic target in MJD proposing that the use of antidepressants in the clinics for 
neurodegenerative diseases may go beyond depression treatment. However, to be translated to clinics 
it is crucial to know its mechanism of action in the MJD context.  
The suppression of ATXN3 aggregation suggests an improvement in the protein homeostasis 
(proteostasis) of neuronal cells. Several lines of evidence support neuroprotective effects of 
antidepressants in neurodegenerative disorders beyond treatment of depression. Neuroprotective 
effects including mitochondrial protection, increased BDNF expression and apoptosis have been  
described in Huntington’s Disease (HD) models upon treatment with psychotropic drugs, including 
SSRI’s6. Activation of the ERK signaling cascade upon stimulation of serotonin receptors was shown to 
reduce Aβ production in Alzheimer’s Disease (AD) mouse and human samples7,8. Additionally, in 
cellular and mouse models of Spinal and Bulbar Muscular Atrophy (SBMA), naratriptan, a serotonin 
receptor agonist, decreased CGRP1 expression, attenuated JNK activity and alleviated pathogenic AR-
mediated neuronal damage9. More associated with the basic functioning of the proteostasis network, a 
recent study described that neuronal serotonin release is sufficient to activate heat shock factor 1 (HSF-
1) and to upregulate molecular chaperones, suppressing protein misfolding and attenuating proteotoxic 
stress in C.elegans10. Furthermore, antidepressant treatment was also described to activate antioxidant 
responses by increasing HO-1 expression through NF-E2-related factor-2 (NRF2) accumulation in the 
nucleus and enhancing Nrf2-DNA binding activity11; and to alleviate endoplasmic reticulum stress (ER)12.  
We described that MOD-5 in C.elegans, the ortholog of the serotonine transporter (SERT) in 
humans is necessary for the therapeutic efficacy of citalopram, as well as the post-synaptic receptors 
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SER-1 and SER-4. Moreover, HSP6, a mitochondrial chaperone, was found to be up-regulated in 
C.elegans and NRF2, an antioxidant response-related transcription factor, was found also up-regulated 
in MCF-7 cells upon citalopram treatment (unpublished data). However, the mechanism of action of 
citalopram, namely its effect on ATXN3 aggregation, remain unclear. Therefore, the main goal of this 
work was to explore and dissect the molecular changes observed in CMVMJD135 mouse nervous 
system upon citalopram treatment. 
 
Material and methods 
Gene expression quantification, qRT-PCR. Brainstem and cerebellum total RNA was isolated 
from 18 and 34 week-old, vehicle- and citalopram-treated WT and CMVMJD135 littermate mice (n=4 
for each group), using TRIZOL (15596-026, Invitrogen, Calrsbad, USA) according to the manufacturer’s 
protocol. RNA samples were treated with DNase I (EN0525, Thermo Scientific®, USA) according to the 
manufacturer’s protocol. First-strand cDNA, synthesized with iScript cDNA Synthesis kit (#170-8891, 
Bio-Rad, USA) was amplified by quantitative reverse-transcriptase PCR (qRT-PCR) as previously 
described13. Primers used for expression quantification are described in table 1. Primers were designed 
using PRIMER-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). qRT-PCR was performed in 7500 
Fast Real-Time PCR System (Life Technologies) and analyzed through 7500 Software v2.3 and ΔΔCt 
method. 
 
Table1. List of primers used for qRT-PCR. 
Primer ID Forward Reverse 
HSC70 TGGCATTTGTGTGGTCTCGT GTGCCGAGATCAATGCCAAC 
HSP105 TCTATTCTGACCCTCAAGGAGTTCC TGTTCCAGCTTCACTGTTGTCTTGC 
HSP90 CACCCTGCTCTGTACTACTACTCGG GCCAATGCCTGTGTCCACCAAAGTC 
HSP70 ATCAGTGGGCTGTACCAGGG TTGACAGTAATCGGTGCCCAA 
HSP60 CTCGGGCCTATGCCAAAGAT TTCTTCCCTTTGGCCCCATT 
HSP40 CGCTACCACCCGGACAAG GGTACCATTAGCACCACCACT 
HSP27 TCACGGCTACTATGTTCGGC CAGAAACGCCTGGAACTTGC 
GRP75 AAGAGAGAGACAGGGGTTGATT CCAGAAGCATCCATGGTAAGG 
HO-1 CAGAAGAGGCTAAGACCGCC GCAGTATCTTGCACCAGGCTA 
NQO1 ACGGTCCTTTCCAGAATAAGAAGA ACCTGGAAGCCACAGAAACG 
IV_BDNF CAGGAGTACATATCGGCCACCA GTAGGCCAAGTTGCCTTGTCCGT 
BDNF GACAAGGCAACTTGGCCTAC TTCGATGACGTGCTCAAAAG 
LC3 TTCTTCCTCCTGGTGAATGG GTGGGTGCCTACGTTCTCAT 
GFAP GGCGAAGAAAACCGCATCAC CCCGCATCTCCACAGTCTTT 
B2m CCTTCAGCAAGGACTGGTCT TCTCGATCCCAGTAGACGGT 
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Western-blot analysis. Protein isolation from mouse brainstem tissue and Western-blot were 
performed as previously described13. The blots were blocked and incubated overnight at 4°C with the 
primary antibody mouse anti-GRP75 (1:1000, ab2799, Abcam), Hsp60 (1:1000, H-300, Santa Cruz 
Biotech), NRF2 (1:1000, C-20, Santa Cruz Biotech) and rabbit anti-GFAP (1:50000, M0761, DAKO 
Corporation, Carpinteria) western-blot of 18 and 34 week-old CMVMJD135 mice, either vehicle or 
treated with citalopram (n=4 for each condition). As a loading control, mouse anti-beta actin (1:10000, 
AC-15, Life technologies) was used. Western-blot detection was performed using Chemidoc XRS 
Software and quantifications with ImageLab Software (Biorad, USA) according to the manufacturer’s 
instructions. 
 
Statistical analysis. One-Way ANOVA was used for paired comparisons. All statistical analyses were 
performed using SPSS 22.0 (SPSS Inc., Chicago, IL). A critical value for significance of two-tailed 
p<0.05 was used throughout the study. 
 
Results 
 
Gene expression analysis in the brainstem upon citalopram treatment in 18 week-old 
CMVMJD135 mice 
To test the hypothesis that an improvement of the proteostasis and/or homeostasis of the 
neuronal cells was underlying the therapeutic effect of citalopram in MJD models, we studied the 
expression of genes encoding components of the proteostasis network, as well as other neuroprotective 
molecules, first at 18 weeks of age, an age at which we already observed an improvement of the 
phenotype of CMVMJD135 mice upon citalopram treatment. In the brainstem (Fig. 1), citalopram 
treatment did not produce striking molecular changes in the expression of several heat shock proteins 
(Fig. 1A), neither protein levels of Hsp60 and GRP75 (Fig. 1B); antioxidant related-molecules (Fig. 1C), 
neither NRF2 protein levels (Fig. 1D) and neurotrophic factors (Fig. 1E). The absence of enhanced 
autophagy upon citalopram treatment was confirmed by the lack of significant differences in LC3 
mRNA levels in the brainstem of CMVMJD135 mice (Fig. 1F). Although not statistically significant, an 
interesting trend towards increase upon citalopram treatment was observed for Hsp40 and GRP75 
chaperones, HO-1 and BDNF. 
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Figure 1. mRNA and protein level profile in brainstem upon citalopram treatment at 18 weeks of age. (A) mRNA 
expression levels for molecular chaperones; (B) Hsp60 and GRP75 protein levels, (C) Antioxidant-related molecules; (D) 
NRF2 protein levels; (E) Neurotrophic factors; (F) Authophagy-related molecules. Bar graph represents the fold changes of 
mRNA levels quantified by normalization to the B2m as an internal control for WT, vehicle and cit treated CMVMJD135 mice 
(n=4 per group, 18 weeks, n=3 technical replicates). Data presented as mean ± SEM, *p<0.05 (One-way ANOVA). 
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Gene expression analysis in the brainstem upon citalopram treatment in 34 week-old 
CMVMJD135 mice 
The same molecules were studied at the end of the pre-clinical trial, in 34 week-old 
CMVMJD135 mice in brainstem and cerebellum. In brainstem, after 29 weeks of citalopram chronic 
treatment, no striking differences were observed in the expression of several heat shock proteins (Fig. 
2A), neither protein levels of Hsp60, GRP75 (Fig. 2B), antioxidant related-molecule (Fig. 2C) NRF2 (Fig. 
2D) and neurotrophic factors (Fig. 2E). The absence of enhanced autophagy upon citalopram treatment 
was confirmed by the lack of significant differences in LC3 mRNA levels in the brainstem of 
CMVMJD135 mice (Fig. 2F). Other autophagy markers, namely atg1, atg5, atg7 and beclin remain to 
be analyzed. 
Also in the cerebellum, no statistical differences were observed for molecular chaperones (Fig. 
3A), antioxidant-related molecules (Fig. 3B), neurotrophic factors (Fig. 3C) and LC3 autophagy marker 
(Fig. 3D). High variability between animals may account for the lack of significant differences in the 
mRNA expression levels.  
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Figure 2. mRNA and protein level profile in the brainstem upon citalopram treatment at 34 weeks of age. (A) Molecular 
chaperones; (B) Hsp60 and GRP75 protein levels, (C) Antioxidant-related molecules; (D) NRF2 protein levels; (E) 
Neurotrophic factors; (F) Authophagy-related molecules. Bar graph represents the fold changes of mRNA levels quantified by 
normalization to the B2m as an internal control for WT, vehicle and cit treated CMVMJD135 mice (n=4 per group, 34 
weeks, n=3 technical replicates). Data presented as mean ± SEM, *p<0.05 (One-way ANOVA). 
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Figure 3. mRNA level profile in the cerebellum upon citalopram treatment at 34 weeks of age. (A) Molecular chaperones, 
(B) Antioxidant-related molecules, (C) Neurotrophic factors; (F) LC3 authophagy marker. Bar graph represents the fold 
changes of mRNA levels quantified by normalization to the B2m as an internal control for WT, vehicle and cit treated 
CMVMJD135 mice (n=4 per group, 34 weeks, n=3 technical replicates). Data presented as mean ± SEM, *p<0.05 (One-
way ANOVA). 
 
Discussion 
Even though it is remarkable to unravel and dissect the neuroprotective effect of citalopram at 
neuropathological level in the MJD context, its mechanism of action in terms of key cellular pathways 
changes upon treatment, still need to be explored.  
Since citalopram strikingly reduces ATXN3 aggregation we hypothesized that this compound 
may be impacting on protein homeostasis. The accumulation of misfolded and aggregated proteins is a 
cytotoxic event implicated in the pathogenesis of several neurological diseases14. Molecular chaperones 
are essential components of the proteostasis network promoting efficient folding and targeting 
misfolding proteins for refolding and degradation. Since an increase in the molecular chaperone 
expression can suppress protein aggregation and toxicity in several models of neurodegenerative 
diseases15–19, we wonder if the citalopram is acting by this mechanism. To test this hypothesis, we 
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analyzed the expression levels of several molecular chaperones in citalopram-treated and non-treated 
CMVMJD135 mice, at two different ages, in brainstem and cerebellum. Although some interesting 
trends towards increased expression were found, the variability between samples did not allow us to 
find statistically significant differences between genotypes and treatment groups. Since we had 
previous evidence of upregulation of hsp6 (mouse GRP75 homolog20) in C.elegans upon treatment 
(Teixeira-Castro A., unpublished data) we also measured the protein levels of GRP75 and Hsp60, two 
mitochondrial chaperones; however, also we detected no differences.  
Our group also found an upregulation of NRF2 in MSC-7 cells upon citalopram treatment 
(Teixeira-Castro A., unpublished data), leading us to focus on this transcription factor that regulates the 
expression of antioxidant enzymes involved in protection against oxidative damage21. Two of these 
antioxidant enzymes are HO-1 and NQO1, for which increased expression has been proved to exert 
neuroprotection in neurodegenerative diseases22–24. A trend towards an induction of HO-1 was also 
observed in total extracts from the cerebellum, without statistical differences. 
It is widely known that SSRI’s, including citalopram, increase the BDNF levels and thus 
contribute to neuroprotection. Here, we also assessed for BDNF levels, including mature and promotor 
IV-dependent BDNF, this one accounting for the majority of the neuronal activity-induced BDNF 
expression25,26. Isoform IV and mature BDNF expression levels were found to have a trend towards an 
increasein the brainstem and in the cerebellum, respectively, and therefore may be exerting 
neuroprotection, but these differences did not reach statistical significance.   
 A possible explanation for the variability between samples and therefore between groups 
(genotype vs treatment) may reside in the fact that MJD, like other polyQ diseases is characterized by 
degeneration of specific brain regions (neurospecificity) keeping others intact, in spite of the ubiquitous 
expression of the mutant proteins27. This pathological feature could be the explanation for the absence 
of striking differences when extracts from the whole brainstem and mainly the whole cerebellum are 
analuzed, even between WT and transgenic animals. Therefore, a transcriptomic/proteomic analysis in 
specific and affected (e.g. pontine nuclei, substantia nigra of the brainstem, deep cerebellar nuclei of 
the cerebellum or spinal cord) vs. non-affected brain regions (e.g. hippocampus), from WT and 
transgenic mouse brains with and without citalopram treatment could certainly identify key cellular 
pathways underlying the effect of this SSRI in MJD.  
Another possibility to try to unravel the molecular changes in specific affected brain regions, 
still in the context of the proteostasis protection, is to perform immunohistochemistry of some of the 
molecules adressed in this study. The in situ characterization could provide additional information and 
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perhaps increased sensibility to localized effects. Although here we were mainly focused on molecules 
related to proteostasis and antioxidant effects, we cannot exclude that other pathways are being altered 
by citalopram. For instance, the effect of citalopram in excitotoxicity, in signaling post-translational 
modifications, in solubility of ATXN3 proteins, in mitochondria dysfunction or axonal transport could 
also be studied. A deep characterization of these parameters will be necessary in CMVMJD135 mouse 
model and their further elucidation upon citalopram chronic treatment of extremely value for the 
understanding of MJD pathogenesis and for the future therapy development.   
 
Conclusion 
In this study we attempted to dissect the molecular mechanisms underlying the 
neuroprotective effects of citalopram in the context of MJD and to provide some clues for the next steps 
in the field. Some interesting trends was observed towards an increase in neuroprotective molecules, 
however; without statistical differences, therefore our question remains unanswered. The continuous 
efforts in understanding, at pathological and molecular levels, the mode of action of citalopram in MJD 
may shed light into the pathogenesis of this disease and into the identification of novel therapeutic 
targets.  
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Abstract 
Machado-Joseph Disease (MJD) or spinocerebellar ataxia type 3 (SCA3) is the most common 
spinocerebellar ataxia worldwide, being a progressive and fatal neurodegenerative disorder caused by a 
polyglutamine (polyQ) expansion in the ataxin-3 gene. Its mechanisms of pathogenesis are still not well 
understood and there is no effective treatment so far. We have previously shown that the treatment of 
an MJD mouse model (CMVMJD135) with citalopram, a selective serotonin re-uptake inhibitor (SSRI), 
starting at pre-symptomatic stage of the disease lead to significant balance and motor coordination 
improvement, suppression of ataxin-3 (ATXN3) nuclear inclusions, and reduction of astrogliosis, among 
other neuroprotective effects. In an attempt to better mirror the clinical situation and further explore the 
potential of this drug, we performed a post-symptomatic citalopram treatment in a more severely 
affected group of CMVMJD135 mice (bearing larger CAG repeat tracts). Citalopram post-symptomatic 
treatment lead to mild improvement in balance and motor coordination and transient improvement in 
tremors, gait and limb clasping in this group of animals of this pre-clinical trial. While confirming the 
beneficial therapeutic effect of citalopram, our results show that the efficacy of treatment with this 
compound is thus reduced when the treatment is initiated later and the disease condition is too severe 
and well-established. This prompts us to suggest early initiation of citalopram treatment in MJD 
patients.  
 
Introduction 
Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 (SCA3) is a clinically 
heterogeneous neurodegenerative disease characterized by variable degrees of ataxia, opthalmoplegia, 
pyramidal dysfunction and peripheral neuropathy1,2. MJD is caused by an expansion of a CAG repeat 
that in the ATXN3 gene, which leads to an abnormally long polyglutamine (polyQ) tract in the encoded 
protein, ataxin-3 (ATXN3)3. At neuropathological level, MJD is characterized by a widespread neuronal 
degeneration affecting multiple neuronal systems and not restricted to the cerebellum, brainstem and 
basal ganglia4. Currently, no effective disease modifying treatment is available for MJD. 
Citalopram is a selective serotonin reuptake inhibitor (SSRI) available as an antidepressant 
since the 1980s in US and Europe and is overall safe and well tolerated drug5,6. Antidepressants and 
other psychopharmacological compounds have conventionally been prescribed to patients with 
neurodegenerative diseases, as a rational complementary therapy, helping them to cope with 
symptoms such as depression and anxiety. However, in the last years, these drugs have been explored 
more meticulously to assess other effects that they may have7. Several antidepressants have shown 
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neuroprotective effects in Alzheimer’s disease (AD), Parkinson’s disease (PD) Huntington’s disease 
(HD) or Spinal and Bulbar Muscular Atrophy (SBMA)8–17. Is it clear that these drugs traditionally 
prescribed for depression or schizophrenia may have more pleiotropic effects than the ones currently 
known. In an unbiased screening of >600 FDA/EMA-approved small molecules for supressors of 
C.elegans mutant ATXN3 induced neurotoxicity, citalopram was found to rescue neurological 
dysfunction and ATXN3 aggregation in this model. Chronic citalopram pre-symptomatic treatment of 
CMVMJD135 mice, strikingly ameliorated motor coordination impairments, reduced mutant ATXN3 
aggregation and exerted neuroprotective effects (Chapter 3, Appendix I). Therefore, this compound 
seems to be a promising therapeutic strategy for MJD. Taking into account the promising results with 
citalopram pre-symptomatic treatment, we performed a follow-up citalopram pre-clinical trial with 
chronic treatment beginning only after the onset of the first motor coordination symptoms of the 
CMVMJD135 mouse model in a group with a higher CAG repeat average, and thus more severe 
disease. This post-symptomatic approach could more closely mirror what happens in MJD patient, and 
thus may serve as a validation of the potential for translation of the previous findings to the clinical 
context. 
 
Material and Methods 
Transgenic mouse model and drug administration. CMVMJD135 mice were generated as 
described previously18. DNA extraction, animal genotyping and CAG repeat size analyses were 
performed as previously described19. The mean repeat size (±SD) for all transgenic mice used in this 
pre-clinical trial was 138±5. Age-matched and genetic background-matched WT animals were used as 
controls. Only male mice were used in this study. We administrated citalopram hydrobromide (CAS 
59729-32-7, kindly provided by Lundbeck, Denmark) in the drinking water at a dosage of 8 mg/kg. To 
define the onset of symptoms we focused on the motor coordination tests that previously showed the 
best improvements upon treatment, i.e. the balance beam walk test and the motor swimming test. 
Treatment was initiated at eleven weeks of age, one week after the onset (ten weeks) of the motor 
coordination symptom appearance this group of animals. The trial was ended at 28 weeks of age, 
when the majority of the transgenic animals could not perform many of the motor tests. For analysis of 
genotype vs phenotype correlations, data obtained from non-treated CMVMJD135 mice of the pre-
clinical trial described in Chapter 3 (mean CAG repeat size of 130±2) were used together with data 
from non-treated CMVMJD135 mice of this pre-clinical trial. All animal procedures were conducted in 
accordance with European regulations (European Union Directive 2010/63/EU). Animal facilities and 
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the people directly involved in animal experiments (SE, SDS, ATC) were certified by the Portuguese 
regulatory entity — Direcção Geral de Alimentação e Veterinária. All the protocols were approved by the 
Animal Ethics Committee of the Life and Health Sciences Research Institute, University of Minho. 
 
Behavioral assessment. Behavioral assessment was performed during the diurnal period, with 5 
males per cage including CMVMJD135 hemizygous transgenic mice and WT littermates (n=15-16 per 
genotype) treated with citalopram or with vehicle (water). Behavioral tests started in a pre-symptomatic 
stage (4 weeks of age) and were conducted until 28 weeks of age (Fig. 1). Neurological tests were 
performed using a selection tests from the SHIRPA protocol, namely assessing tremors, gait quality 
and limb clasping20,21. The stride length was evaluated with footprinting analysis as previously 
described18. Motor behavior was assessed using the balance beam walk test (12 mm and 17 mm 
square and 17 mm round beams) and the motor swimming test19. All behavioral tests were performed 
as previously described19. Body weight was also registered for each evaluation time point. The ARRIVE 
guidelines were followed and taken into consideration throughout the study22. 
 
Immunohistochemistry and quantification of neuronal inclusions. Twenty eight week-old WT 
and CMVMJD135 littermate mice, citalopram-treated and non-treated (n=4 for each group) were deeply 
anesthetized- with a mixture of ketamine hydrochloride (150 mg/kg) plus medetomidine (0.3 mg/kg) 
and transcardially perfused with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde 
(PFA) (Panreac, USA). Brains were removed and post fixed overnight in PFA and embedded in paraffin. 
Slides with 4-µm-thick paraffin sections were subjected to antigen retrieval and then incubated with 
mouse anti-ATXN3 (1H9) (1:750, MAB5360, Milipore) which was detected by incubation with a 
biotinylated anti-polyvalent antibody, followed by detection through biotin-streptavidin coupled to 
horseradish peroxidase and reaction with the DAB (3,3'-diaminobenzidine) substrate (Lab VisionTM 
Ultra-VisionTM Detection kit, Thermo Scientific). The slides were counterstained with hematoxylin 25% 
according to standard procedures. ATXN3 positive inclusions in the pontine nuclei (PN) of either 
vehicle- or citalopram-treated animals (n=4 for each conditions, 4 slides per animal) were quantified 
and normalized for total area using the Olympus BX51 stereological microscope (Olympus, Japan) and 
the Visiopharma integrator system software (Visopharm, Denmark) as previously described19. 
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Genotype vs Phenotype correlation. For analysis of genotype vs phenotype correlations, data 
obtained from non-treated CMVMJD135 mice of the pre-clinical trial described in Chapter 323 (mean 
CAG repeat size of 130±2) were used together with data from non-treated CMVMJD135 mice of this 
pre-clinical trial. Motor performance in the balance beam walk and motor swimming tests were 
analyzed at 26 weeks of age for all animals (n=27), and correlated to their CAG repeat number.   
 
Study design and statistical analysis. Experimental design was based on power analyses for 
optimization of sample size. Mouse sample size calculations were previously performed for each 
behavioral test and pathological analyses assuming a power of 0.95 and 0.8, respectively, and a 
significance level of P<0.0523. Data was analyzed through the non-parametric Mann-Whitney U-test 
when variables were non-continuous or when a continuous variable did not present a normal 
distribution (Kolmogorov-Smirnov test, p<0.05). Continuous variables with normal distributions and 
with homogeneity of variance (Levene’s test) were analyzed with Repeated-Measures ANOVA for 
longitudinal multiple comparisons and One-Way ANOVA for paired comparisons, using Tukey test for 
post-hoc comparisons. Genotype-Phenotype correlations were analyzed through the Pearson correlation 
coefficient. All statistical analyses were performed using SPSS 22.0 (SPSS Inc., Chicago, IL) and G-
Power 3.1.9.2 (University Kiel, Germany). A critical value for significance of p<0.05 was used 
throughout the study. 
 
Results 
Citalopram post-symptomatic treatment has mild limited improvement of neurological 
symptoms without rescuing the body weight loss 
The most striking aspect of the phenotype of CMVMJD135 mice are the presence of motor 
uncoordination, loss of strength and balance impairments, among other neurological symptoms18. In 
the experimental group of animals used in this pre-clinical trial, the severity of the phenotype was 
higher than in previously described groups and the symptoms appeared earlier, due to a higher CAG 
repeat mean. Statistically significant differences in the severity of motor symptoms (beam walk test and 
motor swimming test) between WT and non-treated CMVMJD135 mice were observed at ten weeks of 
age (p<0,05). According to this, citalopram was administered since 11 weeks of age (Fig. 1).  
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Figure 1. Timeline schematic representation of the pre-clinical therapeutic trial. 
Citalopram post-symptomatic treatment did not rescue loss of the body weight of 
CMVMJD135 mice (Fig. 2A). Limited improvements were observed for tremors, which were statistically 
significant at 24 weeks of age, although a trend toward an improvement was observed at all ages 
analyzed (Fig. 2B). Also for limb clasping and gait quality, a trend towards an improvement was 
observed at all ages (Fig. 2C,D), the differences being statistically significant between 20 and 24 weeks 
of age. These ameliorations were thus transient and not maintained when the disease became more 
severely installed.  
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Figure 2. Limited effect of citalopram post-symptomatic treatment in neurological symptoms and body weight of 
CMVMJD135 mice. (A) Body weight, (B) Tremors, (C) Clasping, (D) Gait quality. (WT veh, n=13, WT CIT, n=17, 
CMVMJD135 veh, n=16, CMVMJD135 CIT, n=15) Mild improvement was observed for tremors, clasping and gait quality 
between 20 and 24 weeks of age, while no effect was observed in body weight upon treatment. Data presented as mean ± 
SEM., *p<0.05, **p<0.01 and ***p<0.001. (Repeated-measures ANOVA, Tukey correction, One-way ANOVA and Mann 
Whitney U test for non-continuous variables). 
 
Mild improvement in motor coordination of CMVMJD135 mice upon chronic citalopram 
post-symptomatic treatment 
In this group of CMVMJD135 mice with a higher severity of disease, animals were not able to 
correctly perform the motor and coordination tests until the initially planned end of the pre-clinical trial, 
at 34 weeks of age, mainly for the beam walk test, in which the percentage of falls was increasing 
along the age in non-treated CMVMJD135 mice. Nevertheless, we observed an amelioration in motor 
performance with citalopram treatment in the different beams analyzed (Fig. 3A,B,C), although less 
striking for the 17mm circle beam. No differences were detected in the number of falls from the 17mm 
circle beam at 26 weeks of age (Fig. 3D). In the motor swimming test, there was a trend for citalopram-
treated CMVMJD135 mice to take less time to reach the safe platform when compared to non-treated 
mice; however, this difference did not reach statistical differences along the pre-clinical trial (Fig. 3E). 
Although not so striking as in citalopram pre-symptomatic treatment (Chapter 3), an amelioration in the 
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stride length upon post-symptomatic treatment was observed at 28 weeks of age (Fig. 3F). Tests were 
not continued after this age, due to the higher severity of disease in non-treated CMVMJD135 mice, 
that rendered them unable to perform the beam walk and motor swimming tests, thus we were unable 
to confirm the continuity of amelioration of the stride length in subsequent ages. 
Figure 3. Limited effect of citalopram post-symptomatic treatment in motor coordination of CMVMJD135 mice. (A) Balance 
beam walk test 12mm square, (B) Balance beam walk test 21mm square, (C) Balance beam walk test 17mm circle, (D) 
Percentage of falls from balance beam walk test 17 mm circle, (E) Motor swimming test, (F) Stride length. (WT veh, n=13, 
WT CIT, n=17, CMVMJD135 veh, n=16, CMVMJD135 CIT, n=15) Mild improvements were observed in the 12 and 21 mm 
square balance beams and in the stride length, while no effect was observed in 17mm circle beam and in the motor 
swimming test upon treatment. Data presented as mean ± SEM., *p<0.05, **p<0.01 and ***p<0.001. (Repeated-measures 
ANOVA, Tukey correction and One-way ANOVA). 
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CAG repeat-length correlates with phenotype severity in CMVMJD135 mouse model 
To better understand the relatively decreased effect of citalopram post-symptomatic treatment 
in this group of CMVMJD135 mice several comparisons were performed. The CAG number repeat of 
the animals from the pre-symptomatic pre-clinical trial was confirmed to be significantly less than the 
animals from the post-symptomatic pre-clinical trial (Fig. 4A). A genotype vs phenotype correlation was 
performed at 26 weeks of age, for the performance in motor swimming and beam walk tests in animals 
without treatment (vehicle group from the pre- 23 and post-symptomatic citalopram pre-clinical trial, 
n=23). A statistically significant correlation (p<0,001, n=23) was obtained for both tests at this age, 
indicating an inverse correlation between CAG repeat length and behavior performance (Fig. 4B,C).  
Consistently, the direct comparison between the groups of animals used in the pre- and post-
symptomatic citalopram pre-clinical trials showed a striking difference between the groups concerning 
behavior performances in the beam walk and motor swimming tests, the higher CAG repeat-length 
group (mean ± SD = 138 ± 5) used for this post-symptomatic trial, showing more severe disease and 
faster progression than the group (mean ± SD = 130 ± 2) used for the previous pre-symptomatic trial 
(Fig. 4D,E) (p<0,05).  
When comparing the common behavior tests from the two pre-clinical trials in terms of the 
symptom onset, symptom improvement (light colors corresponding to improvements and white boxes 
with dashed lines corresponding to the rescue of the phenotype, i.e. when the treated animals reached 
the WT level) and treatment onset (Fig. 4F,G) one can clearly see that in addition to our post-
symptomatic treatment, the symptoms also started earlier in this pre-clinical trial due to the higher CAG 
repeat length of this group of animals. These two factors may underlie the differences in terms of 
symptom improvement from the two pre-clinical trials. 
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Figure 4. CAG-repeat length vs phenotype correlation and citalopram pre and post-symptomatic pre-clinical trial 
comparison. (A) CAG repeat number comparison between pre and post-symptomatic citalopram pre-clinical trials 
(CMVMJD135, n=27), (B) Genotype vs phenotype correlation for the motor swimming test at 26 weeks of age 
(CMVMJD135, n=25), (C) Genotype vs phenotype correlation for the beam walk test at 26 weeks of age, (CMVMJD135, 
n=23). Comparison of citalopram pre- and post-symptomatic pre-clinical trials regarding performance of untreated groups in 
(D) the motor swimming test and (E) 12 mm square beam walk test. Data presented as mean ± SEM., *p<0.05 and 
**p<0.01. (Pearson correlation coefficient, Repeated-measures ANOVA, Tukey correction and One-way ANOVA). Comparison 
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(Figure 4.) (cont.) of citalopram (F) pre- and (G) post-symptomatic pre-clinical trials regarding timing and extent of 
improvements in the common tests. Light colors corresponding to improvements upon treatment and white boxes with 
dashed lines corresponding to the rescue of the phenotype, i.e. when the treated animals reached the WT level, for each 
behavioral test. (pre- and post-symptomatic pre-clinical trials with a range between 11 and 17 animals used per group).  
 
Citalopram post-symptomatic treatment did not change the ATXN3 inclusions and neither 
mitigated astrogliosis 
Following the neuropathological observations upon citalopram pre-symptomatic treatment 
(Chapter 3), here we also evaluated the effect of citalopram post-symptomatic treatment in the 
abundance of ATXN3 neuronal inclusions in affected several brain regions, and of astrogliosis in the 
substantia nigra. The treatment with citalopram after the onset of behavior symptoms was not able to 
modify the course of these neuropathological alterations, not affecting the number of inclusions per 
total area, neither impacting in GFAP positive cells in the substantia nigra (Fig. 5). 
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Figure 5. Citalopram post-symptomatic treatment effect in ATXN3 intranuclear inclusions and astrogliosis. (A) Immunohistochemistry and quantification of ATXN3 neuronal inclusions in the 
PN, RtTg, 7N and LRt of vehicle and cit treated CMVMJD135 mice (n=4, 28 weeks). (B) Immunohistochemistry and quantification of GFAP positive cells in substantia nigra (n=4, 28 weeks).
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Discussion 
In order to explore if citalopram is able to modify the course of the symptoms after the onset 
of the phenotype in the CMVMJD135 mouse model of MJD, in this study we started the treatment 
with citalopram 8mg/kg only after the manifestation of the core motor coordination symptoms 
(assessed in beam walk and motor swimming tests). We chose this component of the phenotype 
because results from the previous pre-symptomatic pre-clinical trial (Chapter 3) showed that chronic 
citalopram treatment exerted its effects mostly in the more central nervous system-related 
symptoms rather than on the more peripheral ones (e.g. muscular strength). In this group of 
animals the first motor coordination symptoms occurred at 10 weeks of age. Limited effects were 
observed in motor coordination and balance in the beam walk test in CMVMJD135 mice upon this 
post-symptomatic treatment combined with a higher severity disease condition. Oher neurological 
symptoms such as tremors, gait quality and limb clasping were also transiently attenuated upon 
citalopram treatment, however it did not rescue the body weight loss. Also at the neuropathological 
level, this post-symptomatic treatment was not able to modify the ATXN3 intranuclear inclusions 
neither astrogliosis.  
Correlating the CAG repeat-length with the motor and balance phenotype performance in 
untreated CMVMJD135 mice from pre- and post-symptomatic treatment pre-clinical trial groups, we 
observed that animals with higher CAG repeat-length took more time to complete the tasks, thus 
presenting a stronger phenotype when compared to the previous pre-symptomatic treatment control 
groups. This correlation between CAG repeat-length and clinical features was also described in MJD 
patients, in which patients with higher CAG repeat length patients present earlier age at disease 
onset and worse clinical presentations; however, other factors than repeat size are also thought to 
contribute for the clinical presentation24. The CMVMJD135 mouse model has therefore, the 
advantage of faithfully reproducing this feature of MJD; however, one should take it into 
consideration, whenever possible, for the correct preparation of experimental groups for pre-clinical 
trials, namely for the adequate matching of control and test groups. Even with this increased 
severity, at an early stage of the disease progress, when the symptoms are not fully established and 
some of them are still absent, the neurodegenerative process could probably be overcome by 
treatment. As the disease progresses, however, the regeneration ability may not be sufficient to cope 
with the neurodegenerative process and all the symptoms appear and become strikingly established. 
In the CMVMJD135 mice group studied in this pre-clinical trial, the post-symptomatic treatment with 
citalopram had beneficial effects but it did not lead to such a marked amelioration as we have seen 
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in the previous pre-symptomatic trial23, which may be due to the combination of the late treatment 
and the increased severity of the symptoms. However, a higher efficacy of citalopram in a post-
symptomatic approach cannot be excluded in a group similar to the one tested in the pre-
symptomatic approach. It is therefore crucial to perform another pre-clinical trial (now currently 
ongoing in the lab) in order to be able to answer the question of whether citalopram is only able to 
delay and alleviate the symptoms when they are starting to appear, or also to modify the symptoms 
after their establishment in a group of comparable severity, i.e. with a similar mean number of CAG-
repeats. Nonetheless, our results suggest that citalopram treatment may be less suitable for MJD 
patients in very late stages of the disease and/or with very severe forms of the disease.  
As a dominant autosomally inherited neurodegenerative disease, MJD patients or their 
relatives at risk can benefit from genetic counseling, in which they can be informed of the 
consequences and nature of the disease as well as their probability of developing or transmitting it. 
A pre-symptomatic treatment of the disease would avoid or at least delay the disease onset; 
however, for several personal, social and/or ethical issues the majority of the clinical studies start a 
treatment after the onset of the symptoms (post-symptomatic treatment). Our data suggests that the 
pre-symptomatic gene testing for MJD and the appropriate family counselling could have a positive 
impact not only on subjects’ quality of life, but also on the future of the disease studies. In recent 
years, there has been a growing number of advances and possibilities of therapeutic approaches, 
therefore this molecular genotyping may become of great value to families affected by this disease 
when an effective treatment becomes available. Although still not ongoing, a human clinical trial with 
citalopram treatment could be an excellent opportunity for MJD therapy, especially in a combination 
with pre-symptomatic genetic testing. An additional advantage is that citalopram is an SSRI with few 
side effects25 after long term administration, which could conceivably be administered in a pre-
symptomatic stage of the disease. Pre-symptomatic testing and treatment are still major ethical 
concerns in human patients, implying a balance of the risks of testing and treating in contrast with 
potential benefits; however, it is an emerging concept for several neurodegenerative diseases26,27. 
Another major challenge to a pre-symptomatic clinical trial is the lack of consistent and sensitive 
non-invasive biomarkers, not only for early stages of the disease, but also to its progression. Some 
recent neuroimaging and blood-based transcriptomic studies do exist28,29, however none of the 
resulting candidate biomarkers is ready to be introduced on clinics as a common practice. Also, for 
citalopram we are still lacking an efficacy biomarker limited to its mechanism of action in MJD, 
which could hamper the translation to clinics. Lack of financial support for a rare disease such as 
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MJD could also be another causes of a future delay in the development of new and potentially 
relevant clinical trials. 
Conclusion 
Citalopram post-symptomatic treatment in a higher severity MJD model lead to mild motor 
and balance amelioration and transient improvement in tremors, gait quality and limb clasping, 
without rescuing the body weight loss. At the neuropathological level, post-symptomatic treatment 
did not change the number of ATXN3 intranuclear inclusions and did not improve astrogliosis. The 
possibility of better positive effects of citalopram post-symptomatic treatment is not excluded in 
animals with less phenotype severity. Moreover, citalopram pre-symptomatic treatment could be a 
rational therapeutic possibility in MJD patients having undergone genetic testing.   
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6. Introduction 
In this chapter, the main findings, strengths and limitations of this PhD thesis regarding the 
research questions are summarized, a general discussion is made and conclusions are drawn, based 
on the results presented. Furthermore, suggestions for further research are put forward.  
 
6.1 Pre-clinical trials design: Strengths and limitations 
Drug discovery development and pre-clinical trials are challenging and expensive processes 
approaching hundreds of millions of dollars per drug1–3. However, most of the promising compounds 
identified in pre-clinical trials are not as successful in human patients, contributing to several clinical 
failures. These failure rates could possibly be decreased and optimized by using more stringent criteria 
during the pre-clinical trials. Correct design, execution and reporting of mouse model results help to 
make pre-clinical data more reproducible and translatable to the clinic, reducing the false positive or 
false negative results. Several criteria should be taken into account, as discussed below. 
 
6.1.1 Validity of mouse models of disease   
Animal models are essential to bridge the translational gap between pre-clinical and clinical 
research. Since 1980’s, several types of genetically engineered mouse models have been used in drug 
development and pre-clinical trials, including transgenic, knock-out, and knock-in mouse models. The 
best model for human diseases should assume a number of different criteria: (a) face validity, in 
which the biology and symptoms between a mouse model and human disease should be similar (being 
often limited by the lack of knowledge on the pathogenic mechanisms underlying the disease 
symptoms); (b) construct validity, reflecting the degree to which a model measures what it claims to 
be measuring and (c) predictive validity, in which the same drug should produce the same effects 
between mouse model and humans (being often limited to incomplete correlation between mouse and 
humans in terms of disease mechanisms or drug absorption, distribution, metabolism and excretion). 
Therefore, it is important to choose a model of the disease that satisfies all these criteria, exhibiting 
significant and well characterized phenotype and pathology relevant to the target of interest, based on 
the hypothesized mechanism of action of the drug been studied. However, there is no “one model” for 
each disease. Therefore, tests in different models are an advantage to validate the results obtained. For 
instance, different models of the same disease may have different genetic backgrounds, and 
consequently show high variability in the extent and time course of expression of disease phenotypes 
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and pathology patterns, may have different pharmacokinetics and pharmacodynamics to the same 
drug and may have different drug responses among genders (males vs females).   
The CMVMJD135 mouse model used in this PhD work is the transgenic mouse model of MJD 
with the most extensive pathological and phenotypic characterization so far, exhibiting a high face 
validity. These features make this model a very useful one for pre-clinical trials and hence, the one 
chosen to address the questions of this PhD work. However, a combination of different models can 
eventually come closer to the clinical situation than a single, even highly refined model.  
 
6.1.2 Sample size  
Currently, for ethical (3R policy4,5) and logistic reasons, the number of animals used in pre-
clinical trials is minimized to the most. Sample size should be estimated and depends on the 
predictable magnitude of a specific biological effect, on the inherent variability of the target and on the 
parameters being measured. This number needs to be sufficient for the researcher to detect significant 
differences taking into account the referred variabilities, as well as the statistical power required to 
produce solid data.   
In the pre-clinical trials performed in this PhD work, the sample size necessary for each 
behavioral test and for each molecular and pathological analysis was estimated taking into account the 
standard deviations obtained from previously pre-clinical trails performed in the group. We concluded 
that to detect a 50% of drug effect we needed a variable number of animals for different tests (Table 1 
of supplementary data of the Brain paper provided in Appendix I). These precise calculations of number 
of animals needed to detect significant differences in these pre-clinical trials, will be of extreme value in 
order to better design the future pre-clinical trials, (for instance, to remove some behavioral tests that 
require a very large number of animals in order to detect a significant effect and could not be ethically 
performed). 
 
6.1.3 Gender Balance, Randomization and Blindness 
These three parameters are crucial aspects of a proper pre-clinical trial design which may 
affect the obtained results. Mice should be separated into groups by gender (to exclude gender specific 
drug effects) and age and then randomly assigned to either control or treatment groups. Controls 
should always be included into study design, as a reference point. Due to logistic reasons, only male 
mice were used in the pre-clinical trials in this PhD work, but proper controls were assumed along the 
study. Randomization was not always possible due to treatment administration. For instance, in the 
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citalopram pre-clinical trial, since the drug was given in the water bottle, the animals were distributed 
sequentially along the boxes according to the specific treatment, making randomization also difficult. 
Ideally, researchers conducting the experiments and analyzing the results should be blinded to the 
genotype and treatments. In the case of genotype, the blinding is not possible to maintain, since as the 
MJD-like symptoms progresses in CMVMJD135 mice, it becomes clearly visually detectable. Blindness 
to the treatment was not assumed, being one of the limitations of the current pre-clinical trials, since 
the researcher performing, analyzing and giving the treatment was the same. Nevertheless, efforts are 
being made in order to re-design the following studies and comply with these parameters in the future 
pre-clinical trials. 
 
6.1.4 Drug treatment considerations 
Although human dosage studies are frequently performed before the clinical trials, one major 
concern in clinical trial failures is the inappropriate translation of a drug dosage from one animal 
species to another, and frequently a drug that works well in animals is apparently not effective in 
humans. The animal dosage should not be extrapolated to a human equivalent dosage (HED) by a 
simple conversion based on body weight, as was described for instance in the case of resveratrol 
treatment, claimed to improve the health and life span in mice6,7. In 2007, Reagan-Shaw and 
colleagues suggested the use of the body surface area (BSA) normalization method, based on the idea 
that BSA correlates well across several mammalian species with several parameters of biology, 
including oxygen utilization, caloric expenditure, basal metabolism, blood volume, circulating plasma 
proteins and renal function. According to the formula for dosage translation based on BSA [HED 
(mg/kg) = Animal dosage (mg/kg) * Animal Km/Human Km]8, the VPA mice dosage used in the our pre-
clinical trial (200mg/kg/day) would translate to 16mg/Kg/day in humans, being similar to the usual 
adult initial prescribed dosage by FDA in cases of epilepsy (10 to 15mg/kg/day) (www.drugs.com).  
Using this approach, the citalopram dosages used in the pre-clinical trial described in Chapter 
3 (8 and 13mg/kg/day) would translate to 38 and 63mg/kg/day in humans. The usual adult initial 
dosage of citalopram for depression is 20mg/kg/day, and the maximum dosage currently 
recommended in humans being 40mg/kg/day (www.drugs.com), thus the most effective dosage found 
in our trial is within the recommended range. Recently, this BSA method has also been questioned, 
and it has been proposed that other aspects should be taken into account for interspecies scaling, such 
as physiologic, pharmacokinetic and toxicology data, rather than the simple BSA conversion9. This is 
particularly important in drug discovery strategies in which often no safety and toxicity data is available 
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for new drugs. For the compounds studied in this PhD thesis, although still important, the safety and 
toxicity in humans are guaranteed since they are widely used FDA-approved compounds. Effective 
dosages in humans could be scaled according to the described dosages. Furthermore, one additional 
proof-of concept for the use of these dosages in the pre-clinical trials here performed was the fact that 
these dosages were already described to be non-toxic and effective in mouse models with the same 
genetic background10,11. 
An additional question, no less important and increasingly referred in the modern translational 
medicine, is the gender issue. The majority of the described pre-clinical trials are performed in males 
and only occasionally in females. Sex is a crucial biological variable which may have deep concerns. 
Under-representing female animals in pre-clinical trials may result in a reduced understanding of the 
biological, physiological and pathological mechanisms in females compared with males. Without female 
experiments it is difficult to predict that the results obtained in males will also be applicable to 
females12. One strength of the CMVMJD135 mouse model in this aspect is that the phenotype between 
males and females is highly comparable. However, the compounds tested in the pre-clinical trials 
performed in this PhD thesis were only assessed in males, making it difficult to assume that the drug 
effects will be the same in females. At least for citalopram, it will be valuable to evaluate its effects also 
in female animals.  
Treatment timing should depend on whether the goal is disease prevention, therapeutic 
intervention (i.e. reducing/reversing the established phenotype/pathology), of symptomatic relief. In 
pre-clinical trials, the treatment is often initiated before or just after the onset of the disease, i.e. in a 
pre-symptomatic stage of the disease. This contrasts to the clinical practice, in which treatment is 
usually started after the onset of the symptoms. In this work we performed two pre-symptomatic 
treatment approaches (VPA and Citalopram) aiming at prevent or delaying the onset of the 
symptoms, and one post-symptomatic treatment approach (Citalopram) aiming at reversing and 
relieving the established phenotype oe delaying its progression. Although with promising results in 
citalopram pre-symptomatic treatment, we should take into account that the observed potential 
pharmacological effect could be overestimated in CMVMJD135 mice, as the therapeutic intervention 
occurred earlier in the disease process when compared to the clinical condition. However, as seen in 
Chapter 5, post-symptomatic treatment also had some beneficial effects, even in more severely 
affected animals.  
Further studies on citalopram need to be performed in the CMVMJD135 mouse model; 
however, as a relevant proof-of concept, some of these studies are easier and fast to perform in 
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C.elegans model. In this context, we assessed the necessary treatment duration and initiation in 
C.elegans model of MJD (Appendix I). First we observed that when we take off the citalopram treatment 
in the course of the disease, the symptoms returns after some time (but not instantly), suggesting that 
we need a chronic treatment to exert the therapeutic beneficial effects. Additionally, the treatment 
duration suggests a chronic treatment, since less duration of treatment corresponds to less therapeutic 
efficacy. Finally, when we started to treat the animals one, two, three or four days after the onset of the 
symptoms, it was observed that as the disease becomes more established the beneficial effects are 
less marked. Overall, these C.elegans data suggest that chronic treatment with citalopram starting at 
pre-symptomatic stages may be the best approach. 
Furthermore, the availability of genetic diagnosis for MJD together with our main findings 
supports that it is possible and promising to start the treatment with citalopram early in the disease or 
even pre-symptomatically. 
 
6.1.5 Statistical methods 
The statistical methods of analysis should be chosen before the start of the study and clearly 
described in the methods. Assessment of population distribution (normal vs skewed) will dictate the 
type of the analysis (parametric vs non-parametric). Caution with outliers or high variability should also 
be taken, to correct analyze the data. Exclusion criteria should also be established prior to the study.  
The behavioral results obtained in the pre-clinical trials performed in this work were composed 
of quantitative and qualitative data. Quantitative data were analyzed using parametric methods which 
have to assume that the residuals (i.e. deviation of each observation from its group mean) have a 
normal distribution, that the variances are approximately the same in each group, and that the 
observations are independent of each other. The first two of these assumptions was investigated 
through the Kolmogorov-Smirnov test to check normality of the data distribution, and Levene’s test to 
check homogeneity of variance. When these assumptions were not valid, an appropriate data 
transformation (e.g., logarithmic) was applied to normalize the data. The third assumption was 
assumed for all methods in this study. 
Continuous variables were analyzed through Repeated-Measures ANOVA for multiple 
comparisons to test the overall hypothesis that there are (or not) differences among groups. When no 
differences were found, further comparisons of means were not performed. However, when the ANOVA 
results were significant (p<0,05), Tukey post-hoc comparison test were performed to study the 
differences among individual means. Performing One-way ANOVA for each age to compare means in a 
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longitudinal test is not the most correct analysis to perform because it is not taking into account the 
pooled standard deviation. However, in this type of studies, besides the importance to know if there is a 
significant difference between groups, it is also relevant to know if the treatment significance is more 
pronounced early in the disease, if it takes several weeks to exert effects or if its therapeutic effects are 
only observed at later stages of the disease. For that purpose, we performed One-way ANOVA at each 
age to estimate the initiation of the drug therapeutic effects in the progression course of the disease.  
When  the  assumptions  needed  for  the ANOVA of approximately equal variation in each 
group  and  approximate  normality  of  the  residuals  was  not valid and no scale transformation was 
available to correct the heterogeneity of variance and/or non-normality, a non-parametric test was used 
to compare the equality of population means. For paired group comparison of Rotarod in VPA pre-
clinical trial (Chapter 2) Mann-Whitney U test was used.  
Categorical data, such as the footprinting analysis or SHIRPA obtained results, have a natural 
order such as absent, mild or severe which are also defined numerically (e.g. 0, 1 and 2, respectively). 
This obtained data were analyzed through the Chi-squared data and/or Mann-Whitney U test. The 
correlation analysis was performed with Pearson correlation to assess the strength of the linear relation 
between two numerical variables (e.g. correlation between CAG repeats and motor performance – 
Chapter 5). 
Finally, each histopathological and/or molecular analysis, which are all punctual and non-
continuous variables were analyzed through the One-Way ANOVA test.  
 
6.1.6 Reproducibility 
The experimental results should be replicated in other laboratories to reinforce the scientific 
value findings and, at the end, increase the confidence to translate the results to the human clinical 
trials. CMVMJD135 mice phenotype and pathology was strikingly replicated among pre-clinical trials, 
with attention to genotype vs phenotype correlations, and in other collaborator’s labs (Maria do Carmo 
Costa and Henry Paulson, Department of Neurology, University of Michigan, personal communication) 
reinforcing the reproducibility of this model. The drug treatment reproducibility is also one of the major 
concerns and should also be replicated as well as in other MJD mouse models. In the pre-symptomatic 
VPA pre-clinical trial, no striking amelioration of the phenotype and ATXN3 aggregation was observed. 
However, this does not exclude that the same dosage could improve other behavioral, molecular 
and/or pathological features in another MJD mouse model. It would be of extreme value to reinforce 
the confidence on therapeutic efficacy of citalopram in the context of MJD if the striking effects 
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observed in the CMVMJD35 mice pre-symptomatic pre-clinical trial could be replicated in more MJD 
mouse models. Indeed, this validation study is ongoing in the Paulson laboratory, University of 
Michigan (Maria do Carmo Costa et. al., unpublished data). 
 
6.1.7 Reporting results 
Omission and/or insufficient reporting of experimental animal data may be a reason why pre-
clinical several experiments are not reproduced13,14. For the studies performed in this PhD thesis, which 
are published and in preparation, full details of assay methods, information on the animal model used, 
including genetic background, CAG repeat-length, exclusion criteria and statistical analysis were 
provided according to the ARRIVE guidelines15. An additional concern in this field is that experiments 
with a positive and desirable outcome are more likely to be published than negative results16. It is 
crucial that negative results should also be reported, in peer-reviewed journals or other open-access 
formats, in order to increase efficiency, decrease redundant efforts and learn from others’ experiences.  
 
6.2 Hypothesis-based vs non-hypothesis based therapeutic approaches applied to polyQ 
diseases 
 Despite great progress in elucidating the pathomechanisms underlying polyQ diseases, an 
effective treatment is still lacking, even with several efforts in the field. The current strategies towards 
development of therapies for these diseases can be divided in hypothesis-based and hypothesis-free 
approaches. The strengths of the hypothesis-based approach include the ability to apply molecular and 
chemical knowledge to investigate a specific molecular hypothesis. This type of approach presupposes 
a deep understanding of the pathogenic mechanisms of the disease in study or of related diseases. In 
this work, we started by using the latter strategy, simply by testing compounds shown to be promising 
for other polyQ diseases (or non-polyQ neurodegenerative diseases), namely in the VPA pre-clinical trial 
(Chapter 2).  
 Mechanistic targets can be identified on the basis of biological observations and the only 
condition that needs to be fulfilled is that affecting a single molecular mechanism will be enough to 
obtain a significant therapeutic effect. The therapeutic action can be achieved either if the target is 
involved in the pathological state or specific symptomatology or if the target can indirectly alleviate 
certain consequences of the disease, to produce symptomatic relief or modification of the disease 
process. In this context, we used VPA, which is an FDA-approved compound for treatment of epilepsy, 
bipolar disorder and migraine17 with a relatively safe profile in clinical use. VPA has been shown to have 
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neuroprotective effects in animal models of HD, SBMA and ALS18–20. Also in MJD, VPA was reported to 
counteract neurodegeneration in a Drosophila model21, a human neuronal cell model22 and a C.elegans 
model of the disease23. Taking into account these positive effects of VPA, we hypothesized that this 
compound could thereby be useful for a pre-clinical trial in an MJD mouse model, to further validate 
this therapeutic strategy. However, the results of our pre-clinical trial in the CMVMJD135 mouse model 
concerning the MJD-like neurological symptoms and ATXN3-aggregation, were not the expected neither 
concerning target engagement nor efficacy. Although we cannot rule out that a higher dosage could be 
effective in delaying disease progression. Several other molecular and pathological effects of VPA 
treatment in CMVMJD135 need to be further studied in the future. 
 A disadvantage of the hypothesis-based approach is that the proposed target may not be as 
relevant to the disease pathogenesis as hypothesized, or have a sufficient therapeutic impact. The lack 
of understanding of the entire disease mechanism may in these manner slow the progression of the 
candidate drugs for the disease. There has been a tendency to focus on the possible mechanisms, 
often identified in very simplified model systems (e.g. cell culture models) and to underestimate the 
complexity of physiology in the entire organism. Maybe more time and effort will be required in order to 
understand the complex mechanisms underlying MJD, before advancing to improved targets. At any 
rate, the testing of target-directed compounds is also a way to probe the relevance of candidate targets 
and mechanisms, thus even the “negative” results found in our work can contribute to advance 
knowledge.  
 In the last years, hypothesis-free approaches for polyQ therapies are also gaining relevance due 
do their numerous advantages and the novel technical possibilities for screening. High-throughput 
screening allows the testing of the effects of thousands of drug-like compounds across a panel of 
targets. This approach does not involve a prior deep understanding of the molecular mechanisms and 
frequently reveals interesting disease-modifying agents by the identification of molecules that modify 
the disease phenotype by acting on a previously undescribed target or by acting simultaneously on 
more than one target. This type of strategy is thus contributing not only to provide new avenues for 
defining the pathomechanisms of the disease, but also for direct pathways to therapy. 
 Our group established a C. elegans model of MJD23 and screened a library of FDA/EMA-approved 
compounds for their ability to prevent or delay the neurological dysfunction and the ATXN3 aggregation 
in this model. This screening relied primarily on the phenotypic measures of response (percentage of 
locomotion defective animals) requiring, a priori, few mechanist assumptions. Several promising 
molecules were identified, citalopram being one of the most striking compounds able to reduce the 
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locomotion defective and subsequent ATXN3 aggregation in this MJD model. Although not questionable 
in terms of their value for drug discovery and molecular mechanism studies of the disease, there is a 
need to fill the gap between C.elegans and humans. Therefore, a citalopram pre- and post-symptomatic 
pre-clinical trials using CMVMJD135 mice was performed in this PhD thesis to assess the impact of 
this compound in the multiple symptoms and pathology shown by this model. We show that activation 
of serotonergic signaling with citalopram lead to very striking improvement of the symptoms and 
pathology of CMVMJD135 mice. Taking into consideration the pathogenic mechanisms already 
suggested for MJD, and also our own neurochemical analysis of the CMVMJD135 mice, finding 
serotonergic signaling as a relevant target was surprising.  
 
6.3 Selective Serotonin Reuptake Inhibitors (SSRI’s) for neurodegenerative disorders  
Selective Serotonin Reuptake Inhibitors (SSRI’s) are a class of compounds used to treat 
depression by improving symptoms such as mood, sleep, appetite and concentration by increasing the 
serotonergic signaling. However, current research suggests that SSRIs not only can help treat 
depression, but also may have therapeutic potential as neuroprotective agents. For instance, 
paroxetine administration to HD mutant mice increased serotonin levels, delayed the onset of 
neurodegeneration and motor dysfunction, improved energy metabolism and mouse lifespan24. 
Fluoxetine, another SSRI, improved neurogenesis in HD mutant mice by increasing brain 
neurotrophic factors25. Sertraline, also increased neurogenesis and slowed disease progression in 
another model of HD26. Even citalopram was described to decrease de Aβ production in human 
subjects11,27. It is clear that drugs traditionally prescribed for disorders such as depression or anxiety 
may have more pleiotropic effects than previously anticipated.  
 
6.3.1 Citalopram for MJD: future perspectives 
In accordance to the recent findings of SSRI’s in neurodegenerative diseases, we identified 
citalopram as exerting striking improvements in symptoms and pathology of CMVMJD135 mice. An 
attempts towards understanding of additional neuroprotective effects of citalopram in MJD C.elegans 
and mouse model is ongoing through analysis of several candidate hypotheses (Fig. 1).  
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Figure 1. Hypothesis model for serotonergic signaling effects through citalopram treatment in MJD models. 
The brain serotonin system modulates a diverse array of behavioral and physiological processes, 
including the regulation of motor output that is mediated by central pattern generators28–30, such as 
locomotion. Experimental data have shown that impairment of the serotonergic cerebellar system can 
induce cerebellar ataxia31. However, this system has not been specifically described as affected in MJD 
patients and indeed the structural integrity of the serotonergic raphe nuclei seems preserved, and 
supports the view that depressive symptoms observed in MJD patients are not primarily related to the 
underlying pathological process, but rather are a reactive nature32,33. Likewise, our data also don’t 
confirm an a priori a depletion of serotonin in CMVMJD135 mice nor a serotonin turnover problem in 
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the brain (Appendix I), which suggests that the increase in the serotonergic signaling by citalopram is 
not correcting a neurotransmitter deficiency but exerting other pleiotropic effects. The expression levels 
of the serotonin receptors and/or transporters still need to be addressed in order to understand the 
physiological status of serotonergic signaling in CMVMJD135 mouse model. The fact is that, even in 
the absence of a serotonergic signaling deficiency, the increase in the serotonin levels by citalopram 
was highly effective in rescuing motor symptoms and, more unexpectedly, ATXN3 aggregation. Since 
the total ATXN3 protein levels were measured and no differences were found, we hypothesize that 
citalopram is not acting by promoting degradation of the mutant protein (through autophagy, for 
instance) but exerting a direct link to proteostasis that should be further explored. Although no major 
differences were found in several candidate chaperones (Chapter 3), we do not exclude that differences 
could be detected in specific brain regions, which we were not able to detect in a whole brainstem or 
cerebellum RNA extraction. We hope that the already ongoing transcriptomic analysis of specific 
affected and spared regions in citalopram-treated and non-treated CMVMJD135 mice may provide new 
avenues for treatment and perhaps disclose novel pathogenic mechanisms involved in MJD. A related 
question that remains to be addressed in the CMVMJD135 mice is the effect of citalopram in ATXN3 
solubility, as we observed in C.elegans model of MJD (Appendix I) in which the citalopram was able to 
increase the ATXN3 protein solubility. Several other components of ER stress and/or mitochondria UPR 
may together contribute to a decrease of ATXN3 aggregation, however, not forgetting that aggregation 
is still a matter of discussion in terms of its pathogenicity or its protection shield function from the other 
toxic forms (i.e. intermediate species of aggregation). 
Nevertheless, the citalopram effects were not solely based on aggregation, since a decrease in 
the astrogliosis (neuroinflammation) and a restoration of the cholinergic and Calbindin D-28K positive 
neurons was observed upon treatment. CMVMJD135 mice display astrogliosis measured by the GFAP 
positive astrocytes in the substatia nigra; however, the complete characterization of the inflammatory 
status, for instance in terms of microglia involvement and up or down-regulation of pro- and anti-
inflammatory cytokines is an ongoing study in the lab. A quantitative assessment of the effect of 
citalopram in these molecules may reveal additional contributions to this drug’s neuroprotective effects. 
Also, the midbrain cholinergic system is affected in MJD patients32, and in the CMVMJD135 mouse 
model in which we detected a loss of cholinergic neurons in facial nuclei and in the spinal cord. 
Citalopram is one of the more specific SSRI’s, with little effect in histaminergic, cholinergic, 
dopaminergic, or a-adrenergic receptors and also one of the most tolerable SSRI’s due to its lack of 
drug interactions and low incidence of side effects compared with other molecules. However, in the 
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case of the CMVMJD135 mouse model treated with citalopram, the data suggests than cholinergic and 
serotonergic signaling may be linked, even indirectly, producing positive effects, which still need to be 
explored in the future.  
The loss of Calbindin D-28K positive cells in the cerebellum of CMVMJD135 mouse model 
observed in this PhD work allowed us a double achievement, first the indirect confirmation that 
perturbation of calcium-signaling in Purkinje cells may play a role in the pathogenesis of MJD and 
second, that citalopram is also playing a neuroprotective role by (directly and indirectly) restoring this 
signaling. Calbindin-D28K is a major calcium-binding protein found in mammalian brain34,35 exerting 
essential roles as neuronal buffer36, and in aging and neurodegenerative diseases37–40. In fact, deranged 
calcium signaling was already implicated in neurodegeneration when studied in the YAC84Q mouse 
model of MJD41. It is possible that disruption of Purkinje cell calcium signaling may lead to initial 
cerebellar dysfunction and ataxic symptoms and eventually proceed the Purkinje cell death, although 
as this animals’ age (34 weeks) we still did not observe Purkinje cell loss (Chapter3). These findings 
suggest that the differential expression of calcium-binding proteins in Purkinje cells of CMVMJD135 
mouse model may contribute to their ability to survive excitotoxic insults and that citalopram may be 
helping neurons to cope with deranged neuronal calcium signaling, a hypothesis than needs to be 
further clarified. Also related to calcium signaling is the glutamatergic signaling, dysfunction of which 
may lead to excitotoxicity events, this being one of the pathogenic mechanism widely associated with 
polyQ diseases, including MJD. It was described that L-glutamate-induced excitation of MJD patient-
specific induced pluripotent stem cell (iPSC)-derived neurons initiates calcium-dependent proteolysis of 
ATXN3 followed by the formation of SDS-insoluble aggregates42, and, more recently, that nuclear 
accumulation of mutant ataxin-3 was able to disrupt dendritic differentiation and mGluR-signaling in 
MJD mouse Purkinje cells43. Although not explored in this PhD work, since citalopram was able to 
reduce the ATXN3 aggregation, it seems that calcium and glutamatergic signaling may be explored and 
hypothesized as possible citalopram targets in the CMVMJD135 mouse model, underlying the cleavage 
of ATXN3 protein and promoting its aggregation in specific brain regions.  
Also not deeply studied in this PhD work, but a promising hypothesis lies in the antioxidant 
response effects. Citalopram was described to reduce the oxidative stress in patients with major 
depression44 and other SSRIs were already described to increase the levels of several antioxidant 
enzymes45, suggesting that augmentation of antioxidant defenses may be one of the mechanisms 
underlying the neuroprotective effects of antidepressants and possible with implications also for MJD.  
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In another perspective, SSRI’s are widely prescribed for the chronic treatment of major 
depressive disorder (MDD). Likewise, in this PhD work we observed also citalopram chronic treatment 
was also necessary to exert the neuroprotective effects in MJD models. The molecular changes already 
described to underlie SSRI treatment effects in models of depression include increased production 
and/or increase of neurotrophic factors (i.e. BDNF), increased levels of cell proliferation and neuronal 
migration markers, reduced expression of serotonin autoreceptors and induction of molecules that 
modulate neuronal remodeling. Therefore, it will be valuable to address these alterations in the 
CMVMJD135 mouse model and possible could make a link between the SSRI effects for these two 
different groups of CNS disorders. 
Antidepressant-like effects may also involve epigenetic modifications like DNA acetylation and/or 
most likely DNA methylation. For instance, it was already described that several antidepressants 
caused epigenetic modifications associated with changes in HDAC expression in C56BL/6 mice46, that 
antidepressant response may vary according to epigenetic regulation of BDNF expression47, and that 
some genes may be controlled by epigenetic mechanisms that can be affected by antidepressant 
treatments48. Therefore, epigenetic mechanisms in the CMVMJD135 mouse model and upon 
citalopram treatment may be also one of the further hypothesis to be explored in terms of its possible 
mechanisms in MJD. 
Obviously, more research work should be performed to unravel the neuroprotective actions of 
citalopram in MJD and to replicate these positive findings also in female animals and in other MJD 
mouse models, before undertaking citalopram clinical trials in patients. However, in the absence of 
disease modifying drugs for MJD so far, the recent findings on citalopram, provide and additional hope 
for the future therapeutic developments in MJD, mainly due to the fact that this compound is frequently 
provided for long-term treatment in clinical practice without major side-effects.   
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6.4 Main findings and conclusions of this work 
1. Chronic Valproic acid pre-symptomatic treatment at 200mg/kg/day led to limited and mild 
symptomatic effects at later stages in the CMVMJD135 mouse model; 
2. Chronic Valproic acid treatment did not alter ATXN3 aggregation at 30 weeks of age; 
3. Chronic Citalopram pre-symptomatic treatment with 8mg/kg/day led to striking amelioration of 
motor coordination in the CMVMJD135 mice model; 
4. Chronic Citalopram pre-symptomatic treatment with 8mg/kg/day reduced ATXN3 aggregation and 
astrogliosis at 34 weeks of age; 
5. Chronic citalopram pre-symptomatic treatment with a higher dosage of 13mg/kg/day led to limited 
and mild improvements in the CMVMJD135 mouse model; 
6. Chronic post-symptomatic citalopram treatment led to mild improvements in a group of 
CMVMJD135 mice with higher CAG repeat length and more severe disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER 6 
 
187 
 
References 
1. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug 
development costs. J. Health Econ. 22, 151–185 (2003). 
2. Frederix, G. W. J., Hövels, A. M., Severens, J. L., Raaijmakers, J. a. M. & Schellens, J. H. M. 
[Threshold value for reimbursement of costs of new drugs: cost-effectiveness research and 
modelling are essential links]. Ned. Tijdschr. Geneeskd. 159, A7728 (2015). 
3. Freedman, L. P., Cockburn, I. M. & Simcoe, T. S. The Economics of Reproducibility in Preclinical 
Research. PLoS Biol. 13, e1002165 (2015). 
4. Bulger, R. E. Use of animals in experimental research: a scientist’s perspective. Anat. Rec. 219, 
215–220 (1987). 
5. Russell, W. M. S. The development of the three Rs concept. Altern. Lab. Anim. ATLA 23, 298–304 
(1995). 
6. Baur, J. A. et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 
444, 337–342 (2006). 
7. A compound in red wine makes mice live longer, healthier. Mayo Clin. Health Lett. Engl. Ed 25, 4 
(2007). 
8. Reagan-Shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. 
FASEB J. 22, 659–661 (2007). 
9. Blanchard, O. L. & Smoliga, J. M. Translating dosages from animal models to human clinical trials--
revisiting body surface area scaling. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 29, 1629–1634 
(2015). 
10. Rouaux, C. et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding 
protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis 
mouse model. J. Neurosci. Off. J. Soc. Neurosci. 27, 5535–5545 (2007). 
11. Cirrito, J. R. et al. Serotonin signaling is associated with lower amyloid-β levels and plaques in 
transgenic mice and humans. Proc. Natl. Acad. Sci. U. S. A. 108, 14968–14973 (2011). 
12. Sandberg, K., Umans, J. G. & Georgetown Consensus Conference Work Group. Recommendations 
concerning the new U.S. National Institutes of Health initiative to balance the sex of cells and 
animals in preclinical research. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 29, 1646–1652 
(2015). 
CHAPTER 6 
 
188 
 
13. Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience 
research reporting: the ARRIVE guidelines for reporting animal research. Osteoarthr. Cartil. OARS 
Osteoarthr. Res. Soc. 20, 256–260 (2012). 
14. Hooijmans, C. R., de Vries, R., Leenaars, M., Curfs, J. & Ritskes-Hoitinga, M. Improving planning, 
design, reporting and scientific quality of animal experiments by using the Gold Standard Publication 
Checklist, in addition to the ARRIVE guidelines. Br. J. Pharmacol. 162, 1259–1260 (2011). 
15. Kilkenny, C. et al. Animal research: reporting in vivo experiments--the ARRIVE guidelines. J. Cereb. 
Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 31, 991–993 (2011). 
16. Sena, E. S., van der Worp, H. B., Bath, P. M. W., Howells, D. W. & Macleod, M. R. Publication bias 
in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol. 8, 
e1000344 (2010). 
17. Rosenberg, G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see 
the forest for the trees? Cell. Mol. Life Sci. CMLS 64, 2090–2103 (2007). 
18. Tsai, L.-K., Tsai, M.-S., Ting, C.-H. & Li, H. Multiple therapeutic effects of valproic acid in spinal 
muscular atrophy model mice. J. Mol. Med. Berl. Ger. 86, 1243–1254 (2008). 
19. Feng, H.-L. et al. Combined lithium and valproate treatment delays disease onset, reduces 
neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. 
Neuroscience 155, 567–572 (2008). 
20. Zádori, D., Geisz, A., Vámos, E., Vécsei, L. & Klivényi, P. Valproate ameliorates the survival and the 
motor performance in a transgenic mouse model of Huntington’s disease. Pharmacol. Biochem. 
Behav. 94, 148–153 (2009). 
21. Yi, J. et al. Sodium valproate alleviates neurodegeneration in SCA3/MJD via suppressing apoptosis 
and rescuing the hypoacetylation levels of histone H3 and H4. PloS One 8, e54792 (2013). 
22. Lin, X. P. et al. Valproic acid attenuates the suppression of acetyl histone H3 and CREB activity in 
an inducible cell model of Machado-Joseph disease. Int. J. Dev. Neurosci. Off. J. Int. Soc. Dev. 
Neurosci. 38, 17–22 (2014). 
23. Teixeira-Castro, A. et al. Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by 
the DAF-16 and HSF-1 pathways. Hum. Mol. Genet. 20, 2996–3009 (2011). 
24. Duan, W. et al. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann. 
Neurol. 55, 590–594 (2004). 
25. Grote, H. E. et al. Cognitive disorders and neurogenesis deficits in Huntington’s disease mice are 
rescued by fluoxetine. Eur. J. Neurosci. 22, 2081–2088 (2005). 
  CHAPTER 6 
 
189 
 
26. Duan, W. et al. Sertraline slows disease progression and increases neurogenesis in N171-82Q 
mouse model of Huntington’s disease. Neurobiol. Dis. 30, 312–322 (2008). 
27. Sheline, Y. I. et al. An Antidepressant Decreases CSF A Production in Healthy Individuals and in 
Transgenic AD Mice. Sci. Transl. Med. 6, 236re4–236re4 (2014). 
28. Harris-Warrick, R. M. Neuromodulation and flexibility in Central Pattern Generator networks. Curr. 
Opin. Neurobiol. 21, 685–692 (2011). 
29. MacKay-Lyons, M. Central pattern generation of locomotion: a review of the evidence. Phys. Ther. 
82, 69–83 (2002). 
30. Guertin, P. A. Central Pattern Generator for Locomotion: Anatomical, Physiological, and 
Pathophysiological Considerations. Front. Neurol. 3, (2013). 
31. Chan-Palay, V. Indoleamine neurons and their processes in the normal rat brain and in chronic 
diet-induced thiamine deficiency demonstrated by uptake of 3H-serotonin. J. Comp. Neurol. 176, 
467–493 (1977). 
32. Rüb, U., Brunt, E. R. & Deller, T. New insights into the pathoanatomy of spinocerebellar ataxia type 
3 (Machado-Joseph disease). Curr. Opin. Neurol. 21, 111–116 (2008). 
33. Cecchin, C. R. et al. Depressive symptoms in Machado-Joseph disease (SCA3) patients and their 
relatives. Community Genet. 10, 19–26 (2007). 
34. Celio, M. R. et al. Monoclonal antibodies directed against the calcium binding protein Calbindin D-
28k. Cell Calcium 11, 599–602 (1990). 
35. Zhang, J. H., Morita, Y., Hironaka, T., Emson, P. C. & Tohyama, M. Ontological study of calbindin-
D28k-like and parvalbumin-like immunoreactivities in rat spinal cord and dorsal root ganglia. J. 
Comp. Neurol. 302, 715–728 (1990). 
36. Schwaller, B., Meyer, M. & Schiffmann, S. ‘New’ functions for ‘old’ proteins: the role of the 
calcium-binding proteins calbindin D-28k, calretinin and parvalbumin, in cerebellar physiology. 
Studies with knockout mice. Cerebellum Lond. Engl. 1, 241–258 (2002). 
37. Yuan, H.-H., Chen, R.-J., Zhu, Y.-H., Peng, C.-L. & Zhu, X.-R. The neuroprotective effect of 
overexpression of calbindin-D(28k) in an animal model of Parkinson’s disease. Mol. Neurobiol. 47, 
117–122 (2013). 
38. Riascos, D. et al. Age-related loss of calcium buffering and selective neuronal vulnerability in 
Alzheimer’s disease. Acta Neuropathol. (Berl.) 122, 565–576 (2011). 
39. Sasaki, S. et al. Parvalbumin and calbindin D-28k immunoreactivity in transgenic mice with a G93A 
mutant SOD1 gene. Brain Res. 1083, 196–203 (2006). 
CHAPTER 6 
 
190 
 
40. Geula, C. et al. Loss of calbindin-D28k from aging human cholinergic basal forebrain: relation to 
neuronal loss. J. Comp. Neurol. 455, 249–259 (2003). 
41. Chen, X. et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. 
J. Neurosci. Off. J. Soc. Neurosci. 28, 12713–12724 (2008). 
42. Koch, P. et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-
Joseph disease. Nature 480, 543–546 (2011). 
43. Konno, A. et al. Mutant ataxin-3 with an abnormally expanded polyglutamine chain disrupts 
dendritic development and metabotropic glutamate receptor signaling in mouse cerebellar Purkinje 
cells. Cerebellum Lond. Engl. 13, 29–41 (2014). 
44. Khanzode, S. D., Dakhale, G. N., Khanzode, S. S., Saoji, A. & Palasodkar, R. Oxidative damage and 
major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox 
Rep. Commun. Free Radic. Res. 8, 365–370 (2003). 
45. Behr, G. A., Moreira, J. C. F. & Frey, B. N. Preclinical and Clinical Evidence of Antioxidant Effects of 
Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder. Oxid. 
Med. Cell. Longev. 2012, 1–13 (2012). 
46. Ookubo, M., Kanai, H., Aoki, H. & Yamada, N. Antidepressants and mood stabilizers effects on 
histone deacetylase expression in C57BL/6 mice: Brain region specific changes. J. Psychiatr. Res. 
47, 1204–1214 (2013). 
47. Lopez, J. P. et al. Epigenetic regulation of BDNF expression according to antidepressant response. 
Mol. Psychiatry 18, 398–399 (2013). 
48. Melas, P. A. et al. Antidepressant treatment is associated with epigenetic alterations in the 
promoter of P11 in a genetic model of depression. Int. J. Neuropsychopharmacol. Off. Sci. J. Coll. 
Int. Neuropsychopharmacol. CINP 15, 669–679 (2012). 
 
 
 
 191 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix I 
 
 192 
 
 
 
Serotonergic signalling suppresses ataxin 3
aggregation and neurotoxicity in animal models
of Machado-Joseph disease
Andreia Teixeira-Castro,1,2,3,4,* Ana Jalles,1,2,* Sofia Esteves,1,2,* Soosung Kang,3,5,6
Liliana da Silva Santos,1,2 Anabela Silva-Fernandes,1,2 Ma´rio F. Neto,3,4 Rene´e
M. Brielmann,3,4 Carlos Bessa,1,2 Sara Duarte-Silva,1,2 Adriana Miranda,1,2
Ste´phanie Oliveira,1,2 Andreia Neves-Carvalho,1,2 Joa˜o Bessa,1,2 Teresa Summavielle,7
Richard B. Silverman,3,5,6 Pedro Oliveira,8 Richard I. Morimoto3,4 and Patrı´cia Maciel1,2
*These authors contributed equally to this work.
Polyglutamine diseases are a class of dominantly inherited neurodegenerative disorders for which there is no effective treatment. Here
we provide evidence that activation of serotonergic signalling is beneﬁcial in animal models of Machado-Joseph disease. We identiﬁed
citalopram, a selective serotonin reuptake inhibitor, in a small molecule screen of FDA-approved drugs that rescued neuronal
dysfunction and reduced aggregation using a Caenorhabditis elegans model of mutant ataxin 3-induced neurotoxicity. MOD-5,
the C. elegans orthologue of the serotonin transporter and cellular target of citalopram, and the serotonin receptors SER-1 and SER-4
were strong genetic modiﬁers of ataxin 3 neurotoxicity and necessary for therapeutic efﬁcacy. Moreover, chronic treatment of
CMVMJD135 mice with citalopram signiﬁcantly reduced ataxin 3 neuronal inclusions and astrogliosis, rescued diminished body
weight and strikingly ameliorated motor symptoms. These results suggest that small molecule modulation of serotonergic signalling
represents a promising therapeutic target for Machado-Joseph disease.
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Introduction
The expansion of trinucleotide CAG repeats causes hereditary
adult-onset neurodegenerative disorders such as Huntington’s
disease, spinobulbar muscular atrophy, dentatorubral-
pallidoluysian atrophy and six forms of spinocerebellar
ataxia (Ross et al., 1998). Machado-Joseph disease (or spino-
cerebellar ataxia type 3, SCA3), the most common dominantly
inherited SCA worldwide (Schols et al., 2004), is characterized
by ataxia, ophthalmoplegia and pyramidal signs, associated
with dystonia, spasticity, peripheral neuropathy and amyot-
rophy (Coutinho and Andrade, 1978), without cognitive de-
cline. Pathologically, there is degeneration of the deep nuclei of
the cerebellum, pontine and subthalamic nuclei, substantia
nigra and spinocerebellar nuclei. The genetic basis of
Machado-Joseph disease is the expansion of a polyglutamine
tract within the protein ataxin 3 (ATXN3) (Kawaguchi et al.,
1994). When the polyglutamine tract exceeds 60 consecutive
glutamines, ATXN3 becomes highly aggregation prone, lead-
ing to an imbalance in cellular proteostasis, as aggregation-
associated proteotoxicity dominates over folding and clearance
(Balch et al., 2008; Morimoto, 2008).
Currently there is no treatment for Machado-Joseph dis-
ease that effectively slows disease progression. Efforts to im-
prove patient quality of life and to sustain independence
address the restless legs and extrapyramidal syndromes,
treatment of cramps and of the effects of fatigue (D’Abreu
et al., 2010). Not yet translated to clinical practice are thera-
peutic strategies that include the use of small molecules or
gene targeting to manipulate the concentration, conform-
ation, and/or location of ATXN3. For example, it is
known that modulating the levels of molecular chaperones
Hsp70, alphaB-crystallin and Hsp104 could prevent or in-
hibit ATXN3 aggregation, and promote its disaggregation
(Warrick et al., 2005; Robertson et al., 2010; Cushman-
Nick et al., 2013). Treatment with Hsp90 inhibitors that
increase chaperone expression had beneﬁcial effects, al-
though it failed to achieve the predicted molecular effect of
chaperone induction in animal models of Machado-Joseph
disease (Silva-Fernandes et al., 2014). Likewise, activation of
autophagy, either genetic or pharmacological, lessened
ATXN3 pathogenesis in vivo (Menzies et al., 2010;
Nascimento-Ferreira et al., 2013). In rodents, reversion of
the expanded polyglutamine-associated transcription down-
regulation by a histone deacetylase (HDAC) inhibitor res-
cued ataxic symptoms (Chou et al., 2011). Dantrolene
administration (targeting intracellular calcium homeostasis)
improved motor performance and prevented neuronal loss
(Chen et al., 2008). While silencing of ATXN3 offers poten-
tial, the impact of this type of treatment to date has not been
promising in Machado-Joseph disease mice (Costa Mdo
et al., 2013; Nobrega et al., 2013). For many proposed
therapies, translation into clinical practice will be further
limited by human safety. The traditional approach to
drug discovery, which involves de novo identiﬁcation
and validation of new molecular targets, is costly and
time-consuming, thus limiting the number of new drugs
introduced into the clinic (Shim and Liu, 2014). Moreover,
as the average time required for drug development continues
to increase, there has been renewed interest in drug repur-
posing strategies (Chong and Sullivan, 2007; Shim and Liu,
2014). On the other hand, in past years, the primary cause
of new drug candidate failures has been low therapeutic ef-
ﬁcacy in clinical trials. Among the most frequently proposed
reasons for this shortcoming is the lack of translation of
in vitro and recombinant drug activity to therapeutic
in vivo whole organism systems. As an approach to identify
novel therapeutic strategies, we used Caenorhabditis elegans
(C. elegans), a powerful platform to model neurodegenera-
tive disease and for characterization of small bioactive mol-
ecules (Kaletta and Hengartner, 2006). Previously, we
established a C. elegans model for Machado-Joseph disease
pathogenesis in which expression of mutant ATXN3 in the
nervous system led to its progressive aggregation in distinct
neuronal subtypes and altered motor behaviour (Teixeira-
Castro et al., 2011a). Here, we used this model to screen
a library of FDA-approved small molecules, and identiﬁed
compounds that rescued or ameliorated mutant ATXN3-
mediated neurological dysfunction. By combining compound
treatment with genetic tools, we demonstrate that modula-
tion of serotonergic signalling by selective serotonin reuptake
inhibitors (SSRIs) suppressed mutant ATXN3 aggregation
and neurotoxicity in both C. elegans and mice. This reveals
the utility of the approach by which safe and highly effective
bioactive small molecules can be repurposed to beneﬁt rare
diseases lacking effective therapies. The ﬁnding that sero-
tonin recapture inhibition modulates proteotoxicity may be
relevant for other protein conformation disorders.
Materials and methods
Study design
The overall objective of the study was to ﬁnd novel therapeutic
targets for Machado-Joseph disease. The ﬁrst part of this study
was designed to identify novel suppressor compounds of
mutant ATXN3 pathogenesis in vivo, using a hypothesis-free
approach. The second aim of the study was to validate one of
the identiﬁed drugs in a vertebrate model of the disease. To
achieve the two goals, a small molecule screening of a FDA-
approved library was conducted using a transgenic C. elegans
model of the disease (Teixeira-Castro et al., 2011a). The most
promising hit of the screening regarding human safety, target
speciﬁcity and conservation across evolution was tested in
CMVMJD135 mice (Silva-Fernandes et al., 2014). For all
animal experiments, we ensured blinded outcome assessment.
Experimental design was based on power analyses for opti-
mization of sample size. C. elegans (Supplementary Table 1)
and mice (Supplementary Table 2) sample size calculations
were performed for each behavioural test and pathological
analyses assuming a power of 0.95 and 0.8, respectively, and
a signiﬁcance level of P5 0.05. The effect size was calculated
aiming for a 50% improvement. In general, we used n = 3–4
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per genotype/treatment of C. elegans for motility assays, n = 8–
14 for aggregation (with three replicates) and n = 4 for im-
munoblotting. For mice, we used n = 13–16 per genotype/treat-
ment for behavioural tests, and a group size of four animals
per group for quantiﬁcation of ATXN3 intranuclear inclu-
sions, assessment of astrogliosis and western blot analysis.
All experiments were designed with commitment to the prin-
ciples of reﬁnement, reduction, and replacement and per-
formed according to the FELASA guidelines to minimize
discomfort, stress, and pain to the animals, with deﬁned
humane endpoints (1994).
Nematode strains and general
methods
For a list of strains used in this work and abbreviations, see
Supplementary Table 3. All the strains were backcrossed to
Bristol strain N2 ﬁve to eight times. Standard methods were
used for culturing and observing C. elegans, unless otherwise
noted (Brenner, 1974). Nematodes were grown on nematode
growth medium plates seeded with Escherichia coli OP50
strain at 20C.
Compounds
All the compounds were obtained from the commercial vendors
indicated below and were used without further puriﬁcation. The
Prestwick Chemical LibraryTM (Prestwick Chemical) used for
the C. elegans screening comprised 1120 chemical and pharma-
cologically diverse small molecules. Other compounds used,
including the 11 hits selected for validation, were reordered
from a different manufacturer before repetition of experiments:
17-(allylamino)-17-demethoxygeldanamycin (17-AAG) CAS
75747-14-7 (Biomol); nisoxetine hydrochloride CAS 57754-
86-6 (Sigma); scoulerine CAS 6451-73-6 (Toronto Research);
eburnamonine CAS 4880-88-0 (Santa Cruz); piperlongumine
CAS 20069-09-4 (Biotrend); chlortetracycline hydrochloride
CAS 64-72-2 (Sigma); tiapride hydrochloride CAS 51012-33-0
(Sigma); clemizole hydrochloride CAS 1163-36-6 (Sigma);
metixene hydrochloride CAS 7081-40-5 (Sigma); budesonide
CAS 51333-22-3 (Sigma); noscapine CAS 128-62-1 (Sigma); es-
trone CAS 53-16-7 (Sigma); ﬂuoxetine CAS 56296-78-7
(Kemprotec Ltd.); zimelidine CAS 61129-30-4 (Sigma); lyzergol
CAS 602-85-7 (Sigma); pindolol CAS 13523-86-9 (Sigma); tra-
zodone hydrochloride CAS 25332-39-2 (Sigma); citalopram
hydrobromide CAS 59729-32-7 (Kemprotec Ltd.); escitalopram
(S-citalopram) hydrobromide CAS 219861-08-2 (Kemprotec
Ltd). Citalopram used for studies in mice and vabicaserin
were kindly provided by Lu¨ndbeck.
Drug toxicity assay
Bristol strain N2 was used to screen the Prestwick Chemical
LibraryTM for compound toxicity. The assay was performed in
96-well plate format, in liquid culture (Voisine et al., 2007). Each
well contained a ﬁnal volume of 60ml, comprising 20–25 animals
in egg stage, drug at the appropriate concentration and OP50
bacteria to a ﬁnal OD595 of 0.6–0.8 measured in the microplate
reader (Bio-Rad microplate reader 680). To obtain the age syn-
chronized population of eggs, gravid adults were treated with
alkaline hypochlorite solution (0.5M NaOH, 2.6% NaClO)
for 7min. The animals were then washed in M9 buffer, resus-
pended in S-medium to the appropriate egg number and trans-
ferred into the 96-well plate. The OP50 bacteria were grown
overnight at 37C and 150 rpm in Luria Broth (LB) media, pel-
leted by centrifugation, inactivated by four to six cycles of freeze/
thawing, frozen at 80C and then resuspended in S-medium
supplemented with cholesterol, streptomycin, penicillin and nysta-
tin (Sigma). Worms were grown with continuous shaking at
180 rpm at 20C (Shel Lab) for 7 days. The compound library
was prepared in 100% dimethyl sulphoxide (DMSO, Sigma) and
tested at dilutions corresponding to a maximum concentration of
1% DMSO to avoid solvent-speciﬁc developmental defects and
toxicity. For each compound, two ﬁnal concentrations were
tested (50mM and 25mM). The effect of compounds on
C. elegans physiology was monitored by the rate at which the
E. coli food suspension was consumed, as a read out for
C. elegans growth, survival or fecundity. The absorbance
(OD595) was measured daily. OP50-only (S-medium, no vehicle),
DMSO 1% (vehicle) and DMSO 5% (toxic condition) controls
were used.
C. elegans assays for motility defects
and aggregation
Wild-type (WT, N2), wild-type ATXN3 (AT3WT) and mutant
ATXN3 (AT3q130) animals were grown in liquid culture in a
96-well plate format, with the chemical compounds, as
described above. Four-day-old animals were transferred from
the 96-well plates onto an unseeded nematode growth
medium plate (equilibrated at 20C). Plates were allowed to
dry for 1h before starting the assays. Motility assays were per-
formed at 20C as previously described (Gidalevitz et al., 2006;
Teixeira-Castro et al., 2011a). Motor behaviour assays were run
in triplicates or quadruplicates (n = 3 or 4), with a total of at
least 150 animals tested per genotype and/or compound. For
confocal dynamic imaging and quantiﬁcation of ATXN3 aggre-
gation, live animals were immobilized with 3mM levamisole
(Sigma) and mounted on a 3% agarose pad. All images were
captured on an Olympus FV1000 (Japan) or Zeiss LSM 510
(Germany) confocal microscopes, under a 60 oil (NA = 1.35)
or 63 water (NA = 1.0) objectives. Z-series imaging was
acquired for all vehicle- and compound-treated animals, using
a 515/514nm laser excitation line for yellow ﬂuorescent protein
fusion proteins. The pinhole was adjusted to 1.0 Airy unit of
optical slice, and a scan was acquired every 0.5mm along the
z-axis. The quantiﬁcation of the aggregates was performed as
previously described (Teixeira-Castro et al., 2011a, b). Three
parameters were measured: area of aggregates/total area;
number of aggregates/total area; and number of aggregates.
Values shown are the mean (normalized to vehicle treated con-
trol) of eight or more animals per group, unless noted otherwise.
Chemical and pharmacological
classification of the hits
Hits were manually inspected to categorize them into chemical
and pharmacological classes based on MeSH tree (Medical
Subject Headings; PubMed), ChEBI Ontology (Chemical
Entities of Biological Interest), and ATC (Anatomical
Therapeutic Chemical) fourth level classiﬁcations. The major-
ity of the hits were sorted into heterocyclic, alkaloid, steroid,
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polycyclic, and b-amino alcohol chemical classes, and further
classiﬁed into neurotransmitter, anti-infective, cardiovascular,
anti-inﬂammatory, analgesic, and hormone pharmacological
classes. For a drug that has multiple therapeutic applications,
all classes were equally considered. However, if a new multi-
therapeutic drug shares the same structural and pharmaco-
logical class with a high scored single therapeutic compound,
we considered only a single therapeutic application and clus-
tered the new molecule into the same class. This classiﬁcation
allowed us simple observation of the chemical and pharmaco-
logical classes of the hits.
C. elegans citalopram time course
assays
For time course experiments, animals were grown on nematode
growth medium plates with OP50 supplemented with citalo-
pram. OP50 cultures were prepared as described above and
concentrated 10 with S-media supplemented with strepto-
mycin, penicillin and nystatin (Sigma). Stock solutions of citalo-
pram (2.5mM and 0.5mM) (Kemprotec) or vehicle (DMSO)
were prepared and added to OP50 cultures to a ﬁnal concen-
tration of 25mM or 5mM. Plates were seeded with 200ml of
OP50-citalopram/vehicle and left at room temperature to dry
for at least 3 days. Fresh plates were prepared two to three
times a week to prevent drug degradation. OFF-drug effect
was evaluated by treating the animals for 4 days and after
that time animals were transferred to DMSO plates (vehicle),
shown in Fig. 2D as AT3q130::cit OFF. During the reproductive
period, animals were transferred into new fresh plates every day.
Immunoblotting analysis
For determination of the steady-state protein levels of ATXN3,
the animals were incubated in liquid culture with the chemical
compounds in a 96-well plate format as described above. Four-
day-old animals were transferred from the liquid culture onto
an unseeded nematode growth medium plate (equilibrated at
20C). After 1 h of acclimation 25 individual young adult ani-
mals were picked, boiled for 15min in sodium dodecyl sul-
phate (SDS) sample buffer (to destroy all the aggregates) and
the resulting extracts resolved on a 10% SDS gel, as previously
described (Gidalevitz et al., 2009; Teixeira-Castro et al., 2011).
Immunoblots were probed with anti-ATXN3 mouse (1H9,
MAB5360, Milipore; 1:1000 or 1:150) and anti-tubulin
mouse antibodies (T5168, Sigma; 1:5000); and detected with
horseradish peroxidase-coupled secondary antibodies (Bio-
Rad) and chemiluminescence (ECL western-blotting detecting
reagents, Amersham Pharmacia). Protein isolation from mouse
brainstem tissue and western blot were performed as previ-
ously described (Silva-Fernandes et al., 2010). The blots were
blocked and incubated overnight at 4C with the primary anti-
body rabbit anti-ataxin 3 serum (kindly provided by Dr Henry
Paulson) (1:5000) and mouse anti-GAPDH (G8795, Sigma,
1:1000). As a loading control, mouse ataxin 3 and GAPDH
were used. Western blot quantiﬁcations were performed using
Chemidoc XRS Software with ImageLab Software (Bio-Rad)
or ImageJ software (NIH), according to the manufacturer’s
instructions. ATXN3 fractionation assays were performed as
previously described (Koch et al., 2011), with the following
modiﬁcations: AT3q130 animals were grown for 4 days in
nematode growth medium-citalopram/vehicle plates.
Nematodes were collected and washed in M9 buffer, and re-
suspended in RIPA buffer [50mM Tris, 150mM NaCl, 0.2%
Triton
TM
X-100, 25mM EDTA, supplemented with complete
protease inhibitor (Roche)] before shock freezing in liquid ni-
trogen. After three freeze-thawing cycles, the worm pellet was
ground with a motorized pestle, and lysed on ice, in the pres-
ence of 0.025 U/ml benzonase (Sigma). The lysate was centri-
fuged at 1000 rpm for 1min in a table-top centrifuge to pellet
the carcasses (Nussbaum-Krammer et al., 2013). Protein con-
centration was determined using Bradford assay (Bio-Rad) and
was set to a ﬁnal concentration of 3–4 mg/ml in all experimental
conditions and followed by a 22000 g centrifugation for
30min at 4C. The pellet fractions were separated from super-
natants (Triton
TM
X-100-soluble fraction) and homogenized in
150ml RIPA buffer containing 2% SDS followed by a second
centrifugation step at room temperature. The supernatants
(SDS-soluble fraction) were removed, and the remaining pellets
were incubated for 16h in 100% formic acid at 37 C. After
formic acid evaporation at 37C, the pellet was dissolved in
25 ml Laemmli buffer (SDS-insoluble fraction) followed by pH
adjustment with 2M Tris-base for SDS–polyacrylamide gel
electrophoresis analysis. Gels were loaded with 50 mg of the
Triton
TM
X-100 fraction, 40 ml of the SDS-soluble fraction
and the complete SDS-insoluble fraction. Western blot analyses
were performed as described above.
Lifespan
Assays were performed at 20C as previously described (Morley
and Morimoto, 2004). Approximately 100 hermaphrodites were
cultured on each Petri dish and were transferred to fresh plates
every day until the cessation of progeny production, and about
every 1–3 days thereafter. Animals were scored as dead if they
showed no spontaneous movement or response when prodded.
Dead animals that displayed internally hatched progeny,
extruded gonad or desiccation were excluded.
Transgenic mouse model and drug
administration
CMVMJD135 mice were generated as described previously
(Silva-Fernandes et al., 2014). DNA extraction, animal geno-
typing and CAG repeat size analyses were performed as pre-
viously described (Silva-Fernandes et al., 2010). The mean
repeat size [ standard deviation (SD)] for all mice used
was 130  2. Age-matched and genetic background-matched
wild-type animals were used as controls. Only male mice
were used in this study. We administrated citalopram hydro-
bromide CAS 59729-32-7 (Lu¨ndbeck, Denmark) in the drink-
ing water at two doses (8 and 13mg/kg/day) that roughly
equate to the high dosage range prescribed to human patients
for depression (Cirrito et al., 2011). Treatment was initiated at
5 weeks of age, one week before the expected onset of the ﬁrst
neurological symptoms. The trial was ended at 34 weeks of
age, according to the humane endpoints established for the
non-treated CMVMJD135 mice. All animal procedures were
conducted in accordance with European regulations (European
Union Directive 86/609/EEC). Animal facilities and the
people directly involved in animal experiments (A.T.C., S.E.,
A.S.F., S.D.S.) were certiﬁed by the Portuguese regulatory
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entity - Direcc¸a˜o Geral de Alimentac¸a˜o e Veterina´ria. All of the
protocols performed were approved by the Animal Ethics
Committee of the Life and Health Sciences Research
Institute, University of Minho.
Neurochemical quantification
CMVMJD135 and wild-type male littermate mice (n = 5–8)
were sacriﬁced at 24 weeks of age by decapitation, their
brains were rapidly removed, snap frozen in liquid nitrogen
and dissected. Serotonin (5-HT) and 5-hydroxyindoleacetic
acid (5-HIAA) levels were measured in the substantia nigra,
medulla oblongata and cerebellum by high performance liquid
chromatography, combined with electrochemical detection
(HPLC/EC), as described previously (Santos et al., 2010).
Concentrations of neurotransmitters were calculated using
standard curves and results were expressed in terms of 5-HT
and metabolism content per amount of protein.
Behavioural assessment
Behavioural analysis was performed during the diurnal period
in groups of ﬁve males per cage including CMVMJD135 hemi-
zygous transgenic mice and wild-type littermates (n = 13–16
per genotype) treated with citalopram or with vehicle
(water). All behavioural tests started in a presymptomatic
stage (4 weeks) and were conducted until 30 or 34 weeks of
age. Neurological tests and general health assessment were
performed using the SHIRPA protocol, enriched with the
hanging wire test. The dragging of the paws and the stride
length were evaluated with footprint analysis. Motor behav-
iour was further assessed using the balance beam walk test
(12-mm square and 17-mm round beams) and the motor
swimming test. All behavioural tests were performed as previ-
ously described (Silva-Fernandes et al., 2014). Body weight
was also registered for each evaluation time point.
Immunohistochemistry and
quantification of neuronal inclusions
Thirty-four-week-old wild-type and CMVMJD135 littermate
mice, vehicle- and citalopram-treated (n = 4 for each group)
were deeply anaesthetized [a mixture of ketamine hydrochlor-
ide (150mg/kg) plus medetomidine (0.3mg/kg)] and transcar-
dially perfused with phosphate-buffered saline (PBS) followed
by 4% paraformaldehyde (Panreac). Brains were removed and
post-ﬁxed overnight in paraformaldehyde and embedded in
parafﬁn. Slides with 4-mm thick parafﬁn sections were sub-
jected to antigen retrieval and then incubated with mouse
anti-ATXN3 (1H9, MAB5360, Millipore; 1:100), rabbit anti-
GFAP (Dako Corporation; 1:1000) or rabbit anti- Calbindin
D-28K (AB1778, Millipore, 1:1000) antibodies, which were
detected by incubation with a biotinylated anti-polyvalent anti-
body, followed by detection through biotin-streptavidin
coupled to horseradish peroxidase and reaction with the
DAB (3, 30-diaminobenzidine) substrate (Lab VisionTM Ultra-
VisionTM Detection kit, Thermo Scientiﬁc). The slides were
counterstained with haematoxylin 25% according to standard
procedures. Fifty-micrometre thick vibrotome spinal cord sec-
tions were incubated with goat Anti-Choline Acetyltransferase
(ChAT, Millipore, 1:500) and stained according to
VECTASTAIN

ABC system (Vector Laboratories). Thirty-
four-week-old wild-type and CMVMJD135 littermate mice,
vehicle- and citalopram-treated (n = 4 for each group), were
deeply anaesthetized as mentioned above, transcardially per-
fused with NaCl (0.9%) and the mouse brains embedded in
O.C.T. and rapidly frozen in isopentane (Sigma, CAS#78-78-
4) chilled in liquid nitrogen. Slides with 30-mm thick cryostat
sections were incubated with anti-ChAT according to the Lab
VisionTM Ultra-VisionTM Detection kit instructions. ATXN3
positive inclusions in the pontine nuclei, reticulotegmental nu-
cleus of the pons, facial motor nucleus and lateral reticular
nucleus; stained astrocytes (GFAP-positive) in the substantia
nigra; Calbindin D-28K positive neurons in the cerebellar
cortex; ChAT-positive neurons in the facial motor nucleus
and in the ventral horn of the lumbar spinal cord of either
vehicle- or citalopram-treated animals (n = 3–4 for each condi-
tion, four slides per animal) were quantiﬁed and normalized
for total area using the Olympus BX51 stereological micro-
scope (Olympus) and the Visiopharma integrator system soft-
ware (Visopharm) as previously described (Silva-Fernandes
et al., 2014).
Statistical analysis
Data were analysed through the non-parametric Mann-
Whitney U-test when variables were non-continuous or when
a continuous variable did not present a normal distribution
(Kolmogorov-Smirnov test, P50.05). Continuous variables
with normal distributions and with homogeneity of variance
(Levene’s test) were analysed with repeated measures ANOVA
for longitudinal multiple comparisons and one-way ANOVA
or Student’s t-test for paired comparisons, using Tukey or
Bonferroni tests for post hoc comparisons. When these two
latter assumptions were not valid, an appropriate data trans-
formation (e.g. logarithmic) was applied, and the data were re-
analysed (body weight, balance beam walk test and motor
swimming test). When logarithmic data transformation did
not reduce the heterogeneity of variances (hanging wire test),
several mathematical models were applied. In this test, the best
ﬁt model was the logarithmic and the treatment differences
were analysed according the R squares of the CMVMJD135
groups, with a normal residual distribution. Statistical analysis
of C. elegans survival assays was performed using the log rank
(Mantel-Cox) test. All statistical analyses were performed
using SPSS 20.0/22.0 (SPSS Inc.) and G-Power 3.1.9.2
(University Kiel, Germany). A critical value for signiﬁcance
of P50.05 was used throughout the study.
Results
A whole animal screen identifies
small molecules that ameliorate
mutant ataxin 3-mediated neuronal
dysfunction
To identify small bioactive molecules with therapeutic value
for Machado-Joseph disease, we screened a commercially
available compound library, composed mainly of FDA/
EMA-approved drugs, using a C. elegans model of
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Machado-Joseph disease pathogenesis (AT3q130) in which
mutant ATXN3 expressed in neurons caused aggregation
and motility defects (Teixeira-Castro et al., 2011). The
strategy, validation approach and compound safety assays
are depicted in Supplementary Figs 1 and 2. In the primary
screen we identiﬁed 48 compounds (Fig. 1A) that amelio-
rated mutant ATXN3-mediated locomotion defects, show-
ing a percentage of effect to non-treated animals higher
than 50% within a conﬁdence interval of 95%
(Supplementary Fig. 3A). The hit compounds were categor-
ized into chemical and pharmacological classes based on
MeSH tree, ChEBI Ontology, and ATC fourth level classi-
ﬁcations. While the chemical structure classiﬁcation of the
hit compounds revealed marked heterogeneity, they were
enriched for speciﬁc pharmacological activities, namely
modulators of neurotransmission (adrenergic, serotonergic,
cholinergic, dopaminergic and histaminergic), anti-
infectious, cardiovascular, anti-inﬂammatory, analgesic
and hormone-related actions (Supplementary Fig. 3B).
A representative compound for each pharmacological clus-
ter (Table 1) was further assessed for safety (Supplementary
Fig. 2B) and ability to ameliorate motility impairment of
mutant ATXN3 animals (Fig. 1B). The motility of wild-
type animals was not increased by any of these hit com-
pounds, suggesting that their action is speciﬁcally targeting
mutant ATXN3-mediated pathogenesis (data not shown).
Next, we examined whether these compounds affected pro-
tein aggregation in neurons of AT3q130 animals in vivo,
and showed that the majority also decreased mutant
ATXN3 aggregation (Fig. 1C). The reduction in ATXN3
aggregation was not due to decreased steady state levels of
ATXN3 protein, suggesting a mechanism more likely related
to folding stability than enhanced clearance (Fig. 1D). In
summary, this C. elegans AT3q130 repurposing screen iden-
tiﬁed compounds with novel activity as suppressors of
ATXN3 pathogenesis.
Pharmacological and genetic
inhibition of C. elegans SERT
suppresses ATXN3 pathogenesis
Among the largest class of compounds that suppressed
mutant ATXN3-mediated pathogenesis were those that af-
fected serotonergic neurotransmission and modulated 5-HT-
mediated signalling (Fig. 1E). Of these, citalopram is a SSRI
with a proven safety record that is widely used for treatment
of depression (Mandrioli et al., 2012). The primary molecular
target of citalopram is the 5-HT transporter (SERT, encoded
by SLC6A4), which is responsible for 5-HT reuptake by ser-
otonergic neurons (Blakely et al., 1994). This target speciﬁcity
and conservation prompted us to further examine the effects
of citalopram on Machado-Joseph disease pathogenesis.
Treatment with citalopram caused complete rescue of
mutant ATXN3-mediated neuronal dysfunction (Fig. 1E),
with a dose-response proﬁle and a derived half-maximal ef-
fective concentration (EC50) value of 1mM (Supplementary
Fig. 4A). Citalopram exists as a racemic mixture but its effects
are largely due to the S-enantiomer, escitalopram; this and
other SSRIs also had beneﬁcial effects on AT3q130 animals
(Supplementary Fig. 4B). Normal behaviour and motility, de-
velopment and fecundity in wild-type animals were not af-
fected by SSRI treatment (Supplementary Fig. 4C).
Importantly, citalopram treatment signiﬁcantly reduced
mutant ATXN3 aggregation in C. elegans neurons
(Fig. 2A), and increased ATXN3 solubility (Fig. 2B), as as-
sessed by biochemical fractionation (Koch et al., 2011), with-
out affecting the overall level of protein (Fig. 2C).
On continuous exposure to citalopram, the survival of
AT3q130 animals was rescued (Supplementary Fig. 4D
and E) and their neuronal dysfunction was restored
through to Day 14 of age (Fig. 2D). This beneﬁcial effect
declined when citalopram was withdrawn, and neurotox-
icity returned after 3-4 days OFF treatment (AT3q130::cit
OFF, Fig. 2D). Maximum protection required early treat-
ment (from the egg stage through to Day 4 of adulthood)
(Fig. 2E); moreover, the extent of drug exposure period was
critical, as 2 days of treatment were insufﬁcient to exert
beneﬁcial effects (Fig. 2F).
In C. elegans, there is one 5-HT transporter orthologue
of the vertebrate SERT, MOD-5 (Ranganathan et al.,
2001). To conﬁrm the beneﬁcial effect of pharmacological
inhibition of serotonin recapture, we showed that genetic
ablation of MOD-5 rescued mutant ATXN3-mediated
motor dysfunction and aggregation in C. elegans
(Fig. 2G). Pharmacogenetic analysis also supported
MOD-5 as a cellular target of citalopram in the nematode,
as drug treatment did not further ameliorate mutant
ATXN3-mediated pathogenesis in the absence of MOD-5.
In contrast, estrone (a steroid hormone) was able to further
reduce the motility impairment of mod-5; AT3q130 ani-
mals (Fig. 2G), which is consistent with independent
modes of action for these two compounds.
The role of 5-HT receptors was examined using pharma-
cological and pharmacogenetic approaches (Fig. 3A).
Activation of postsynaptic 5-HT receptors by the 5-HT2C
receptor (HTR2C) agonist vabicaserin (Dunlop et al.,
2011) and stimulation of the presynaptic 5-HT autorecep-
tors by buspirone (Takei et al., 2005), dihydroergotamine
(Villalon et al., 2003) (Fig. 3B), lysergol (Pertz et al., 1999)
or pindolol (Corradetti et al., 1998) (Fig. 1D) ameliorated
mutant ATXN3-mediated motor dysfunction. Consistent
with this, genetic ablation of the 5-HT postsynaptic G-
protein coupled receptor SER-1 (Hamdan et al., 1999)
enhanced AT3q130 aggregation and locomotion defects
(Fig. 3C). Likewise, the effect of citalopram was also de-
pendent on these receptors. Additionally, ablation of the
SER-4 (Olde and McCombie, 1997) autoreceptor, which
by eliminating the negative feedback likely increases 5-HT
availability, restored locomotion and reduced ATXN3 ag-
gregation in vivo (Fig. 3D). Taken together, these results
support the idea that pharmacological and genetic inhib-
ition of MOD-5 restores motility and suppresses aggrega-
tion of AT3q130 through modulation of 5HTR activity.
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Figure 1 Identification of small-molecule suppressors of ATXN3 pathogenesis. (A) Graphical representation of the results of the
C. elegans-based screening in which we assessed a subset of 599 compounds of the Prestwick Chemical library. Black lines represent the mean
percentage of animals with locomotion impairment for untreated AT3q130, AT3WT and wild-type animals. Grey dots show the mean of
percentage of locomotion impaired AT3q130 animals upon treatment for each compound. The red line represents the assay cut-off to a minimum
of 50% of effect in animals’ motor behaviour. The red dot represents the percentage of locomotion impaired AT3q130 animals upon citalopram
treatment, as obtained in the primary screen. (B) Motility analysis of AT3q130 animals treated with the top 11 hit compounds found in the screen
(n = 4,  SD), **P5 0.01, ***P5 0.001 (Student’s t-test). (C) Quantification of AT3q130 aggregation by confocal imaging and fluorescence
intensity (n5 10,  SD) *P5 0.05, **P5 0.01, ***P5 0.001 (ANOVA, Bonferroni’s test). (D) Human ATXN3 expression in AT3q130 animals
treated with the top hit compounds (n = 4–6  SEM). *P5 0.05 (Student’s t-test). (E) Motility analysis of AT3q130 animals treated with com-
pounds targeting serotonergic neurotransmission found in the screen (n = 4,  SD), *P5 0.05, **P5 0.01, ***P5 0.001 (Student’s t-test).
WT = wild-type; AT3WT = wild-type ATXN3 expressing animals; AT3q130 = mutant ATXN3 expressing animals.
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Table 1 Small molecule suppressors of ATXN3 pathogenesis grouped by their pharmacological action
Cluster Pharmacological action Drug Structure Number of hit
compounds
1 Neurotransmitter Adrenergic Nisoxetine HCl
O
N
O CH3
CH3
ClH
8
Propylamine
2 Neurotransmitter Serotonergic Scoulerine
N
OH
O
OH
O
CH3
CH3
H
Chiral 8
Alkaloid
3 Neurotransmitter Cholinergic Metixene HCl OH2
S
N
CH3
ClH
2
Heterocyclic
4 Neurotransmitter Dopaminergic Tiapride HCl
ClH
O
N
O
CH3
S
CH3
O
O
N CH3
CH3
2
Benzamide
5 Neurotransmitter Histaminergic Clemizole HCl
N
N N
Cl
ClH
3
Heterocyclic
6 Anti-inflammatory Budesonide
OCH3
O
O
OH
OH CH3
CH3
O
H
H
H
Chiral 5
Steroid
7 Cardiovascular Eburnamonine
N
N
CH3
O
H
Chiral 5
Alkaloid
8 Hormones/Hormone substituents Estrone O
CH3
OH
H
H
H
Chiral 4
Steroid
9 Analgesic Noscapine
N
O
O
CH3O
CH3
O
OO
O
CH3
CH3
HH
Chiral 2
Alkaloid
10 Anti-infective Chlortetracycline HCl ClHChiral
OH
N
OH O
OH
CH3CH3
CH3OH
O
NH2
O
Cl
OH
H
8
Polycyclic
11 Etc. Piperlongumine
O
O
CH3
O
CH3
CH3
N
OO 9
Heterocyclic
*HCl = hydrochloride.
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Citalopram treatment improves
motor balance and coordination
of CMVMJD135 mice
To further investigate the therapeutic potential of citalo-
pram, we used a transgenic mouse model of Machado-
Joseph disease, CMVMJD135, that displays progressive
Machado-Joseph disease-like motor decline and
neuropathology, including ATXN3-positive intranuclear in-
clusions in the CNS (Silva-Fernandes et al., 2014).
Although CMVMJD135 mice showed no changes in base-
line 5-HT levels measured by HPLC (Fig. 4), oral admin-
istration of citalopram (8mg/kg) to these animals (study
design; Fig. 5A) prevented their decreased body weight
gain (Fig. 5B) and had signiﬁcant beneﬁcial effects on the
motor phenotype. While there was only marginal
Figure 2 Early life chronic citalopram treatment suppressed mutant ATXN3 aggregation and neuronal dysfunction in
C. elegans. (A) Aggregate quantification in AT3q130 animals upon citalopram (cit) treatment. (B) Representative western blot analysis of ATXN3
protein upon biochemical fractionation of AT3q130 protein extracts (out of n = 3). (C) Human ATXN3 protein levels in AT3q130 cit animals. (D)
Motility of citalopram-treated wild-type (WT::cit) and AT3q130 (AT3q130::cit) animals and OFF-drug effect (AT3q130::cit OFF) as disease
progressed. (E) Motor behaviour of AT3q130 cit animals treated for 4 days, with treatment initiation at the indicated days and (F) treatment
duration for the indicated days. (G) Locomotion impairment and aggregation load of AT3q130 animals in the mod-5 background and upon treatment
with citalopram, S-citalopram and fluoxetine. For motor behaviour assays: (n = 3–4  SD), *P5 0.05, **P5 0.01, ***P5 0.001 (Student’s t-test). For
aggregate quantification: (n5 8  SD), *P5 0.05, **P5 0.01, ***P5 0.001 (ANOVA, Bonferroni’s test). For western blot: (n = 4  SD), P4 0.05
(Student’s t-test). TX100 = Triton
TM
X-100; FA = formic acid; cit = citalopram; S-cit = S-citalopram; fluox = fluoxetine; WT = wild-type.
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Figure 3 Serotonergic signalling improves ATXN3 pathogenesis in a G-protein coupled receptor-dependent manner. (A)
Schematic of a serotonergic synapse showing that 5-HT is synthesized and released into the synaptic cleft, where it activates postsynaptic 5-HT
receptors. Vabicaserin may activate the regulatory signalling coupled with SER-1. Pindolol, lysergol and DHE probably antagonize the 5-HT
autoreceptor SER-4, whereas the 5-HT1A receptor agonist buspirone may desensitize the receptor, shutting down the stop production signal
mediated by 5-HT autoreceptors in presynaptic neurons. (B) Motor behaviour of AT3q130 animals treated with vabicaserin, buspirone and
dihydroergotamine. (C) Motility defects and aggregation load of AT3q130 animals in a ser-1 genetic background, with and without cit, S-
citalopram and estrone treatments. (D) Motility performance and mutant ATXN3 aggregation phenotypes of AT3q130 animals in the absence of
SER-4. For motor behaviour assays: (n = 3–4,  SD), *P5 0.05, **P5 0.01, ***P5 0.001 (Student’s t-test). For aggregate quantification:
(n5 12,  SD) *P5 0.05, **P5 0.01, ***P5 0.001 (ANOVA, Bonferroni’s test). DHE = dihydroergotamine; DMSO = dimethyl sulphoxide; cit
= citalopram; S-cit = S-citalopram; fluox = fluoxetine.
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improvement in the dragging of the paws (Supplementary
Fig. 5A) and limited effects on exploratory activity
(Supplementary Fig. 5B), grip strength (Supplementary
Fig. 5C) and hindlimb tonus (Supplementary Fig. 5D), cita-
lopram treatment restored stride length to wild-type levels
at advanced stages of the trial (Fig. 5C). Moreover, treated
animals showed reduced tremors (Fig. 5D), reduced limb
clasping (Fig. 5E), and improved gait quality (Fig. 5F).
Citalopram treatment also resulted in a striking improve-
ment in balance and motor coordination as compared to
vehicle-treated CMVMJD135 mice. In the balance beam
walk test, we observed major improvements in the 12mm
square beam from 20 to 34 weeks of age (Fig. 6A and
Supplementary Video 1) and also in a wider (17mm)
round beam (Supplementary Fig. 5E). The most remarkable
beneﬁts of citalopram were observed in the motor swim-
ming test (Fig. 6B), since at many time points and until
quite late in the trial citalopram treated animals were in-
distinguishable from wild-type (Supplementary Video 2).
Overall, these results demonstrate that citalopram can
reduce the impairment in motor coordination of the
Machado-Joseph disease mouse, with less beneﬁt on
strength, suggesting effects at the level of the brainstem,
midbrain or cerebellum, rather than on spinocerebellar
tracts and muscle innervation. Treatment also signiﬁcantly
delayed disease progression in mice.
Citalopram treated wild-type mice behaved similarly to
their untreated littermates, conﬁrming the speciﬁcity of the
effect (Supplementary Fig. 6). Moreover, CMVMJD135
mice treated with a dosage of 13mg/kg showed more
limited improvements when compared to vehicle-treated
controls in all paradigms mentioned above
(Supplementary Fig. 7).
The analysis of brain tissue from CMVMJD135 mice
showed that citalopram treatment (8mg/kg) mitigated re-
active astrogliosis (Fig. 6C) and decreased ATXN3 intra-
nuclear inclusions in the brainstem (Fig. 6D), analogous to
the reduction of neuronal aggregates in C. elegans. This
reduction was observed in the pontine nuclei, reticuloteg-
mental nuclei of pons and facial motor nuclei of
CMVMJD135-treated mice when compared to their ve-
hicle-treated counterparts (Fig. 6D); the impact of citalo-
pram was less marked in the lateral reticular nuclei. This
reduced ATXN3 aggregation did not correspond to lower
levels of ATXN3 protein levels in the brainstem (Fig. 6E),
suggesting that the effect of citalopram in mice is similar to
that in C. elegans, affecting folding and stability of ATXN3
rather than clearance of the mutant protein. Citalopram
treatment also had neuroprotective effects, rescuing loss
of ChAT-positive motor neurons in the facial motor
nuclei (Fig. 7A). The same trend was observed for motor
neurons of the ventral horn of the lumbar spinal cord
(Fig. 7B), albeit without statistical signiﬁcance, in agree-
ment with the observed phenotypic effects upon treatment.
The mild reduction in Calbindin D28-K-positive cells seen
in the cerebellar cortex of CMVMJD135 mice was also
circumvented by citalopram treatment (Fig. 7C).
Figure 4 CMVMJD135 mice show normal levels of 5-HT
and 5-HT metabolic turn over at fully symptomatic stages
of disease. Levels of 5-HT, 5-HIAA and 5-HT turnover (5-HIAA/5-
HT) were measured by HPLC (A) in the cerebellum (n = 5 wild-
type; n = 7 CMVMJD135), (B) medulla oblongata (n = 6 wild-type;
n = 8 CMVMJD135) and (C) substantia nigra (n = 5 wild-type; n = 5
CMVMJD135) at 24 weeks of age. Data presented as the
mean  SEM. P4 0.05 (Student’s t-test). TO = turnover;
WT = wild-type.
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Discussion
In this study we describe a small molecule screen using a
collection of FDA/EMA-approved drugs to identify modu-
lators of neuronal dysfunction in transgenic C. elegans ex-
pressing mutant ATXN3. By using two model systems, we
combined the ease and speed of screening in C. elegans, the
ability to use genetics and selected small molecule agonists
and antagonists of receptors and transporters to validate
pathways, and the relevance of subsequent conﬁrmation
in a vertebrate model of Machado-Joseph disease. This
led to the identiﬁcation of neuroactive compounds,
among which modulators of the serotonergic pathway
that strongly suppressed Machado-Joseph disease patho-
genesis in vivo. In support of this screening strategy,
many of the suppressors of ATXN3 pathogenesis identiﬁed
in our study have been shown to be effective in other neu-
rodegenerative disorders, including Parkinson’s and
Alzheimer’s disease, and also in Machado-Joseph disease
(Clarke et al., 1966; Perenyi et al., 1985; Kanai et al.,
Figure 5 Impact of citalopram treatment at 8mg/kg on the neurological deficits of CMVMJD135 mice. (A) Schematic repre-
sentation of the preclinical therapeutic trial. Significant differences observed between vehicle (n = 13) and citalopram-treated CMVMJD135 mice
(n = 16) in (B) body weight (P = 0.001, 20–34 weeks) and (C) stride length (P = 0.015, 30 weeks). (D) Tremors, (E) limb clasping and (F) gait were
evaluated from 18 to 34 weeks of age with phenotype amelioration from 22 to 34 weeks of age. (n = 13–16,  SD), *P5 0.05, **P5 0.01 and
***P5 0.001 (Mann-Whitney U-test for non-parametric variables and ANOVA, Tukey correction for continuous variables). cit = citalopram.
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Figure 6 Citalopram treatment ameliorates balance and motor coordination and suppresses mutant ATXN3 aggregation in
Machado-Joseph disease mice. Significant differences observed between vehicle (n = 13) and citalopram-treated CMVMJD135 mice (n = 16) in
the (A) square beam (P5 0.001, 20–34 weeks) and (B) motor swimming (P5 0.001, 14–34 weeks) tests. (C) Immunohistochemistry and
quantification of GFAP-positive cells per area in substantia nigra from wild-type, vehicle- and citalopram-treated CMVMJD135 mice (n = 5 per
group, 34 weeks). (D) Neuronal inclusions in the pontine nuclei, reticulotegmental nucleus of the pons, facial motor nucleus and lateral reticular
nucleus of vehicle and citalopram-treated CMVMJD135 mice (n = 4, 34 weeks). (E) Brainstem immunoblots and quantification of total human
ATXN3 protein from vehicle and citalopram-treated CMVMJD135 mice (n = 5, 34 weeks). Data presented as mean  SEM, *P5 0.05 and
**P5 0.01 [ANOVA, Tukey correction (A and B) and one-way ANOVA (C–E)]. Scale bars = 20 mm. cit = citalopram; WT = wild-type; SN =
substantia nigra; PN = pontine nuclei; RtTg = reticulotegmental nuclei of pons; 7N = facial motor nuclei; LRt = lateral reticular nuclei.
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2003; Cho et al., 2009; Cirrito et al., 2011). A more in-
depth understanding of the mechanism of action of these
suppressors of expanded ATXN3 toxicity and their ability
to modulate aggregation offers new opportunities for small-
molecule therapeutics for Machado-Joseph disease and
other protein conformational diseases.
Citalopram and other SSRIs suppressed Machado-Joseph
disease pathogenesis in the C. elegans and mouse
models, showing beneﬁcial effects on motility/coordination,
aggregation of mutant ATXN3, and disease progression.
MOD-5 (and SERT) inhibition by citalopram likely results
in increased extracellular 5-HT levels and enhanced seroto-
nergic neurotransmission that can elicit 5-HT dependent
effects on neuronal activities, adaptation (Blier and de
Montigny, 1999; El Mansari et al., 2005; Schilstrom
et al., 2011), and remodelling (Musazzi et al., 2010;
Bessa et al., 2013). Indeed, ablation of the postsynaptic
receptor SER-1 (Hamdan et al., 1999), which is pharmaco-
logically similar to the mammalian 5-HT2 receptor, aggra-
vated ATXN3 pathogenesis. The beneﬁcial action of
citalopram required SER-1, suggesting that the downstream
effects of this drug are mediated by signalling cascades
involving this receptor. Furthermore, ablation of SER-4,
which shares similarity to vertebrates’ 5-HT1 autorecep-
tors, rescued motor neuron dysfunction and reduced
ATXN3 aggregation in vivo.
The therapeutic effects of SSRIs for amelioration of
mutant ATXN3-mediated neurotoxicity in both C. elegans
and mice required chronic treatment; likewise, citalopram
prolonged treatment is necessary in depression (Blier and de
Montigny, 1999). Such SSRI treatment modalities result in
5-HT1A autoreceptor desensitization (Blier and De
Figure 7 Citalopram treatment shows neuroprotective effects in CMVMJD135 mice. (A) Immunohistochemistry and quantification
of ChAT-positive cells per total area in the facial motor nucleus from wild-type, vehicle and citalopram-treated CMVMJD135 mice (n = 4 per
group, 34 weeks). (B) Immunohistochemistry and quantification of ChAT-positive cells per total area in the lumbar region of the ventral
horn of the spinal cord (LSC) from wild-type, vehicle and citalopram-treated CMVMJD135 mice (n = 3–4 per group, 34 weeks). (C)
Immunohistochemistry and quantification of Calbindin D28K-positive Purkinje cells per total area in the cerebellar cortex from wild-type, vehicle
and citalopram-treated CMVMJD135 mice (n = 4 per group, 34 weeks). Data presented as mean  SEM, *P5 0.05 and **P5 0.01 (one-way
ANOVA). Scale bars = 200 mm (A) and 100 mm (B and C). cit = citalopram; WT = wild-type; 7N = facial motor nuclei; LSC = lumbar spinal cord;
CBX = cerebellar cortex.
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Montigny, 1983; Lanfumey et al., 2008), which inactivates
the negative feedback mechanism taking place in presynap-
tic neurons, thereby increasing 5-HT availability and acti-
vating postsynaptic receptors (Lanfumey and Hamon,
2004). Pindolol, a b-adrenergic receptor partial agonist
with 5-HT1A receptor antagonist properties, when com-
bined with SSRIs, results in a signiﬁcant decrease in time
to ﬁrst response compared with SSRIs alone. Moreover, a
faster desensitization of 5-HT1A autoreceptors by a direct
agonist (e.g. buspirone) may also accelerate the therapeutic
efﬁcacy of SSRIs (Blier and Ward, 2003). Consistently,
targeting 5-HT autoreceptors by chronic treatment amelio-
rated mutant ATXN3-mediated pathogenesis in C. elegans.
Serotonin receptors in nematodes and mammalians, while
homologous, may not be functionally identical
(Komuniecki et al., 2004); therefore, it would be important
to identify the speciﬁc 5-HT receptors required for citalo-
pram’s effect on toxicity and aggregation of mutant
ATXN3 in mice.
In Huntingdon’s disease mouse models, SSRI treatment
resulted in striatal and memory preservation and extended
survival (Lauterbach, 2013). Citalopram has also been
shown to be beneﬁcial in models of Alzheimer’s disease
and in healthy human volunteers by reducing amyloid-b
in the CSF (Cirrito et al., 2011; Sheline et al., 2014). The
need for chronic and early symptomatic treatment in
Machado-Joseph disease suggests a neuroprotective mech-
anism rather than immediate effects on signalling cascades
(Sheline et al., 2014) or correction of an imbalance of 5-HT
in Machado-Joseph disease mice. Moreover, the effect of
citalopram and MOD-5 inactivation on aggregation
ATXN3 is consistent with an impact of serotonergic neuro-
transmission on the rebalance of proteostasis state of the
organism. Indeed, it has been recently described that the
release of serotonin from neurons signals to distal tissues
the activation of protective mechanisms to prevent proteo-
toxicity (Tatum et al., 2015).
Comparing the effects obtained with citalopram with
those described in the literature for other molecules with
positive effect in Machado-Joseph disease models, this SSRI
appears to have a higher therapeutic efﬁcacy. From our
own work, when we compare the current results with the
previous ﬁndings for the Hsp90 inhibitor 17-DMAG (Silva-
Fernandes et al., 2014), we observe a more pronounced
therapeutic effect of citalopram. Namely, the manifestation
of motor swimming defects was delayed 8 weeks by
17-DMAG treatment versus at least 20 weeks by citalo-
pram treatment; also, at 30 weeks, the percentage of
effect of 17-DMAG in this test was 33%, and that of cita-
lopram was 79%. The difference in performance between
the treated groups (normalized to the respective non-treated
groups) in the two experiments was statistically signiﬁcant
at this age (P = 0.018).
In conclusion, the efﬁcacy of citalopram in suppression of
ATXN3 pathogenesis in two disease models, as well as its
safety record of being widely used in depression patients,
prompts us to suggest this drug for clinical trials in patients
with Machado-Joseph disease.
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Supplementary Figure 1. Strategy used in the C. elegans small molecules screening and validation using 17-AAG. (A) 
Strategy used in the C. elegans screening: (i) determination of safe concentrations for each compound; (ii) identification of 
compounds that rescued or ameliorated AT3q130-mediated locomotion impairment; (iii) and determination of the impact on 
mutant ATXN3 aggregation of the top hit  compounds. (iv) One selected suppressor of ATXN3 pathogenesis in C. elegans 
was tested in the CMVMJD135 mouse model. (B) AT3q130 animals were treated with 17-AAG (previously shown to 
decrease motility impairment in this model (Teixeira-Castro et al., 2011)) at the indicated concentrations, and percentage of 
locomotion defective animals was determined (n = 3, ± s.d.), *P < 0.05, ** P < 0.01 and *** P < 0.001 (Student’s t-test). 
OD, optical density; WT, wild-type animals; AT3q130, mutant ATXN3 expressing animals; Loc. Def, locomotion defective; 
ND, modulators of neuronal dysfunction; A, Aggregation. 
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Supplementary Figure 2. Prestwick library compound toxicity evaluation using the food clearance assay. (A) Example of five 
of the 1,120 compounds tested is given here. The OD of the E. coli OP50 suspension was measured daily of WT animals 
treated with each drug at 50 and 25 μM. The mean OD was calculated for each day from triplicate samples and plotted 
over time. In this example, Prestw-885 administration to WT animals prevented food consumption, as OD levels remained 
high during the seven days, and was therefore classified as not safe at the concentrations tested. The other compounds 
shown were classified as safe, as the OD decrease paralleled the one of control samples. Control DMSO (DMSO 1%) 
corresponds to drug vehicle and Control S-medium to OP50-only S-medium (no vehicle). (B) Food clearance assay for a new 
batch of the hit compounds selected from the primary screen. Control DMSO (DMSO 1%) corresponds to drug vehicle and 
DMSO at 5% (DMSO 5%) was used as positive (toxic compound) control. Food consumption was slower when WT animals 
were treated with clemizole at 50 μM, and similar to control (DMSO 1%) when treated with a lower dosage of 25 μM. 
Therefore, subsequent clemizole treatments were set to 25 μM, as this concentration was deemed safe to the nematodes. 
WT, wild-type. 
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Supplementary Figure 3. C. elegans-based small molecule screening for suppressors of mutant ATXN3- mediated 
neurotoxicity. (A)  Histogram shows percentage of effect frequency for the 599 Prestwick library compounds tested. Green 
bars show hit compounds of the screening, i.e. those which show a percentage of effect greater than 50%, within a 95% 
confidence interval. (B) Pharmacological and structural classification of the small molecules that actively ameliorated 
mutant-ATXN3 mediated neurological dysfunction in C. elegans. Pharmacological classification identified eleven major 
clusters, whereas at the chemical structure level the hit compounds found were clustered into nine groups. A subset of the 
compounds was included in more than one pharmacologic category, as they may have multiple targets. Scoulerine, for 
example, has been described to target 5-HT-, alpha-adreno- and GABA-receptors (Ko et al., 1993, Eisenreich et al., 2003).  
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Supplementary Figure 4. SSRI treatment restores motility and survival of AT3q130 animals. (A) Dose-response profile of 
locomotion defects of AT3q130 animals upon cit treatment. (B), Other SSRIs - S-cit and fluox - showed similar effect on 
motor behavior of the AT3q130 animals. (C) Motility performance of AT3WT upon cit, S-cit and fluox treatments (n = 3-4 ± 
s.d.), *P < 0.05, ** P <0.01, *** P <0.001 (Student’s t-test). (D) Survival of AT3q130 animals upon cit treatment and (E) 
statistics. cit, citalopram; S-cit, S-citalopram; fluox, fluoxetine; AT3WT, wild-type ATXN3 animals. 
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Supplementary Figure 5. Impact of citalopram treatment at 8 mg/kg on the neurological deficits and muscle strength of 
CMVMJD135 mice. (A) Mild improvement in the dragging of the paws at 14 weeks of age. (B) No improvement in 
exploratory activity. (C) No effect on muscle strength tests: hanging wire and forelimb strength, and on (D) hindlimb tonus. 
(E) Effects of cit treatment on balance of CMVMJD135 mice when crossing a round 17 mm beam at 32-34 weeks, (n = 13-
16, ± s.d.), *P < 0.05, **P < 0.01 and ***P < 0.001 (Mann-Whitney U test for non-parametric variables and  ANOVA, Tukey 
correction for continuous variables. For hanging wire test: R squares comparison of the logarithmic model for CMVMJD135 
groups). cit, citalopram. 
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Supplementary Figure 6. Impact of citalopram treatment at 8 mg/kg on body weight and on motor behavior of WT mice. (A) 
Body weight, (B) beam walk and (C) motor swimming tests of vehicle and cit treated WT mice. Cit treatment resulted in a 
significant increase in body weight (Treatment: F1,18 = 5.337, P = 0.033). No differences between WT and cit treated WT 
mice were observed in the beam walk (Treatment: F1,16 = 0.748, P = 0.40) and motor swimming tests (Treatment: F1,14 = 
0.043, P = 0.839). (n = 10 ± s.e.m.), *P < 0.05, **P < 0.01 and ***P < 0.001 (Repeated-measures ANOVA). cit, 
citalopram; WT, wild-type. 
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Supplementary Figure 7. Treatment with a higher dosage of citalopram (13 mg/kg) led to a limited improvement of 
neurological symptoms of CMVMJD135 mice.  (A) Body weight, (B) stride length, (C) beam walk and (D) motor swimming 
tests of vehicle (n = 14) and cit treated (13 mg/kg) WT (WT cit13) mice (n = 17) and of vehicle (n = 16) and cit treated (13 
mg/kg) CMVMJD135 mice (CMVMJD135 cit13) (n = 13). No differences were observed in body weight between 
CMVMJD135 and CMVMJD135 cit13 mice (Genotype: F1,67 = 31.335, P < 0.001; Treatment: F2,67= 14.181, P = 0.000007; 
Genotype*Treatment F1,67 = 1.425, P = 0.237; Post-hoc Tukey test (vehicle versus cit treated CMVMJD135 mice, P = 0.431). 
Cit treated WT mice showed a significant increase in body weight (Tukey test, P = 0.007). No differences were observed in 
stride length upon treatment. Regarding the balance beam walk test, a marginal amelioration was detected at 20 and 24 
weeks of age (One-way ANOVA, Tukey test, P = 0.03 and P = 0.031, respectively; Genotype: F1,49 = 124.181, P < 0.001; 
Treatment: F1,49 = 2.478, Genotype*Treatment: F1,49 = 2.478, P = 0.122). In the motor swimming test, significant differences 
upon treatment were observed only at 22 and 34 weeks of age (One-way ANOVA, Tukey test, p = 0.016 and p = 0.041, 
respectively, Genotype: F1,64 = 118.157, P < 0.001, Treatment: F2,64 = 19.959, P < 0,001; Genotype*Treatment: F1,64 = 6.3, P = 
0.015). Data presented as mean ± s.e.m., *P < 0.05, **P < 0.01 and ***P < 0.001 (Repeated-measures ANOVA, Tukey 
correction). cit13, citalopram at 13 mg/kg; WT, wild-type. 
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Supplementary Table 1. Power analyses of the C. elegans behavior and pathological phenotypes. n needed is the number of 
subjects or observations needed for the specified power. The power of each statistical test was set to 95%, which is the 
probability that it correctly rejects the null hypothesis when it is false. The P-values were calculated by Students t-test or 
One-Way ANOVA followed by Bonferroni post hoc analysis. If P < 0.05, they are labeled as red bold letters. When actual n ≥ 
n needed, they are labeled as blue bold letters.  
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Supplementary Table 1. (cont.) Power analyses of the C. elegans behavior and pathological phenotypes.  
 
Supplementary Table 2. Power analyses of the behavior and pathological phenotypes in CMVMJD135 mice. 
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Supplementary Table 2. (cont.)  Power analyses of the behavior and pathological phenotypes in CMVMJD135 mice. 
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Supplementary Table 3. List of strains, abbreviations and crosses used in this work. 
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Legends of Supplementary Videos  
Supplementary Video 1. Citalopram treatment improved the balance, coordination and time spent to reach the platform of 
CMVMJD135 mice in the beam walk test. Balance beam walk test of 30 week-old WT, vehicle and citalopram treated 
CMVMJD135 mice.  
  
Supplementary Video 2. Citalopram treatment ameliorated the coordination and time spent to reach the platform in the 
motor swimming test of CMVMJD135 mice. Motor swimming test of 30 week-old WT, vehicle and citalopram treated 
CMVMJD135 mice. 
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